HEPARIN A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Heparin: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00532-8 1. Heparin-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on heparin. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON HEPARIN ................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Heparin ......................................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 60 The National Library of Medicine: PubMed ................................................................................ 67 CHAPTER 2. NUTRITION AND HEPARIN ....................................................................................... 115 Overview.................................................................................................................................... 115 Finding Nutrition Studies on Heparin ...................................................................................... 115 Federal Resources on Nutrition ................................................................................................. 117 Additional Web Resources ......................................................................................................... 118 CHAPTER 3. ALTERNATIVE MEDICINE AND HEPARIN ................................................................. 121 Overview.................................................................................................................................... 121 National Center for Complementary and Alternative Medicine................................................ 121 Additional Web Resources ......................................................................................................... 132 General References ..................................................................................................................... 135 CHAPTER 4. DISSERTATIONS ON HEPARIN ................................................................................... 137 Overview.................................................................................................................................... 137 Dissertations on Heparin ........................................................................................................... 137 Keeping Current ........................................................................................................................ 138 CHAPTER 5. PATENTS ON HEPARIN .............................................................................................. 139 Overview.................................................................................................................................... 139 Patents on Heparin .................................................................................................................... 139 Patent Applications on Heparin ................................................................................................ 160 Keeping Current ........................................................................................................................ 186 CHAPTER 6. BOOKS ON HEPARIN ................................................................................................. 187 Overview.................................................................................................................................... 187 Book Summaries: Federal Agencies............................................................................................ 187 Book Summaries: Online Booksellers......................................................................................... 188 Chapters on Heparin .................................................................................................................. 189 CHAPTER 7. PERIODICALS AND NEWS ON HEPARIN.................................................................... 191 Overview.................................................................................................................................... 191 News Services and Press Releases.............................................................................................. 191 Academic Periodicals covering Heparin .................................................................................... 193 CHAPTER 8. RESEARCHING MEDICATIONS .................................................................................. 195 Overview.................................................................................................................................... 195 U.S. Pharmacopeia..................................................................................................................... 195 Commercial Databases ............................................................................................................... 196 Researching Orphan Drugs ....................................................................................................... 197 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 201 Overview.................................................................................................................................... 201 NIH Guidelines.......................................................................................................................... 201 NIH Databases........................................................................................................................... 203 Other Commercial Databases..................................................................................................... 205 APPENDIX B. PATIENT RESOURCES ............................................................................................... 207 Overview.................................................................................................................................... 207 Patient Guideline Sources.......................................................................................................... 207 Finding Associations.................................................................................................................. 209 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 211 Overview.................................................................................................................................... 211
viii Contents
Preparation................................................................................................................................. 211 Finding a Local Medical Library................................................................................................ 211 Medical Libraries in the U.S. and Canada ................................................................................. 211 ONLINE GLOSSARIES................................................................................................................ 217 Online Dictionary Directories ................................................................................................... 217 HEPARIN DICTIONARY ............................................................................................................ 219 INDEX .............................................................................................................................................. 303
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with heparin is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about heparin, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to heparin, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on heparin. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to heparin, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on heparin. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON HEPARIN Overview In this chapter, we will show you how to locate peer-reviewed references and studies on heparin.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and heparin, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “heparin” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Comparison of Carbogen Inhalation and Intravenous Heparin Infusion Therapies in Idiopathic Sudden Sensorineural Hearing Loss Source: Acta Otolaryngologica. Supplement 529: 86-87. 1997. Contact: Available from Scandinavian University Press North America. 875 Massachusetts Avenue, Suite 84, Cambridge, MA 02139. (800) 498-2877 or (617) 4976515. Fax (617) 354-6875. Summary: This article reports on a study which compares the effect of carbogen (5 percent carbon dioxide and 95 percent oxygen) inhalation and intravenous heparin (an anticoagulant) on sudden sensorineural hearing loss (SNHL). The patients were unselected patients with idiopathic sudden SNHL who were treated at a Department of Otolaryngology as inpatients: 44 patients were treated with carbogen inhalation and 43
4
Heparin
with heparin infusion. Conventional audiograms and speech audiometry were performed in the acute stage, after a treatment of 5 days, at a 1 month control, and at a 6 month control visit. The PTA (hearing threshold) at the pretreatment stage was 62 dB in the heparin and 55 dB in the carbogen group. One month later, the corresponding figures were 34 and 32 dB (the difference was not statistically significant). The authors conclude that neither treatment method proved superior in the treatment of sudden SNHL. The authors briefly discuss their findings. 2 figures. 10 references. •
Review Article: Potential Therapeutic Applications and Mechanisms of Action of Heparin in Inflammatory Bowel Disease Source: Alimentary Pharmacology and Therapeutics. 14(11): 1403-1409. November 2000. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Unfractioned heparin was recently reported to be beneficial in the treatment of inflammatory bowel disease (IBD). This article reviews the potential therapeutic applications and mechanisms of action of heparin in IBD. The available uncontrolled data show that the drug may be effective in steroid resistant ulcerative colitis (UC) with a percent of complete clinical remission of over 70 percent, after an average of 4 to 6 weeks of therapy. The administration of unfractioned heparin is not currently justified by the very limited available data. The worsening of rectal bleeding is infrequent in treated UC patients and only rarely does it require blood transfusion or a colectomy (removal of part of the colon). Low molecular weight heparin was used in a single trial in patients with steroid refractory UC, with results similar to those observed with unfractioned heparin. Since a prothrombotic state has been described in IBD, and microvascular intestinal occlusion (blockage of the smallest blood vessels in the intestine) seems to play a role in the pathogenesis of IBD, it is reasonable that part of the beneficial effects of unfractioned heparin in IBD may result from its anticoagulant properties. However, beyond its well known anticoagulant activity, unfractioned heparin also exhibits a broad spectrum of immunomodulating and anti inflammatory properties, by inhibiting the recruitment of neutrophils and reducing pro inflammatory cytokines. Moreover, heparin can restore the high affinity receptor binding of basic fibroblast growth factor; this would aid healing of the ulcerated mucosa. The authors conclude that unfractioned heparin may represent a safe therapeutic option for severe, steroid resistant UC, although randomized, controlled trials are needed to confirm this data. 1 figure. 2 tables. 71 references.
Federally Funded Research on Heparin The U.S. Government supports a variety of research studies relating to heparin. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions.
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to heparin. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore heparin. The following is typical of the type of information found when searching the CRISP database for heparin: •
Project Title: A PEPTIDE APPROACH TO IMPROVE VEIN GRAFT EFFICACY Principal Investigator & Institution: Panitch, Alyssa; Assistant Professor; Bioengineering; Arizona State University P.O. Box 873503 Tempe, Az 852873503 Timing: Fiscal Year 2004; Project Start 01-JAN-2004; Project End 31-DEC-2009 Summary: (provided by applicant): While much of the PI's previous research has been peripherally related to biomedicine, it was all done as an engineer's approach to solve biomedical problems. The materials were designed with only a basic understanding of the biological and medical needs. The proposed training opportunity would provide the PI with an in depth knowledge of some aspects of vascular medicine and physiology as well as added knowledge in mathematical modeling and peptide chemistry. The overall goal is to expand the PI's experience and training in biomedicine as well as in peptide chemistry and modeling to position her for a lifetime of research in biomedicine. Cardiovascular disease is the leading cause of death in the United States. The treatment of cardiovascular disease often involves surgically bypassing occluded segments of blood vessels with human saphenous vein grafts. The development of vein graft stenosis within 1 year after implantation occurs in up to 20-40% of grafts and frequently leads to end-organ failure, including myocardial infarction and extremity amputation. Shortterm graft failure is due to technical problems and vasospasm during harvest and preparation. Long-term graft failure is due to a hyperplastic wound healing response, intimal hyperplasia. The purpose of this proposal is to develop a protein/peptide based therapeutic agent to enhance graft patency. The hypotheses of this investigation is that synthetic phosphorylated heat shock related protein human (HSP20) analogues (pHSP20) can be optimized and delivered in a controlled manner that will prevent vein graft spasm and intimal hyperplasia. The specific aims are to: 1) Optimize TAT-pHSP20 as a functionally active biomolecule, la) Develop and synthesize a panel of analogues of the TAT-pHSP20 peptides, lb) Determine the bioactivity of the peptides ex vivo using strips of human saphenous vein grafts. 2) Develop and characterize controlled release systems for TAT-pHSP20 to ensure sustained delivery of the biomolecule in an effective therapeutic concentration. 2a) Determine the association and release of TAT from the heparin biogel. 2b) Determine the bioactivity of the biogel ex vivo in a muscle bath using strips of human saphenous vein grafts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A POXVIRAL PROTEIN THAT INHIBITS CHEMOKINE FUNCTION Principal Investigator & Institution: Krathwohl, Mitchell D.; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 15-SEP-1999; Project End 31-MAY-2004 Summary: The candidate's long term goals are to become a fully independent investigator and join the faculty of an academic medical school. The short term goals are to gain superior skills and background understanding of molecular biology and receptor
6
Heparin
biology. The career development plan provides for intense mentoring, didactic instruction and close supervision by an advisory committee. The environment at this institution provides a number of individuals with superior skills in immunology, virology, molecular biology and chemokine biology. The broad, long term goals of this project are to understand the role of chemokines in viral infection and to develop novel compounds to inhibit the inflammatory response. The theoretical model to be used is that virus infection of cells results in a release of chemokines that attempt to recruit inflammatory cells. The molluscum contagiosum virus (MCV) is able to then make a protein that specifically blocks the effects of these released chemokines, thus preventing an inflammatory response and elimination of the virus itself. The specific hypotheses to be tested are: 1) the viral protein is made very early in the viral life cycle in order to effectively block the innate immune response. 2) The viral protein is able to block the action of multiple chemokines and block the chemotaxis of multiple inflammatory cell types. 3) The viral chemokine accomplishes it's effects by binding to but not activating chemokine receptors. 4) Structural features of the viral protein at the amino terminus and an internal site known as the heparin binding site are important for the function of this protein. The specific aims of this research are: 1) To characterize the time course of production after infection of the viral chemokine inhibitor protein, MC148R, by infecting keratinocytes with MCV and testing for mRNA production and protein production. 2) To identify the ability of MC148R to block chemotaxis induced by a panel of chemokines, and to identify which subsets of inflammatory cells are blocked by MC148R. 3) To characterize the ability of MC148R to bind to chemokine receptors and induce an intracellular signal. Binding will be assayed by radioactively labeling MC148R and demonstrating radioactivity on cells carrying cloned chemokine receptors. Intracellular signaling will be assayed using a calcium flux assay in cells with cloned chemokine receptors. 4) To determine the regions of MC148R that are important for blocking chemotaxis by constructing mutant proteins at both the amino terminus and the internal heparin binding site. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A PUTATIVE HEPARIN RECEPTOR IN SMOOTH MUSCLE CELLS Principal Investigator & Institution: Lowe-Krentz, Linda J.; Associate Professor; Biological Sciences; Lehigh University Bethlehem, Pa 18015 Timing: Fiscal Year 2002; Project Start 01-JUN-1995; Project End 31-JUL-2005 Summary: (provided by applicant): The overgrowth of vascular smooth muscle cells is a hallmark of the late stages of vascular disease and contributes to the eventual blocking of affected arteries. Heparin has been shown to slow smooth muscle cell growth in vitro and in selected in vivo studies. Heparin effects on vascular smooth muscle cells have been explained by theories including heparin receptors, heparin interaction with growth factors and endocytosis of heparin. Data from the P.I.'s laboratory implicate a heparin receptor and signal transduction involving cGMP production and specific MAPK phosphatases. The proposed research aims to test the hypothesis that heparin treatment of cultured heparin-sensitive vascular smooth muscle cells will result in decreased activity of upstream signal steps in the MAPK pathway and decreased SAPK pathway activity through heparin's interaction with the heparin receptor previously identified in the P.l.'s laboratory. The proposed research will evaluate heparin and heparin receptor effects on upstream signaling from the PDGF receptor through SOS, Ras, and Raf using heparin, anti-heparin receptor antibodies, cGMP analogs, and PKG blockers. Studies of heparin effects on MAPK activity throughout the cell cycle will evaluate whether additional MAPK activity seen throughout the cycle is decreased, or
Studies
7
whether the heparin effects are only at the Gi release from GO check point. The proposed research will evaluate signaling in response to Angiotensin II activation to determine whether the heparin effects on smooth muscle cell MAPK signal transduction are limited to MAPK activation in response to growth factors, or can modulate MAPK signaling regardless of activation system. These studies will also include evaluation of stress kinase activity in heparin treated smooth muscle cells to examine whether these parallel pathways are altered by heparin as might be expected based on our information about the mechanism by which MAPK activity is decreased. Finally, this study will continue work aimed at identifying a clone for the heparin receptor to enable further studies regarding the mechanism of heparin action. Together these studies will confirm the importance of the heparin receptor in heparin induced changes in vascular smooth muscle cells and will provide a significant advancement in understanding of how heparin alters sensitive vascular smooth muscle cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION OF HEMOSTASIS Principal Investigator & Institution: Bennett, Joel S.; Professor; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-MAR-1996; Project End 31-JAN-2006 Summary: Hemostatic and thrombotic disorders are among the leading causes of morbidity and mortality in the United States. Platelet activation and the subsequent binding of macromolecular ligands to the integrin alphaIIbbeta3 are critical events in the pathogenesis of these disorders. The objective of this SCOR Program is to further understanding of the mechanism and consequences of platelet activation, both at the laboratory and clinical levels, with the ultimate goal of providing a rational basis for new and novel therapies. The SCOR Program is composed of five projects and one core unit. Project 1 examines the structural features of alphaIIbbeta3 involved in its activation by platelet agonists. The structure of its ligand binding sites and its cytoplasmic and transmembrane domains will be studied, as well the interaction of the cytoplasmic domains with the platelet cytoskeleton. The latter studies are based on hypothesis that the platelet cytoskeleton regulates alphaIIbbeta3 function. Project 2 examines the biochemistry and cell biology of the platelet protein pleckstrin, asking how pleckstrin regulates cytoskeletal organization, how it affects megakaryocyte development, and what are its physiological ligands. Project 3 examines the consequences of eicosinoid receptor activation. Questions to be addressed include the role of thromboxane receptor activation in atherogenesis and plaque progression, and whether thromboxane receptor activation in atherogenesis and plaque progression, and Project 4 is to define the molecular basis of heparin- associated thrombocytopenia (HIT). The antigenic sites on PF4/heparin responsible for HIT will be characterized, the pathogenicity of various HIT antibodies for thrombosis will be studied, and two murine HIT models will be used to identify factors that predispose to thrombosis. Project 6 is based on the observation that most platelet agonists active platelets via one or more G protein coupled receptors on the platelet surface. Questions asked include whether simultaneous activation of multiple G proteins is required for platelet activation, what are the consequences in vivo of sustained signaling through G proteins, and do RGS proteins limit the duration of G protein signaling to prevent inappropriate platelet activation? The five projects will be supported by an Administrative Core that provides for the administrative and secretarial requires of the SCOR Program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
8
•
Heparin
Project Title: AIRWAY INFLAMMATION
EPITHELIAL
CONTROL
OF
ALLERGIC
LUNG
Principal Investigator & Institution: Corry, David B.; Assistant Professor of Medicine; Medicine; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2009 Summary: (provided by applicant): The long-term objectives of this laboratory are to elucidate the immunopathologic basis of airway obstruction in a murine model of asthma. This proposal will investigate the role the epithelium plays in allergic lung inflammation and focus specifically on two epithelium-derived immunoregulatory molecules, Clara cell secretory protein (CCSP) and syndecan-1. Clara cells are nonciliated respiratory epithelial cells that secrete one of the most abundant airway proteins, CCSP. The airway epithelium also sheds the heparin sulfate proteoglycan syndecan-1 into the airway. Although the biological functions of CCSP remain unclear, it is an antiprotease potentially capable of neutralizing exogenous proteases, which our laboratory has shown are critical to the induction of allergic airway disease. CCSP may also regulate adaptive immune responses of the airway by influencing epitheliumderived factors necessary for growth and survival of T cells. Our preliminary studies show that both CCSP and syndecan-1 down-regulate airway Th2 responses provoked by exogenous proteases. Thus, CCSP and syndecan-1 are immunosuppressive with regard to allergic lung inflammation, but their precise mechanisms of action remain uncertain. In Aim 1, we will dissect the major mechanism by which CCSP attenuates allergic inflammation. We will focus specifically on T cell-dependent effects and explore T helper effector differentiation in vitro and in vivo, Th2 homing to lung and Th2 activation and cytokine production in vitro. Where effects are observed, we will correlate immunosuppressive activities with the antiprotease potential of CCSP. For Aim 2, we will explore the potential of CCSP for prevention/amelioration of allergic lung disease. Mice will be challenged intranasally with CCSP during immune induction with protease-containing allergens and following established allergic lung inflammation to evaluate these two endpoints. Efficacy of CCSP will be compared to a specific protease inhibitor, streptomyces subtilisin inhibitor (SSI). Finally, Aim 3 will explore how syndecan-1 modulates allergic inflammation, either through effects of the core protein or the heparin sulfate side chains. We will extend these mechanistic studies to understand if either CCSP or syndecan-1 directly suppress Th2 function in vitro. Together, our findings will provide broad insight into how the epithelium modulates allergic inflammation, potentially identifying novel therapeutic targets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTI ANGIOGENIC ACTIVITY OF CLEAVED HMW KININOGEN Principal Investigator & Institution: Mccrae, Keith R.; Associate Professor of Medicine; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2005 Summary: (Applicant's Description) High molecular weight kininogen (HK) is an abundant plasma glycoprotein that plays a central role in contact activation. HK is cleaved to two-chain high molecular weight kininogen (HKa) on the endothelial cell surface. Cleavage of HK to HKa leads to the release of bradykinin, and is accompanied by a dramatic structural arrangement. Although binding of bradykinin to endothelial cells leads to well-defined responses, functional consequences that result from binding of HKa have not been reported. We have observed that HKa, but not HK, inhibits endothelial proliferation and induces endothelial apoptosis in a Zn2+-dependent
Studies
9
manner. Proliferation is inhibited by 50% at an HKa concentration of 10 nM. In contrast, HKa does not inhibit the proliferation of aortic smooth muscle or trophoblast cells, or tumor-derived cell lines. In mice, HKa inhibits the neovascularization of basic FGFcontaining Matrigel plugs. Modeling of HKa domain 5 (D5), which also induces endothelial cell apoptosis in a Zn2+-dependent manner, reveals that the structure of the heparin and zinc-binding pharmacophores within this domain closely resemble those within the antiangiogenic polypeptide, endostatin. We have also identified peptides from the endothelial cell binding regions of HKa domains 3 and 5 that inhibit endothelial cell proliferation at low micromolar to nanomolar concentrations; D5, but not D3-derived peptide exhibit Zn2+ dependence. Further insight into the mechanism of HKa is provided by the observations that HKa causes apoptosis of only subconfluent, proliferative endothelial cells, and that culture of endothelial cells on collagen I, IV or a smooth muscle cell-derived matrix protects against HKa-induced apoptosis. In this application, we propose to further define the mechanism of Hka-induced endothelial cell apoptosis, and to use site-directed mutagenesis to determine whether the Zn2+binding pharmacophore(s) in domain 5 are important in antiangiogenic activity. We will also characterize the in viva antiangiogenic activity of HKa domains 3 and 5, as well as peptides derived from them. Finally, we propose to identify the endothelial cell receptor that mediate the antiangiogenic effects of Hka. These studies should provide new information concerning the physiologic regulation of angiogenesis, and may lead to identification of new antiangiogenic agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIGENS OF KAPOSI'S SARCOMA ASSOCIATED HERPESVIRUS Principal Investigator & Institution: Chandran, Bala; Professor; Microbiology, Molecular Genetics, and Immunology; University of Kansas Medical Center Msn 1039 Kansas City, Ks 66160 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-JAN-2007 Summary: (Provided by the applicant): The AIDS-defining illness Kaposi's sarcoma (KS) and several lines of evidences suggest that Kaposi's sarcoma-associated herpesvirus (KSHV) or HHV-8 is vital for KS pathogenesis. The long-term objective of this research is to examine the role of HHV-8 in the pathogenesis of KS. Serological studies conducted in the last funding period suggest that HHV-8 lytic replication precedes AIDS-KS. To determine the role of lytic replication in KS pathogenesis, the focus of the present study is on HHV-8 binding and entry interactions with host cells, with a rationale that these interactions per se may have a role in the pathogenesis of KS. In vitro and in vivo, HHV8 has a broad tropism. Our studies show that this broad cellular tropism may be in part due to HHV-8's interaction with the ubiquitous host cell surface heparin sulfate (HS)like molecules. HHV-8 envelope glycoprotein gB interacts with HS and rabbit anti-gB antibodies neutralized HHV-8 infection. Sequence analyses show that among the HHV8 glycoproteins, and among all the gB of human and animal herpesviruses sequenced to date, only HHV-8 gB possesses the "RGD" (Arg-Gly-Asp) amino acids in the extracellular domain. The "RGD" amino acids is the minimal peptide region of many proteins known to interact with host cell integrins critical for the regulation of gene expression, cellular growth and differentiation. We hypothesize that HHV-8 envelope glycoprotein gB interaction with host cell surface integrins may play a vital role in the biology of HHV-8 infection and in the pathogenesis of HHV-8 associated KS. To examine this hypothesis, four major specific aims have been formulated: (1) To determine whether HHV-8 recognize host cell surface integrin molecules (2) To determine the role of integrins in HHV-8 interactions with host cells (3) To determine
10
Heparin
the interactions between HHV-8 gB and the cell surface integrins. (4) To determine the morphological and molecular consequences of HHV-8 and HHV-8 gB interactions with cell surface integrins. These studies are significant since they will provide an insight into the biology of HHV-8 and it's role in the pathogenesis of KS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTITHROMBIN REGULATION OF COAGULATION PROTEASES Principal Investigator & Institution: Rezaie, Alireza R.; Associate Professor; Biochem and Molecular Biology; St. Louis University St. Louis, Mo 63103 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2003 Summary: Antithrombin (AT), a plasma serine protease inhibitor (serpin), inactivates factor Xa and thrombin by a branched pathway, suicide substrate inhibition mechanism in which an initial reversible Michaelis complex is converted into a tetrahedral or an acyl-enzyme intermediate similar to the normal reaction of these enzymes with their true substrates. In contrast to true substrates, however, a conformational change in the reactive site loop of the serpin leads to insertion of the loop into the A-beta-sheet of the molecule. This results in distortion of the catalytic machinery so that the intermediate is deacylated very slowly and, therefore, is trapped as a kinetically stable, irreversible complex. Unlike AT, binding of the non-serpin inhibitor, tissue factor pathway inhibitor, to factor Xa traps the protease as a reversible, high affinity Michaelis complex. AT is relatively inactive unless it binds to the heparin-like glycosaminoglycans, which are either present in the microvasculature or therapeutically administered for prophylaxis and treatment of venous thrombosis. The low inhibitory activity of AT is due to partial preinsertion of the reactive site loop of AT into the A-beta-sheet of the molecule. Heparin binding to AT induces a conformational change in the reactive site loop of the serpin that causes the expulsion of this inserted region thereby conferring a canonical conformation for the loop that is complimentary to the active site pocket of protease. We have prepared several serpin and protease mutants to investigate the following five Aims: 1) determine the contribution of the catalytic Ser195 of the proteases in binding to the serpin and non-serpin inhibitors; 2) determine whether the AT-protease complexes are trapped as tetrahedral or acyl-enzyme intermediates; 3) determine how heparin might catalyze the AT inactivation of factor Xa in the prothrombinase complex; 4) determine whether there is a heparin binding "exosite" on factor Xa, analogous to that in thrombin; and 5) determine the structural basis for the partial loon preinsertion and the resulting non-canonical conformation of the reactive site loop of the serpin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BARRIER FOR INTRAPORTAL ISLET TRANSPLANTATION Principal Investigator & Institution: Chaikof, Elliot L.; J.E. Skandalakis Professor; Surgery; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2004; Project Start 30-SEP-1999; Project End 31-JUL-2009 Summary: (provided by applicant): A significant obstacle in islet transplantation is the high rate of primary nonfunction and early islet destruction, which has been observed after intraportal islet infusion, both in animal models and in clinical trials. Substantial evidence now suggests that an acute blood mediated inflammatory injury is largely responsible for the observed functional stunning or destruction of islets and may well amplify subsequent immune reactions. In this proposal, we hypothesize that physiologically relevant anti-coagulant/anti-inflammatory processes establish an important paradigm for the design of a conformal islet encapsulation barrier that is
Studies
11
"actively" anti-inflammatory. Specifically, we plan to fabricate an ultrathin film on the islet surface by a strategy of layer-by-layer (LbL) polymer assembly. Maladaptive inflammatory responses will be modulated by incorporating into the thin film, thrombomodulin (TM) and heparin, as inhibitors of thrombin dependent responses and CD39 as an inhibitor of purinergic mediated (i.e. ATP/ADP) procoagulant/proinflammatory pathways. In this manner, the islet cell mass required to achieve euglycemia will be reduced and long-term graft survival enhanced. Specifically, we intend to: (1) Fabricate a biocompatible conformal islet encapsulation barrier of deemed permeability by a strategy of layer-by-layer (LbL) polymer assembly. Porcine and mouse islets will be conformally coated with a polymer film and their short-term function and viability characterized. The ability of a conformal coating to prevent activation of the coagulation cascade and enhance islet engraftment will be defined using established allograft (B 10.BR -> C57/BL6) and xenograft (Porcine -> C57/BL6) models. (2) Determine the complementary effects of surface-bound heparin and thrombomodulin as interactive anti-inflammatory strategies designed to optimize islet engraftment and long-term islet survival. The ability of a TM and heparin containing conformal coating to prevent activation of the pro-inflammatory responses will be determined in vitro and in vivo and the capacity to enhance islet engraftment and long-term survival characterized. (3) Define the capacity of CD39 to abrogate prothrombotic and proinflammatory pathways that contribute to primary islet non-function and late islet destruction. CD39 will be incorporated onto conformally coated islets, either alone or as a component of TM and heparin containing films. The capacity of CD39 to potentiate the anticoagulant/anti-inflammatory properties of a protein C activating polymer coating will be determined. Enhancement of islet engraftment and long-term survival will be investigated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GROUPS
BIOMEDICAL POLYMERS WITH HEPARIN-BINDING END
Principal Investigator & Institution: Ward, Robert S.; President; Polymer Technology Group, Inc. 2810 7Th St Berkeley, Ca 94710 Timing: Fiscal Year 2004; Project Start 01-AUG-2004; Project End 31-JAN-2005 Summary: (provided by applicant): Endpoint immobilization of heparin on the surface of polymeric biomaterials is a well-established method for improving thromboresistance. The most effective currently-available heparinization methods are costly, multi-step procedures that may degrade the mechanical properties of the base polymer. This makes them impractical for both low-cost devices like IV catheters and for prosthetic implants in which retention of physical-mechanical properties is vital for assuring safety and efficacy, e.g., circulatory support devices and vascular grafts. The proposed study will determine the feasibility of synthesizing tough, thermoplastic polyurethane biomaterials with built-in covalently bonded end groups with binding sites for heparin. A novel diamine-diamide-alcohol (PIME-SME) synthesis procedure will be optimized for high yield and low cost. Several samples of Bionate (r), a biostable polycarbonate-urethane, will then be synthesized using the mono-functional PIME-SME in a range of bulk concentrations. The use of this new surface modifying end group will avoid the reduction of mechanical properties associated with modifications to the polymer backbone previously used for binding heparin. Heparinization will be performed by simply soaking the device or component made from the subject polymer in dilute heparin solution. Highly surface specific Sum Frequency Generation Vibrational Spectroscopy will be used to assure maximum concentration of heparin
12
Heparin
binding groups at the surface of the polymer before exposure to heparin, and to measure the resulting surface heparin concentration following heparin binding. The activity of the adsorbed heparin will first be determined by a chromogenic anti-Xa heparin assay. A biological assay that measures the amount of antithrombin III (ATIII) that binds to the heparinized surface will also be used to determine if the adsorbed heparin maintains a conformation that binds ATIII. From the analytical characterization and the biological assays, the optimal bulk concentration of PIME-SME will be determined to provide maximum heparin binding on the surface of the modified polymers. During Phase II, scale up to manufacturing on our existing continuous reactor will be performed following extensive in vivo and in vitro testing. In Phase III The Polymer Technology Group will offer polyurethanes and device components with heparin binding capacity for sales or license, as part of its existing catalog of biomaterials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMIMETIC SCAFFOLDS FOR MULTIPLE GROWTH FACTOR DELIVERY Principal Investigator & Institution: Andreopoulos, Fotios M.; Surgery; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2004; Project Start 12-JUL-2004; Project End 31-MAR-2007 Summary: (provided by applicant): Chronic, non-healing wounds are a major health problem with more than 10 million Americans per annum receiving treatment, at a cost of greater than 10 billion dollars. Exogenous growth factor therapy for the treatment of chronic and acute wounds has shown promising results in accelerating the rate of healing in in-vitro and in vivo models. Unfortunately, inadequate methods of locally delivering active growth factors in a timely order limit the widespread utilization of growth factor therapy in a clinical wound management setting. A major challenge lies in the development of sophisticated peptide delivery systems that mimic the endogenous release profiles of growth factor production during the natural tissue repair process. We hypothesize that bioactive scaffolds impregnated with multiple growth factors that are released at controlled rates, offer the possibility of augmenting the rate of healing to a greater extent than a single growth factor therapy. This study is sought to a) understand how we can predictably modulate the sequential delivery of multiple growth factors from a single polymeric scaffold by manipulating the scaffold's properties and b) evaluate the synergistic effects of dual controlled growth factor delivery in cutaneous repair. We propose two Specific Aims. In AIM 1a we will synthesize biodegradable, polyethylene glycol-heparin (PEG-heparin) hydrogel scaffolds with tunable physical properties that release at controlled rates two well-known tissue repair factors, namely epidermal growth factor (EGF) and basic fibroblast growth factor (b-FGF). In AIM 1b we will determine the significance of controlled delivery on peptide bioactivity in an in vitro milieu and in AIM 2 we will assess the ability of the growth factor releasing scaffolds to promote cutaneous regeneration in a partial thickness wound model. The sequential delivery of these factors will be programmed by: a) controlling the physical properties of the scaffold (e.g. light exposure, gel composition), b) altering the growth factor loading capacity and c) pre-encapsulating each one of these factors (i.e. depending upon the preferred order of release) within biodegradable poly (lactide-co-glycolide) (PLG) microspheres before they are loaded into the gel scaffold. The heparin content of the gel scaffold will stabilize EGF and b-FGF and serve as a docking station for the prolonged release of the peptides to the wound area. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
13
Project Title: CARCINOGENESIS AND DRUG DEVELOPMENT Principal Investigator & Institution: Lippard, Stephen J.; Professor of Chemistry; Chemistry; Massachusetts Institute of Technology Room E19-750 Cambridge, Ma 02139 Timing: Fiscal Year 2002; Project Start 01-JUL-1980; Project End 31-JAN-2006 Summary: (Applicant's Description): The objective of this training program i s to produce young scientists qualified to make original research contributions in the chemical sciences related to cancer, both its prevention and treatment by chemotherapy. Ten faculty members of the Chemistry Department constitute the core research team around which the educational offerings of the program are built. Predoctoral candidates admitted to the program first complete a rigorous selection of courses and examinations after which they concentrate in one of several available research areas, also available to postdoctoral trainees, for their Ph.D. dissertation. Included in this offering are projects in the molecular basis of carcinogenesis, mechanistic studies of anticancer drugs, the synthesis of new antitumor agents including combinatorial chemistry, and new approaches to chemotherapeutic intervention through the study of cell surfaces and signal transduction. A new requirement has been introduced that postdoctoral associates take one course of direct relevance to cancer biology. Specific projects include cellular responses to DNA damage; mechanistic and synthetic studies of platinum anticancer drugs; chemical methods for the analysis of carcinogen metabolism; DNA damage, carcinogenesis and molecular biomarkers for cancer epidemiology; purine biosynthesis as an appropriate target for new antitumor agents; inhibitors of ribonucleotide reductases; bleomycins and enediynes as antitumor antibiotics; synthetic and biochemical studies of heparin-like glycosaminoglycans; the use of the fumagillin family of natural products as probes; the development of general synthetic methodology appropriate for combinatorial chemistry and rapid throughput screening; and strategies to prepare anticancer agents. In addition to their research, graduate and postdoctoral students in the program are required to expand their knowledge through participation in a regularly scheduled seminar program and by travel to key scientific meetings. At MIT, trainees present their research results, listen to presentations by their colleagues, and hear a variety of lectures by c a n c er researchers in the greater Boston community. Included are epidemiologists and clinical oncologists as well as basic scientists, to give the trainees a comprehensive picture of the roles of environmental factors in the etiology of cancer and of chemotherapy in the prevention and clinical management of the disease. At national and international meetings, members of the training grant give papers and attend sessions on work related to their own project as well as the projects of others on the training grant. Their experiences are then related to other trainees in the program upon returning to MIT. Education in the proper conduct of science and in scientific ethics is required through assigned readings and participation in regularly scheduled sessions with the faculty in which case studies are presented and discussed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CATABOLISM OF COAGULATION FACTOR VIII Principal Investigator & Institution: Saenko, Evgueni L.; American National Red Cross Washington, Dc 20037 Timing: Fiscal Year 2002; Project Start 01-FEB-2001; Project End 31-JAN-2005 Summary: (Investigator's abstract) Factor VIII (fVIII) is an important plasma component required for haemostasis, since genetic defects in this molecule cause a life-threatening coagulation disorder known as Hemophilia A. This genetic disease is treated by repeated infusions of expensive fVIII products. A more effective therapy can be
14
Heparin
provided if the molecular basis of fVIII clearance is understood and a novel recombinant fVIII protein with a prolonged lifetime in circulation is developed. We have previously found that the low density lipoprotein receptor-related protein (LRP), the main endocytic liver receptor, and cell surface heparan sulfate proteoglycans (HSPGs) cooperate in the clearance of fVIII, since simultaneous blocking of these two receptor systems dramatically prolonged the lifetime of fVIII in mice. While in purified system both LRP and HSPGs were shown to interact with fVIII via the sites located within the A2 domain, the precise molecular events responsible for fVIII catabolism are currently not well characterized. We propose to identify the amino acid residues critical for fVIII interaction with LRP and HSPGs by mutational analysis of the regions previously identified as LRP and HSPGs binding sites of fVIII. The mutations will be introduced into B-domain depleted recombinant fVIII, which is functionally identical to plasmaderived fVIII and is presently used for Hemophilia A therapy. We will express these fVIII mutants in mammalian cells and test them for binding to LRP and heparin, used as model of HSPGs, in purified systems. The catabolism of the mutants will be examined in vitro using LRP-expressing cells and in vivo in a murine model of Hemophilia A. These experiments will identify fVIII mutants with reduced binding to LRP and HSPGs and will clarify the role of these two receptor systems in fVIIII clearance. The proposed studies should develop an insight into the mechanism of fVIII regulation in circulation and will provide a basis for generation of a novel type of recombinant fVIII products, having a prolonged lifetime in circulation. Development of such fVIII derivatives, which may be prospective for less expensive Hemophilia A therapy, is the long-term goal of our studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESPONSES
CEREBELLAR
PROTEOGLYCANS
IN
SONIC
HEDGEHOG
Principal Investigator & Institution: Rubin, Joshua B.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: This proposal examines the regulation of sonic hedgehog (Shh) response in developing cerebellum. Sonic hedgehog produces multiple morphogenetic and mitogenic effects during development including cerebellar granule cell proliferation. Dysregulation of Shh has profound developmental consequences and is implicated in several cancers. The mechanism of Shh signaling is poorly understood and lags far behind our knowledge of several other growth factors. In Drosophila, Tout-velu, a putative glycosyltransferase involved in the synthesis of heparin sulfate proteoglycans (HSPG) is necessary for Hh response. There are multiple examples of HSPG modulation of growth factor signaling and several diseases of HSPG synthesis with significant developmental abnormalities and increased cancer risks. We have focused on the effects of HSPGs on Shh receptor binding and signaling in the developing mouse cerebellum. In preliminary studies we have demonstrated direct interaction of Shh with heparin, and shown that reduction of cell surface HSPGs results in decreased Shh induced proliferation consistent with the effect of the Tout-velu mutation. Surprisingly, these same treatments result in increased Shh binding. Further, we have found that cerebellar expression of EXT2, a vertebrate Tout-velu homolog, increases with age and is more abundant in post-mitotic granule cells. We hypothesize that the synthesis of HSPGs is regulated during cerebellar development and is a determinant of Shh binding and Shh responses. We will test our hypotheses by determining the pattern of expression of EXT family members (EXT1-3, L1-3) in developing cerebellum. We will measure Shh
Studies
15
pathway activation in primary cultures of cerebellum from Ptc-LacZ (plus/minus) mouse and Shh receptor binding after genetic and biochemical manipulation of HSPG synthesis. The necessity for direct HSPG-Shh interactions will be determined by sitedirected mutagenesis of the putative Shh heparin binding domain. Taken together these experiments will generate novel information regarding HSPG modulation of the relationship between Shh binding and signaling and may shed new light on the mechanisms by which dysfunction of Shh and HSPG produce disease. In addition, these studies will provide me with the opportunity to learn the techniques of modern cell and molecular biology and establish the skills with which to study neural developmental. Dr. Rosalind Segal's laboratory in the Department of Pediatric Oncology at the DanaFarber Cancer Institute provides an excellent environment for me to develop as an independent investigator. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF GROWTH OF VASCULAR WALL CELLS Principal Investigator & Institution: Libby, Peter; Chief, Cardiovascular Medicine; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-JUL-1985; Project End 31-JUL-2003 Summary: (Adapted from Applicant's Abstract): The investigators will test four hypotheses regarding positive and negative growth control and cytokine- inducible functions of vascular smooth muscle cells (SMC) and endothelial cells (EC): 1. Heparin binding growth factors (HBGFs) contribute to SMC growth during atherogenesis. a) They will monitor expression of FGF family members and heparin binding epidermal growth factor like molecule (HB-EGF) in normal and atheromatous arteries from humans and rabbits. b) They will test whether cytokines regulate HBGF expression by cells found in human atheroma. c) They will study whether membrane bound forms of HB-EGF participate in "juxtacrine" signaling (stimulation requiring cell-cell contact), and whether proteolysis regulates HB-EGF action by release of surface-bound precursors. 2. Certain inflammatory stimuli can mobilize active IL-1beta from a preformed precursor pool in vascular EC. EC in vitro and in vivo contain immunoreactive IL-1beta. They hypothesize that this is inactive 33 kD pro-IL-1beta that requires proteolytic processing for biological activity. They will study the control by inflammatory mediators of IL1beta processing in EC and SMC which may represent an additional level of local regulation of this multipotent cytokine. 3. Monocyte- colony stimulating factor (M-CSF) promotes SMC growth during atherogenesis. a) They will determine whether human SMC transfected with c-fms, the M-CSF receptor, respond mitogenically to M-CSF. b) They will test whether SMC express membrane bound forms of M-CSF that may participate in "juxtacrine" signaling. c) They will localize c-fms expression in experimental and human atheroma to determine if SMC express this receptor in vivo during atherogenesis. 4. They will test whether local activity of a cytokine inducible nitric oxide synthase (iNOS) in SMC modulates the growth and other non-contractile functions of SMC and other cells. a) They will characterize cDNAs encoding iNOS in SMC. b) They will raise antibodies against SMC iNOS and probe its expression in vivo. c) They will test whether NO or NOS activity modulates the proliferative and matrix stimulatory effects of mediators such as PDGF, TGFs, and HBGFs on SMC. d) They will test whether NO or NOS expression by SMC inhibit mitogenic responses of Tlymphocytes, and might thus modulate local immune responses during vascular diseases. The results of this study should help unravel mechanisms of arterial pathology, to understand normal vascular homeostasis, and to aid the rational design of therapies for prevalent vascular diseases.
16
Heparin
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--VECTOR Principal Investigator & Institution: Snyder, Richard O.; Assistant Professor; University of Florida Gainesville Gainesville, Fl 32611 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2009 Summary: It is essential that investigators affiliated with this program be provided with consistently high titer, pure rAAV preparations. Therefore, the Vector Core Laboratory at the University of Florida has three objectives. The first objective of the Vector Core Laboratory is to make the highest quality preclinical vector for the investigators affiliated with this program conducting pre-clinical gene transfer experiments, as well as, safety and toxicology studies to support the AAV platform. Each virus preparation is now produced using a mini-Ad plasmid DNA system to eliminate Ad contamination. Small-scale preparations of rAAV 1, 2, and 5 vectors are purified by iodixanol gradient centrifugation followed by heparin affinity or anion exchange chromatography. Largescale preparations of rAAV2 are purified by a newly developed method that uses FPLC chromatography on heparin sulfate, phenyl Sepharose, and cation exchange columns. All virus stocks are subjected to stringent quality control assays to assess purity, particle titer, infectious titer, particle to infectivity ratio and potential contamination by rcAAV. The second objective of the vector core is the routine and large-scale production and purification of other AAV serotypes, including AAV1, AAV5, AAV7, and AAV8 vectors, and capsid mutants of AAV serotypes 2, 1, and 5. Assays and specific reagents will be developed to accurately determine the titers of the different serotype vectors and the capsid mutants. The third objective of this proposal is to develop viral vectors targeted to bronchial epithelial cells in order to provide a highly specific delivery of the cystic fibrosis (CF) gene, as well as to diminish the transduction of collateral tissues thereby reducing the required dose of vector to the patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DECIDUAL SIGNALS IN THE ESTABLISHMENT OF PREGNANCY Principal Investigator & Institution: Soares, Michael J.; Professor; University of Kansas Medical Center Msn 1039 Kansas City, Ks 66160 Timing: Fiscal Year 2002; Project Start 02-MAY-2002; Project End 31-MAR-2007 Summary: The establishment and maintenance of pregnancy require the appropriate development of a specialized maternal tissue, referred to as decidua. Decidual cells arise from uterine stroma via the actions of progesterone, form intimate relationships with placental structures, and facilitate the development of the embryo. Among the important functions of decidual cells are their hormone/cytokine producing capabilities. Hormone/cytokines related to prolactin (PRL) are prominent decidual cell secretory proteins and include, decidual/trophoblast prolactin-related protein (d/tPRP). The uteroplacental PRL family contributes to the regulation of uterine inflammatory cell responses accompanying pregnancy. D/tPRP has been shown to associate with heparin containing molecules in the extracellular matrix and specifically interact with eosinophils. Eosinophils are a part of the maternal inflammatory response and must be controlled in order to ensure the establishment of pregnancy. We hypothesize that the decidual cell product, d/tPRP, participate in the modulation of maternal adaptations to pregnancy, including mediation of the anti-inflammatory actions of progesterone. In this research project, we propose to investigate decidual cell signaling. In Aim 1 we propose to identify cellular responses to d/tPRP. Aim 2 focuses on determining mechanisms
Studies
17
underlying the interactions of d/tPRP with heparin and eosinophils. Under Aim 3 we examine d/tPRP- eosinophil interaction in vivo. The planned research utilizes cellular and molecular and in vitro and in vivo strategies. Data derived from the proposed experimentation will improve our understanding of the nature of decidua cell signaling and the role of the decidual PRL family in the regulation of viviparity. These findings will provide considerable insight into the etiology of developmental disorders associated with pregnancy failure and will also have important ramification on our understanding of the control of eosinophil functions in aberrant processes such as immune disease and cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DESIGNING MECHANISM-BASED ANTICOAGULANTS Principal Investigator & Institution: Desai, Umesh R.; Associate Professor; Medicinal Chemistry; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Thrombotic and vascular disorders are among the leading cause of deaths in the US annually. Unfractionated heparin and low-molecularweight heparins have become major anticoagulant drugs for use in these hematological disorders with combined annual sales of more than $ 3 billion. Unfortunately heparin and low molecular weight-based anticoagulation therapy is beset with several problems including bleeding complications. Heparin anticoagulation therapy is primarily based on the ability to accelerate the inhibition of factor Xa and thrombin by antithrombin, a plasma serine proteinase inhibitor. At the molecular level, heparin binding induces a conformational change in antithrombin ('activation') to greatly enhance its ability to inhibit factor Xa. However, the polyanionic nature of heparin also results in non-specific interactions leading to the numerous undesirable side effects. Alternative approaches based on rationally designed small non-sugar heparin-mimics that eliminate these side effects and possibly possess advantages, such as oral activity, are therefore highly desirable. Our central hypothesis is that efficient activation of antithrombin leading to specific inhibition of factor Xa can be achieved with small non-sugar molecules. We propose to synthesize and study rationally designed small organic molecules as conformational activators of antithrombin. Towards this end we will I) synthesize and characterize rationally designed bicyclic-unicyclic, bicyclic-linker-unicyclic and bicyclicbicyclic activators of antithrombin, II) investigate the molecular interaction of antithrombin with designed, small heparin mimetics using biochemical and biophysical techniques, and III) design rational advanced organic, non-sugar activators based on initial promising leads. Detailed investigation of the rationally designed molecules will provide the knowledge to deduce quantitative structure-function relationship critical for the design of an effective non-sugar heparin-mimic. These aims will be investigated utilizing computerized molecular modeling; fluorescence spectroscopic study of interactions; rapid kinetic determination mechanism of interaction; enzyme kinetics; and synthetic organic chemistry. This fundamental research will establish the principles of effective conformational activation of antithrombin by small nonheparin molecules for accelerated inhibition of factor Xa. Successful completion of this research will contribute fundamental knowledge for the design of an effective anticoagulant I) with reduced non-specific adverse effects normally associated with heparin therapy and II) with better oral activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
18
•
Heparin
Project Title: RECEPTORS
DIFFERENCES
IN
SYNAPTIC
VS
NONSYNAPTIC
AMPA
Principal Investigator & Institution: Arai, Amy C.; Pharmacology; Southern Illinois University Carbondale 900 S. Normal Carbondale, Il 629014709 Timing: Fiscal Year 2002; Project Start 09-FEB-2001; Project End 31-JAN-2005 Summary: AMPA-type glutamate receptors mediate most excitatory synaptic transmission in the brain. Receptor binding studies have shown that AMPA receptors exist in two distinct states with 20-fold different affinities. It is suggested that the two forms are differentially localized with synaptic receptors being of the low-affinity type and non-synaptic receptors of the high-affinity type. Thus, AMPA receptors in patches excised from the soma (and hence of non-synaptic origin) may have different kinetic properties than those in synapses. This would entail that somatic and synaptic receptors contribute differentially to neurological disorders involving excitotoxic damage to neurons. This proposition will be tested by examining if differences between synaptic and non-synaptic AMPA receptors are also detected with physiological measures and if they correspond to the high-low affinity distinction seen in binding. To facilitate this comparison, both physiological data and binding data will be collected under equivalent conditions. Aim One will determine 'physiological KD' values for equilibrium currents in patches excised from hippocampal pyramidal cells and compare them with binding affinities obtained in the same buffer and at the same temperature. The results will then be compared with similar measures from recombinant AMPA receptors stably expressed in HEK293 cells that appear to be entirely of high affinity (Aim Two) and with data from synaptic receptors in autapses of cultured neurons, which presumably are of low affinity (Aim Three). It is further known that binding to the low-affinity receptors can be modulated about two-fold by biochemical manipulations such as treatment with concanavalin A, phospholipase A2 or neuroaminidase. The consequences of some of these treatments for AMPA receptor kinetics will be examined in Aim Four using the same approach. It was also observed that high affinity receptors, unlike their lowaffinity counterpart, are highly unstable at 37 degrees C and it seems likely that this is related to the fast 'run-down' of AMPA receptor currents in patch experiments. Determining which cellular factor stabilizes the low-affinity receptors will constitute the Fifth Aim of this application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DRUG ELUTING STENT GRAFT FOR TREATMENT OF AAA Principal Investigator & Institution: Bajgar, Clara; Implant Sciences Corporation 107 Audubon Rd, #5 Wakefield, Ma 01880 Timing: Fiscal Year 2002; Project Start 11-FEB-2002; Project End 31-JUL-2002 Summary: (provided by applicant): Abdominal aortic aneurysms (AAA) affect approximately two percent of women and five percent of men over age sixty five, and are almost certainly fatal if allowed to rupture. Although surgery involving vascular grafts or endovascular graft systems is widely accepted as a standard treatment for AAA, new, minimally invasive stent grafting technologies are rapidly entering the market. Stented aneurysms are, however, like stented postangioplasty arteries, subject to thrombolysis and restenosis. Heparin and Heparin derivatives are commonly used to treat thrombolysis; several pharmacotherapeutic agents are claimed to control restenosis. Implant Sciences proposes to improve drug delivery to AAA sites by incorporating Heparin and a restenosis-inhibiting drug into a non-erodable, biodurablepolyurethane graft-coating. Rapamycin, based on its success in recently completed and
Studies
19
highly publicized clinical trials when delivered from an eluting stent directly to percutaneous coronary revascularization sites, is the inhibitor of choice. To sequester the drugs, an eluting polymer currently marketed in Europe as VascuLink will be employed. By substituting for systemic drug administration localized, time-release, multi-drug delivery via a coated-stent, the proposed device not only affects a lifesaving repair but also, by minimizing Heparin and Rapamycin doses, reduces the potential for adverse side effects. PROPOSED COMMERCIAL APPLICATION: Although endovascular repair of AAA is not likely to replace surery, it can be extended to many patients who were previously considered poor surgical candidates. Compared to open surgery the hospital stay and the recovery times are shorter, both perceived positively by the patient (improved quality of life) and by the healthcare system (cost effectiveness). With the population aging and approximately 100,000 new AAA cases diagnosed every year, the commercial potential is significant, and, with the newer, improved devices, will become even more so. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTIVE AND NON-TOXIC ANTAGONIST TO HEPARIN AND LMWH Principal Investigator & Institution: Park, Yoon-Jeong J.; Industrail Science & Technology Network 2101 Pennsylvania Ave York, Pa 17404 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-JAN-2004 Summary: To prevent heparin-induced bleeding, protamine is used in nearly 2,000,000 cardiac/vascular operations to reverse the anticoagulant effects of heparin. Intravenous use of protamine, however, can cause life-threatening adverse reactions. In fact, the combined use of heparin and protamine was suggested as the major cause of morbidity and mortality for patients undergoing such surgeries. Although many attempts have been made, to date, protamine remains as the sole clinical heparin antidote; due to its unmatched reliability, efficacy, and low costs. A recent authoritative review by clinicians concluded that the ideal heparin-neutralizing agent should be a compound that provided all advantages and yet lacked anaphylactic potential of protamine. An explicit examination of the mechanism of heparin neutralization and protamine toxicity by us suggests that complete heparin neutralization may require only a small arginine-rich fragment in protamine, whereas the toxicity of protamine is attributed primarily to its polycationic and polymeric nature. Thus, a chain-shortened low molecular weight protamine (LMWP), if it can be derived from protamine to contain only the heparinneutralizing domain, could be this ideal heparin- neutralizing agent. Further, this LMWP may also be devoid of antigenicity and immunogenicity; both are known to contribute significantly to protamine toxicity. The ultimate goal of this SBIR project is therefore to develop LMWP to be a non-toxic, wholesale protamine substitute. During the Phase I work, the feasibility of this approach was successfully demonstrated. In this Phase II application, the focus is to demonstrate the utility of the approach in aborting all patients, either diabetic or non-diabetic, with or without pre- development of antiprotamine antibodies in their system, from possible attack of protamine allergy. In Phase III, ISTN will team up with identified industrial partners to proceed FDAapproved clinical trials, standarization of the compound under GMP, and commercialization of the final LMWP products. PROPOSED COMMERCIAL APPLICATION: Our assessment made in Section 3.5.3.3 indicates that the annual protamine production totals 1 metric ton in the US and 10 metric tons worldwide. The main objective of this SBIR project is to develop LMWP as a non-toxic protamine substitute without the risk of protamine allergy. If proves successful, it is expected that
20
Heparin
LMWP would become a wholesale replacement of protamine in all its pharmacological and clinical uses. The commencial potential of this project is therefore enormous. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTS OF STRETCH ON IC AND NORMAL UROTHELIA Principal Investigator & Institution: Chai, Toby C.; Associate Professor; Surgery; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 15-JUN-2001; Project End 31-MAY-2006 Summary: (Adapted from the Applicant's Abstract): Interstitial cystitis (IC) patients typically present with extreme urinary frequency, urgency and pelvic pain. It has a 10:1 female:male predominance. Since the pathophysiologic picture of IC is unclear, cure remains elusive and treatment options are largely ineffectual. Even the diagnosis of IC is controversial. An objective diagnostic criterion is the cystoscopic appearance of glomerulations after bladder hydrodistention (stretch) under anesthesia. Recent data disputed the diagnostic specificity of this procedure because hydrodistention of control bladders resulted in glomerulations. Based on the investigators' preliminary data which showed that IC urothelia responded to stretch significantly differently than controls in cystoscopic appearance, levels of urinary heparin binding epidermal growth factor-like growth factor (HB-EGF), antiproliferative activity (APF), and adenosine triphosphate (ATP), they propose to test these hypotheses: 1. Bladder glomerulations, which appear after hydrodistention, are specific for NIH-IC symptoms criteria (NISC). 2. Male patients with chronic non-bacterial prostatitis (prostatitis class III or chronic pelvic pain syndrome, CPPS) and NISC have post-hydrodistention glomerulations whereas males with CPPS and no NISC do not. This observation would further strengthen the association of glomerulations with NISC. 3. Some NISC patients improve symptomatically after hydrodistention and degree of improvement correlates with changes in urinary markers (APF, HB-EGF and ATP). 4. In vitro stretch of IC urothelial cells results in increased ATP, HBEGF and decreased APF activity compared to stretch of control cells. 5. There is increased expression of P2X1 and P2X3 ATP receptors in IC compared to control bladder urothelium and suburothelium. This project is unique because it links clinical and laboratory data to test the central hypothesis that IC urothelia respond differently to stretch. Only human samples will be used to provide optimal clinical relevance. Findings from this study will clarify the current diagnostic dilemma regarding specificity of glomerulations for diagnosing IC and determine the therapeutic efficacy of hydrodistention. Furthermore, this study will explore the exciting new discovery that ATP released by stretched IC cells is significantly higher compared to controls. ATP may mediate nociception in the bladder. Urothelial stretch thus appears to be an important consideration in diagnosis, treatment and pathophysiology of IC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENGINEERING FGF-1 FOR INCREASED ANGIOGENICITY Principal Investigator & Institution: Brey, Eric M.; Surgery; Loyola University Chicago Lewis Towers, 13Th Fl Chicago, Il 60611 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): Critical limb ischemia results in 150,000 nontraumatic lower limb amputations annually, with over half occurring in diabetic patients. The long-term goal of this research is to design a growth factor that can be used to increase blood flow in ischemic limbs of diabetic patients. This proposal is driven by the hypothesis that fibroblast growth factor-one (FGF-1) can be engineered for increased
Studies
21
angiogenicity by creating chimeras with vascular targeting sequences and using site directed mutagenesis to modify specific amino acids sequences involved in thrombin degradation and heparin dependence. A chimera of FGF-1 fused with a peptide sequence that binds angiogenic endothelial cells (NGR) will be synthesized and characterized. The in vitro mitogenicity of this chimera (NGR/FGF-1) for endothelial, smooth muscle, and mural precursor cells will be determined, as will its susceptibility to thrombin degradation and heparin dependence. A fibrin gel model will be used to quantify the in vitro angiogenicity of NGR/FGF-1 and determine its 3D spatial localization in relation to vessel sprouts. The in vivo angiogenicity of NGR/FGF-1 and other previously designed FGF-1 mutants will then be quantified using a novel 3D technique and a simple collagen gel model. This gel, implanted in a mouse model of diabetes will be used to identify the growth factors with the strongest angiogenicity. The two most angiogenic growth factors will then be assessed for their ability to promote angiogenesis and increase blood flow in a diabetic mouse model of critical limb ischemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ESTROGENS AND INSULIN RESISTANCE IN WOMEN Principal Investigator & Institution: Olefsky, Jerrold M.; Professor; Medicine; University of California San Diego La Jolla, Ca 920930934 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-MAY-2007 Summary: (provided by applicant): There are genetic and environmental causes of insulin resistance, and clearly these two inputs can be additive and interactive. A high fat intake is an important environmental factor which can cause, or exacerbate, insulin resistance and enhance the risk for the development of Type II diabetes. Our recent studies have shown that lipid/heparin infusions lead to insulin resistance in men, but not in pre-menopausal women. We also have preliminary data showing that postmenopausal women are fully susceptible to fat-induced insulin resistance and that estrogen replacement therapy re-establishes the protective state. In addition, we have conducted a series of studies in rats, demonstrating that estrogenization (endogenous or exogenous) will protect females from fat -induced insulin resistance. Based on these findings, we propose that men and non-replaced post-menopausal women will exhibit fat-induced insulin resistance, whereas, adequately estrogenized women will be protected. We will test these ideas, not only by employing the lipid/heparin infusion glucose clamp technique, but also by placing experimental subjects on control and high fat diets. It is also possible that adequate estrogen can ameliorate the effects of other physiologic causes of insulin resistance. Thus, we also will conduct studies to determine whether estrogenization can protect women from the insulin resistance induced by obesity and aging. Using muscle biopsy samples collected during the glucose clamp studies, we will conduct experiments aimed at identifying cellular mechanisms for these protective effects of estrogens. We also propose an extensive series of animal studies, in which we will explore in more detail the mechanisms of estrogen protection from fatinduced insulin resistance. We will conduct studies in normal male and female rats, ovariectomized rats, and old estrogen deficient female rats+/- treatment with estradiol, an estrogen antagonist, or estrogen receptor isoform specific agonists. Studies in mice with deletion of the alpha or beta forms of the estrogen receptor, as well as muscle specific estrogen receptor specific knockout animals are also proposed. We will also determine whether the fat cell secreted protein ACRP3O is modulated by estrogen status, and whether the insulin sensitizing effects of ACRP3O are responsible for the estrogen induced protection from insulin resistance. If the concepts contained in this
22
Heparin
application prove correct, then these findings could have significant implications concerning the mechanisms of insulin resistance as well as the treatment and possibly prevention of this disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXTRAVASCULAR THROMBIN REGULATION BY HEPARIN COFACTOR II Principal Investigator & Institution: Church, Frank C.; Professor; Pathology and Lab Medicine; University of North Carolina Chapel Hill Aob 104 Airport Drive Cb#1350 Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 01-JUL-1984; Project End 31-JUL-2005 Summary: (provided by applicant): Thrombosis is a major cause of morbidity and mortality in Western man. It is important to understand how the body regulates both thrombin activity and production. Our long-term goal is to understand the interactions between the "glycosaminoglycan (GAG)-dependent" serine protease inhibitor (serpin) heparin cofactor II (HCII), GAGs and thrombin and attempt to define how these interactions regulate the "cytokine-like" effects of thrombin on thrombin responsive cells. The serine protease thrombin has a key role in blood coagulation and other host defense mechanisms. Thrombin has two distinct types of activities: (i) those related to hemostasis, which are primarily manifest at sites of intravascular injury; and (ii) cytokine-like activities, which are primarily manifest in the extravascular stroma. There is much clinical evidence to suggest that antithrombin (AT) controls the first type of thrombin activity. We have a theory that HCII in the presence of extravascular proteoglycans regulates the second type of thrombin activity. We also hypothesize that thrombin dysregulation in atherosclerotic vessels is partly due to the loss of HCII-GAG interactions because of changes to proteoglycans with the progression of disease. Finally, we have a hypothesis that HCII activity is dependent upon unique protein-GAG interactions to displace its acidic domain for thrombin inhibition. To test these hypotheses, we propose to one, examine the mechanism of HCII-thrombin inhibition in the presence of GAGs, and to "transfer" the HCII structural elements for GAGdependent activity to a non-GAG-dependent serpin (alpha1-protease inhibitor) by sitedirected mutagenesis; two. crystallize HCII and crystallize thrombin-HCII acidic domain peptides, and to study structure-function relationships of the acidic domain; and three, characterize the ability of HCII to regulate thrombin's cytokine-like activity for mononuclear leukocytes and endothelial cells exposed to pro- and antiatherogenic substances, and to study the in vivo localization of HCII, AT, and thrombin antigen in normal and atherosclerotic vessel wall. While it is evident that inhibition of plasmaderived proteases is achieved by specific interactions, there are many essential molecular and cellular details that remain to be described. The information provided by the experiments outlined in this grant proposal will further define the mechanism of how HCII functions in thrombosis, especially related to atherosclerosis. Understanding the molecular and cellular properties of HCII may lead to new insight into the pathophysiology and therapies of cardiovascular diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FATTY ACIDS, ANGIOTENSIN AND OXIDATIVE STRESS Principal Investigator & Institution: Egan, Brent M.; Associate Professor; Pharmacology; Medical University of South Carolina P O Box 250854 Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 15-AUG-1997; Project End 31-MAR-2005
Studies
23
Summary: (provided by applicant): BACKGROUND: Obese hypertensives have elevated plasma non-esterified fatty acids (NEFAs) including oleic acid. Oleic acid induces a PKC-dependent increase of reactive oxygen species in vascular smooth muscle cells. In volunteers consuming diets low in anti-oxidants for 3 weeks, raising plasma NEFAs with an infusion of Intralipid and heparin increased blood pressure (BP) about l4/8 mmHg and elevated plasma F2-isoprostanes, an index of oxidative stress, p
Project Title: INTERACTION
FLOW
EFFECTS
ON
ENDOTHELIAL/TROPHOBLAST
Principal Investigator & Institution: Douglas, Gordon C.; Associate Professor; Cell Biology & Human Anatomy; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 956165200 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): In humans and higher primates, fetal trophoblasts gain access to the lumens of dilated uterine capillaries and migrate along endothelium against the flow of blood eventually remodeling spiral arteries. Our general hypothesis is that migration of trophoblasts within uterine blood vessels is regulated by blood flowderived shear stress. New data now show that trophoblasts migrate against flow when
24
Heparin
cultured on top of confluent uterine endothelial cells. To account for these observations, two, not mutually exclusive, mechanisms are proposed. First, we suggest that shear stress causes an asymmetric distribution of immobilized chemokines or adhesion molecules on endothelial cells that generates a haptotactic gradient directing trophoblast migration against flow. Second, we suggest that interaction of trophoblasts with immobilized chemokines and/or adhesion molecules on endothelial cells results in trophoblast activation causing trophoblasts to respond to shear stress by migrating against flow. Four aims will allow us to distinguish these mechanisms and characterize the features that define the shear stress-dependent migratory phenotype. First we will use videomicroscopy to characterize the effect of different levels of shear stress on the directional migration of trophoblasts on uterine endothelial cells. Aim 2 uses confocal microscopy to study the role of chemokines and endothelial adhesion molecules in shear stress-mediated trophoblast migration. We will also use migration checkerboard assays to determine whether chemokine- or adhesion molecule-induced trophoblast migration is haptotactic, chemotactic or chemokinetic. Aim 3 determines the effect of shear stress and trophoblast-endothelial interaction on induction of a migratory trophoblast phenotype. We will use confocal microscopy to characterize the leading edge/trailing edge distribution of CCR5, beta1 integrin, and cytoskeletal elements in trophoblasts exposed to different levels of shear stress in the presence of endothelial cells. Expression of these proteins will be quantiated by laser scanning cytometry, immunoblotting, and quantitative RT-PCR analysis. Function-blocking antibodies will identify the role of trophoblast adhesion molecules and chemokine receptors in flow-induced migration on endothelium. Aim 4 will use quantitative laser scanning cytometry to examine the expression of chemokine receptors, chemokines, and adhesion molecules in intravascular trophoblasts and endothelial cells in serial sections of uterine tissue. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLYCOSYLATED NANOPARTICLES TO INHIBIT RECEPTOR CLUSTERI Principal Investigator & Institution: Wei, Alexander; Associate Professor; Chemistry; Purdue University West Lafayette West Lafayette, in 479072040 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2009 Summary: (provided by applicant): Receptor tyrosine kinases and other cell-surface receptors are known to activate signal transduction pathways by ligand-induced dimerization or clustering, resulting in a range of important health-related consequences such as cell proliferation, inflammatory response, and angiogenesis. Receptor clustering is often promoted by heparin-binding proteins complexed onto nearby proteoglycans. This proposal will develop a new class of receptor inhibitors based on a novel concept called anti-clustering, in which nanometer-sized complexes will bind to multiple receptors but retain them in arrested states. Sulfated oligosaccharide ligands will be grafted onto colloidal gold nanoparticles, which will serve as multivalent scaffolds for the selective recruitment and orientation of heparin-binding signaling proteins such as growth factors or chemokines. Synthetic strategies will be developed for functionalizing nanoparticles with orthogonally protected oligosaccharides, which will be deprotected and sulfated in variable order to generate libraries of glycosylated nanoparticles (GNs) with variable sulfation patterns. Specific Aims include: (1) a robust method for encapsulating nanoparticles in nondesorptive coatings and functionalizing them with orthogonally protected oligosaccharides at low surface densities; (2) orthogonal protecting-group strategies for synthesizing disaccharides with up to 32 different sulfation patterns; (3) generation and characterization of sulfated GN libraries; (4)
Studies
25
screening of GNs for highaffinity binding to fibroblast growth factors (FGFs), and their subsequent evaluation as inhibitors (anticlustering agents) against FGF receptormediated signal transduction using a cell proliferation assay. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HB-EGF AND INTESTINAL ISCHEMIA/REPERFUSION Principal Investigator & Institution: Besner, Gail E.; Professor; Children's Research Institute 700 Children's Dr Columbus, Oh 432052664 Timing: Fiscal Year 2002; Project Start 15-JAN-2002; Project End 31-DEC-2005 Summary: The broad, long term objectives are to utilize the cytoprotective abilities of heparin-binding EGF-like growth factor (HB-EGF) in the treatment of intestinal ischemia/reperfusion (I/R) injury. The goal of the present study is to determine the means by which HB-EGF decreases expression of inducible nitric oxide synthase (iNOS) and production of reactive oxygen species (ROS) within the intestine following I/R injury. We have shown that administration of HB-EGF during the ischemic phase of an I/R episode in rats substantially attenuates the extent of intestinal tissue damage and decreases mortality; as well, the post-I/R expression of iNOS, systemic appearance of nitric oxide, and generation of ROS within the affected intestine are significantly decreased. Using in vitro studies, we have demonstrated that treatment with HB-EGF decreases cytokine- induced upregulation of iNOS in human intestinal epithelial (DLD1) cells, and reduces generation of ROS by leukocytes and rat intestinal epithelial cells. Our hypothesis is that HB-EGF decreases tissue injury following I/R by limiting the increased expression of iNOS and ROS that occur in this setting. To test this hypothesis, the application has two specific aims: (I) To delineate the protective effects of HB-EGF in an in vivo model of intestinal I/R injury, and (II) To elucidate the mechanisms by which HB-EGF attenuates the post-I/R increase in iNOS and ROS. The research design and methods are to clarify issues regarding the dose, route, and timing of HB-EGF administration in vivo, and to use our animal model of intestinal I/R to characterize the effects of HB-EGF on expression of iNOS, ROS, antioxidant enzymes and proinflammatory cytokines by the intestine post-I/R. In Aim II, DLD-1 cells will be used to determine if HB-EGF alters the rate of iNOS mRNA transcription or its stability, and if NF- kappaB activation occurs following HB-EGF administration. Human umbilical vein endothelial cells will be used to determine if HB- EGF affects the conversion of xanthine dehydrogenase to the oxidase form, and human leukocytes will be used to determine the effects of the peptide on NAPDH oxidase expression and function. The health relatedness of this work is to eventually perform clinical trials of the use of HB-EGF in patients with intestinal I/R injury, and the data generated in this proposal will allow us to obtain important information regarding the mechanisms of HB- EGF intestinal cytoprotection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEPARAN SULFATE PROTEOGLYCAN /PROSTATE CANCER METASTASIS Principal Investigator & Institution: Farach-Carson, Mary C.; Professor; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2003; Project Start 17-SEP-2003; Project End 31-JUL-2008 Summary: The interactions between prostate cancer cells and the bone stroma facilitate the progression of metastases growing in bone and bone marrow. Understanding the bone stromal microenvironment and its postive impact on growth of prostate cancer
26
Heparin
cells at both cellular and molecular levels will allow us to develop novel therapeutic strategies specifically targeted to bone metastases. Heparin/heparan sulfate binding growth factors (HBGF) produced by bone marrow, by prostate cancer cells themselves, and sequestered in the bone matrix stimulate growth of metastatic prostate cancer cells. Agents that disrupt interactions between prostate cancer cells and the bone environment are expected to reduce the growth of metastatic prostate cancer cells at bony sites. Our hypothesis is that heparan sulfate proteoglycans in the stromal extracellular matrix, the most abundant of which is perlecan, function as co-receptors to deliver heparin binding growth factors to prostate cancer cell HB growth factor receptors. Three overall specific aims are proposed to test this hypothesis and to dissect the complex HBGF-mediated paracrine actions occurring between marrow stromal cells and prostate cancer cells. These studies will take advantage of prior work in our laboratory that has generated powerful reagents for disrupting HBGF-dependent signaling. Specifically, two types of interventions, a heparin binding protein (HIP) and related bioactive peptide and a perlecan ribozyme that we have generated will be tested for the ability to interfere with HBGF stimulation of prostate cancer cell growth. Strong preliminary studies indicate that PIn knockdown by an active ribozyme inhibits growth of prostate cancer cells in a mouse model. Together, our studies will complement other projects in the program project focusing on the important role of the stromal-epithelial interactions supporting prostate cancer progression. Finally, this project will support the training of a ribozyme core technician who will work with us in Delaware but who will be responsible for production of functional ribozymes as needed for other projects in the program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPARIN COFACTOR II ACTIVATION MECHANISM Principal Investigator & Institution: Foshay, Miriam C.; Biochem and Molecular Biology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Heparin cofactor II (HCII) is a thrombin inhibitor found in relatively high concentration in plasma and in most tissues of the body. A member of the serpin superfamily, it is important to the prevention of thrombosis and arteriosclerosis. Heparin and dermatan sulfate accelerate its rate of inhibition 10[3] to 10[4]-fold through an allosteric mechanism that is only partly understood. This unique mechanism appears to involve binding of the N-terminus of HCII to exosite I of thrombin following the binding of glycosaminoglycans (GAG). Although some of the residues involved in this mechanism have been identified through site-directed mutagenesis, the structural changes that occur have not been identified. Another unusual feature of HCII is its active site sequence, which makes the serpin more sensitive to activation by particular GAG and therefore confers greater site specificity. This proposal seeks to use a combination of heteronuclear single quantum correlation (HSQC) NMR and fluorescence spectroscopy to elucidate in solution the sequence of events leading to HCII activation. A proposed model will be tested through the following specific aims 1) to determine the relative mobility of the N-terminus and its binding site(s), including the binding site of the hirudin-like acidic region, 2) to establish the activation mechanism by monitoring changes following the binding of heparin and dermatan sulfate, and 3) to determine whether the reactive center loop is partially inserted in beta-sheet A, and whether that insertion is affected by the binding of GAG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
27
Project Title: HEPARIN ON HYPOXIC PULMONARY HYPERTENSION AND REMODELING Principal Investigator & Institution: Hales, Charles A.; Professor of Medicine; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 01-JUL-1987; Project End 31-MAY-2005 Summary: Thickening of the media with intrusion on the vascular lumen contributes substantially to the pulmonary hypertension seen in primary or secondary pulmonary hypertension. Heparin has been shown to be antiproliferative and antihypertrophic for systemic and pulmonary artery smooth muscle cells (PASMC) in vitro and has been variably effective at inhibiting in vivo remodeling in several systemic and pulmonary models. We have found that commercial heparin lots vary widely in their antiproliferative activity. However, an effective antiproliferative heparin in vitro for PASMC proliferation can prevent hypoxic pulmonary hypertension in mice, rats and guinea pigs and can reverse it in guinea pigs even in the presence of continued hypoxia. We have also shown that heparin's ability to inhibit PASMC proliferation and in vivo pulmonary hypertension correlates with its ability to prevent mitogen stimulation of the Na+/H+ antiporter. We have found that highly specific antagonists of the Na+/H+ antiporter such as dimethyl amiloride (DMA) can inhibit PASMC proliferation in response to growth factors in vitro and can substantially prevent hypoxic pulmonary hypertension and remodeling in rats. As we dissect the chemistry of antiproliferative heparins we have shown, among other things, that the protein core is unimportant and that 3-0-sulfate is not an important feature in full-length heparin. We have made new heparin derivatives by O-acetylating heparin with butanoyl and hexanoyl which are more potent antiproliferative agents on PASMC than native heparins and are nonanticoagulant. We have found that in PASMC heparin stimulates the production of the cell cyclin kinase inhibitors p21 and p27 which are inhibitors of cell proliferation in other cells. With this progress we hope to continue our pursuit of an effective treatment for pulmonary hypertension with the following specific aims: 1) Continue examining strongly versus weakly antiproliferative heparins in order to discover the reasons for the differences with a goal of amplifying the antiproliferative potency and perhaps divorcing it from the anticoagulative and osteopenic properties. 2) Determine in the pig, as a preclinical trial in a large mammal, if heparin or heparin fragments or the Na+/H+ inhibitor DMA are effective at preventing hypoxic pulmonary hypertension and 3) Determine if heparin's mechanism of action in preventing SMC proliferation is via stimulation of the cyclin kinase inhibitors p21 and p27. Thus, this proposal may lead to new therapeutic agents for humans with pulmonary hypertension and may elucidate a new understanding of how heparin prevents PASMC growth. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEPARIN SEQUENCES FOR APPLICATIONS TO HEMOSTASIS Principal Investigator & Institution: Seeberger, Peter H.; Firmenich Assistant Professor; Chemistry; Massachusetts Institute of Technology Room E19-750 Cambridge, Ma 02139 Timing: Fiscal Year 2002; Project Start 30-SEP-2000; Project End 31-JUL-2004 Summary: Heparin-like glycosaminoglycans (HLGAGs) are the most acidic naturally occurring biopolymers, found in the extracellular matrices. These complex polysaccharides play a key role in regulating the biological activity of several proteins in the coagulation cascade and in hemostasis. The relationship between structure and activity of HLGAGs is still very poorly understood due to the complexity and heterogeneity of these polymers. It has become increasingly evident that defined lengths
28
Heparin
and sequences of HLGAGs are responsible for binding to a particular protein and modulating its biological activity. Detailed structure-activity studies on HLGAG oligosaccharides have suffered from the lack of pure material. Due to the complexity and heterogeneity of these polysaccharides there are, at the present time, no feasible approaches for the preparation of defined HLGAG oligosaccharides. Determination of structure-activity relationships of HLGAGs creates an opportunity for the discovery of novel therapeutic interventions for a variety of disease states. The principal investigator's present an entirely novel approach to the generation of defined HLGAG oligosaccharides by combining the enzymatic degradation of natural heparin with chemical synthesis. The program will draw from extensive expertise in enzymatic degradation of HLGAGs using heparinases, chemical synthesis of complex oligosaccharides and an understanding of the biological activities of HLGAGs. This relatively simple synthetic strategy would particularly lend itself to the solid support synthesis of defined HLGAG sequences, much like peptides and oligonucleotides are currently assembled. This novel and interdisciplinary program initially will be aimed at providing a proof-of-principle for the strategy to assemble HLGAG sequences involved in coagulation and hemostasis processes. However, areas of clinical opportunities of HLGAGs go beyond hemostasis, and can include angiogenesis and growth factor mediated signal transduction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNE THROMBOCYTOPENIA/T*
MECHANISMS
IN
HEPARIN-INDUCED
Principal Investigator & Institution: Reilly, Michael P.; Medicine; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): Heparin-induced thrombocytopenia/thrombosis (HIT/T) is the most frequent cause of drug-induced antibody-mediated thrombocytopenia, a common cause of life-and limb-threatening platelet activation and thrombosis, and a model to study how an exogenous molecule (heparin) induces antibody formation against a self protein (platelet factor 4; PF4). Although antibodies to heparin/PF4 complexes are found in essentially all patients with HIT/T, it is unclear how antibody formation is initiated, why only a small subset of these antibodies cause disease or the mechanism by which they initiate thrombosis. We have recently developed a double transgenic mouse model and showed in vivo that heparin, PF4, antibodies to the heparin/PF4 complex, and the platelet Fc receptor for IgG, FcgammaRIIA are both necessary and sufficient to recapitulate the severe thrombocytopenia and thrombosis seen in patients with HITT. We have also found that PF4 and heparin form large oligomeric complexes that are immunogenic in vitro and are recognized by HIT antibodies. We will use these new findings to explore the immune mechanisms of antibody development, antigen recognition and pathogenesis of thrombosis in HIT through three interrelated aims. In Specific Aim 1 we will determine the heparin:PF4 ratio that supports the development of thrombocytopenia and thrombosis in vivo using mice in which the endogenous mouse PF4 has been knocked out. In Specific Aim 2 we will examine the structure of heparin/PF4 oligomers, their recognition by HIT antibodies, molecular composition, capacity to promote antibodymediated platelet activation through FcgRIIA, and uptake and processing by dendritic cells. We will develop a library of human IgG1 and IgG2 antibodies to these complexes in XenoMouseII mice. In Specific Aim 3 we will systematically vary four host factors important to HIT/T development in vivo, in order to determine their contribution to the
Studies
29
spectrum of human disease. The antibody source and titer, the heparin:PF4 structure, Fcg receptor variants that influence the balance of platelet activation and splenic clearance, and atherosclerotic vasculature will be examined in genetically-defined mouse models. Taken together these studies will provide insight into the development of self-reactive antibodies and thrombosis in patients with HIT/T, facilitate development of new diagnostic tests to identify patients at risk, provide a platform to design rational inhibitors of antibody development and provide a model to test new therapies for this serious disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITOR-RESISTANT THERMOSTABLE DNA POLYMERASES FOR PCR Principal Investigator & Institution: Coleman, William J.; Group Leader; Kairos Scientific, Inc. 10225 Barnes Canyon Rd, #a110 San Diego, Ca 92121 Timing: Fiscal Year 2004; Project Start 01-MAY-2004; Project End 31-JAN-2005 Summary: (provided by applicant): DNA-based analytical and diagnostic procedures are increasingly exploiting the ability of PCR amplification technology to rapidly and accurately provide information about biological samples, often in a high-throughput format. Several key methods also rely on quantitative analysis of the amplification reactions. However, many types of tissue, blood and other clinical samples which can be used to generate template DNA for PCR amplification contain endogenous inhibitors of DNA polymerases. These inhibitors can seriously interfere with the analysis by creating false negative results. Such inhibitors include heparin and heine in blood, and bile salts in feces. In addition, a number of reagents used for DNA extraction or detection inhibit PCR reactions. We propose to use a combination of directed evolution and patented screening technology to create thermostable DNA polymerase variants that are resistant to common PCR inhibitors. Our sotid-phase MicroColonylmager (MCI) Technology is superior to conventional liquid-phase methods for analyzing mutagenized libraries of enzymes because it enables screening of 3,000-10,000 variants per assay while at the same time minimizing the amount of substrate required. By creating application-specific polymerase variants engineered to resist inhibitors, this technology will provide PCR users with cost-effective and time-saving reagents that will improve the reliability of their assays. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INITIATION AND REGULATION OF BLOOD COAGULATION Principal Investigator & Institution: Lella, Vijaya Mohan Rao.; Professor; Biochemistry; University of Texas Hlth Ctr at Tyler 11937 Us Highway 271 Tyler, Tx 75708 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-MAR-2005 Summary: Tissue factor (TF)-dependent blood coagulation plays a primary role in hemostasis after tissue injury and also in pathogenesis. Binding of factor VII to TF is the initial step in TF-dependent blood coagulation. A key reaction must then follow: activation of the bound factor VII to give rise to catalytically active VIIa/TF complexes. Little is known about how the activation of factor VII and the subsequent VIIa/TFcatalytic activity are regulated in vivo and to what extent anti-coagulantly active cell surface heparin sulfate proteoglycans play a role in the regulation of these critical steps in TF-induced coagulation. Further, which specific amino acid side chains in VIIa and TF are involved in the recognition of tissue factor pathway inhibitor (TFPI) and the cell biology of VIIa/TF remain unknown. The primary focus of the present proposal is to
30
Heparin
obtain important information on these unanswered questions. The specific goals are: (1) Test a hypothesis, both in vitro and in vivo, that cell surface heparin sulfate proteoglycans limit activation of factor VII bound to TF expressed on cell surfaces and thereby regulated TF-induced coagulation (2) Test a hypothesis that recognition structures for substrate factor X presents in VIIa/TF complex contribute to the enhancing effect of Xa during the quaternary complex formation of VIIa/TF/TFPI/Xa (3) Test a hypothesis that cell surface TF redistributes upon complex formation with VIIa, Xa and TFPI and define the role of TFPI in this process (4) Test a hypothesis that the binding of TFPI/Xa to cell surface VIIa/TF affects internalization of cell surface VIIa/TF complexes and elucidate the intracellular trafficking of internalized VIIa and TF. In the proposed studies, various well established techniques, such as radioligand binding, coagulation assays, electron microscopy, and a rabbit intravascular coagulation model system will be used. Information obtained from these studies will aid in understanding important clinical issues, such as why infused factor VIIa is effective in controlling the bleeding in hemophiliacs. The above studies will further our understanding of the structural mechanism of macromolecular assembly of VIIa/TF/TFPI/Xa. Such an understanding may lead to the design and application of therapeutic measures aimed at the treatment of hemorrhagic disease and thrombotic complications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERLEUKIN-6 EXPRESSION AND FUNCTION IN ADIPOSE CELLS Principal Investigator & Institution: Harp, Joyce B.; Associate Professor; Nutrition; University of North Carolina Chapel Hill Aob 104 Airport Drive Cb#1350 Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Elevated interleukin-6 (IL-6) is associated with fat wasting in systemic infection and cancer cachexia. However, important new data indicates that circulating IL-6 is also elevated in human obesity, and adipose tissue is the principal source of this elevation. Because obesity is among the most prevalent public health challenges in the United States, it is important to understand IL-6 expression and function in adipose tissue, and to determine whether dysregulated expression of adipose tissue IL-6 is involved in the development of obesity and obesity-related co-morbidities. IL-6 traditionally signals through STAT3 activation, but in differentiating preadipocytes, IL-6 inhibits and STAT3 appears to be necessary for adipocyte formation. In this proposal we propose the following Specific Aims. Aim 1: To determine mechanisms involved in IL-6induced inhibition of adipogenesis. We hypothesize that greater than or equal to 10 ng/ml IL-6 inhibits the preadipocyte to adipocyte conversion by altering normal cell cycle progression and subsequent adipogenic transcription factor expression. We will determine in 3T3-L1 preadipocytes the effect of IL-6 on cell cycle progression and differentiation. Using chimeric GM-CSF- gp130 receptor transfections, the signaling mechanisms involved to transduce IL-6 effects will be explored. To explore the physiological relevance of IL-6 in adipose tissue, we will determine whether IL-6 knockout mice have altered adipose tissue growth, glucose, and lipid metabolism on normal and high fat diets. Aim 2: To characterize adipose tissue IL-6 expression in animal models of obesity. We find IL-6 mRNA is expressed in adipose tissue of lean mice, but it has been reported that obese db/db mice do not express IL-6 mRNA in adipose tissue. Since glucocorticoids repress IL-6 expression, we hypothesize that IL-6 expression is depressed in adipose tissue of ob/ob and db/db mice by high systemic
Studies
31
corticosterone levels that are characteristic of these models of obesity. We also predict that IL-6 expression is elevated in adipose tissue of diet-induced obese (DIO) mice, similarly to obese humans. DIO mice retain normal corticosterone levels with the development of obesity. We will characterize IL- 6 expression in adipose tissue of lean control, DIO, ob/ob, and db/db all on a C57BL/6J background at baseline and in response to glucocorticoid agonists and antagonists, and thiazolidinediones. Aim 3: To identify the differentiation-induced STAT3 activating ligand. Our new pilot data indicate that IL-6 is not the autocrine factor responsible for MDI-induced STAT3 activation, but that the heparin binding ligand midkine (MK) is. In this Aim, we will confirm our preliminary studies, and determine whether midkine is the sole STAT3 activating ligand released upon MDI stimulation of 3T3-LI cells. Aim 4: To determine the role of STAT3 activation in adipogenesis. We hypothesize that activation of STAT3 is necessary for adipogenesis. We will block MDI-induced STAT3 activation by overexpression of PIAS3. Alternately, we will mimic STAT3 activation by overexpression of a constitutively active STAT3 to determine whether STAT3 activation alone is necessary and sufficient to induce adipogenesis. The role of STAT3 in fat pad formation will be investigated by implantation into the subcutaneous space of nude mice human preadipocytes that express vector, PIAS3, or constitutively active STAT3. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIGAND-BINDING IN THE REACTION MECHANISM OF DAO Principal Investigator & Institution: Gassner, George T.; Chemistry and Biochemistry; San Francisco State University 1600 Holloway Ave San Francisco, Ca 941321722 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005 Summary: (provided by applicant): Diamine oxidase (DAO) activities are elevated in boundaries separating quiescent and rapidly dividing cells where the transformation of molecular oxygen and biogenic amines to aminoaldehydes and hydrogen peroxide by these enzymes may play a significant role in the regulation of cell division in normal and cancerous tissues. Biochemical studies of this enzyme will help to elucidate the molecular mechanism of cellular response to changes in polyamine concentration in normal and disease states. Here we propose to 1) develop and optimize purification schemes for diamine oxidase from bovine liver and kidney and evaluate the substrate specificities of these isoforms 2) identify the role of manganese in ligand-binding and the catalytic mechanism, 3) characterize the heparin, and nucleic acid-binding interactions of DAO and the modulation of its catalytic activity associated with these biopolymers. The primary structure, glycosylation, cofactor content, specific activity, and substrate specificities of the purified isozymes will be compared. Catalytic reaction mechanisms of the purified enzymes will be studied through a combination of ligand binding, steady state, and pre-steady state kinetic measurements. DNA, RNA, heparin, and metal binding mechanisms, as well as the polynucleotide sequence binding specificity of these isozymes will be investigated by using a combination of titrametric, stopped-flow and continuous flow measurements. The role of polynucleotide, metal, and heparin-binding in catalysis will be established through the measurement of ligandspecific effects on steady-state kinetic parameters and reaction product distributions. The influence of nucleic acid binding on individual reaction steps will be established by observing changes in the kinetics of the oxidative and reductive half reactions by stopped-flow spectroscopy. The role of polyamines in the DAO-nucleic acid binding interaction and the kinetics of oxidation of DAO with polyamines will be investigated. Elevated concentrations of diamines and increased diamine oxidase activity generates significant concentrations of hydrogen peroxide and aminoaldehydes, which may lead
32
Heparin
to oxidative damage and the formation of inter- and intramolecular cross-links between reactive groups of susceptible proteins and nucleic acids. Products recovered from in vitro reactions of defined composition will be screened for DAO-induced molecular modifications by capillary electrophoresis and mass spectrometry. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MACROPHAGE MECHANISMS
CHYLOMICRON/B48
RECEPTOR,
BINDING
Principal Investigator & Institution: Bradley, William A.; Professor of Medicine; Medicine; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2005 Summary: ApoB is essential to life yet excess apoB100 or apoB48 is atherogenic and associated with increased risk of cardiovascular disease. We identified and cloned a new, unique receptor (R) for dietary triglyceride-rich lipoproteins (TGRLP), the apoB48 R. It is constitutively expressed on monocyte-macrophages (MM), including human atherosclerotic foam cells and bone marrow precursors, and endothelial cells (ECs), cells intimately involved in hemostasis and atherothrombogenesis as well as hemopoiesis, immune function and tissue nutrition. Although we have documented that the apoB48 R binds to apoB48, major questions remain on the precise mechanism(s) of binding and why normal VLDL and LDL have low affinity for this R--which microdomain of apoB48 is necessary for R binding and how the other apoB regions, apoproteins, and lipid constituents modulate binding of lipoproteins to this R. Our published and preliminary data support the hypotheses that (1) an apoB48 microdomain that is required for binding is at or near the lipoprotein lipase binding site, is not releaseable by trypsin, is not in a heparin binding domain, and is masked in normal VLDL and LDL; (2) apoB48 R binding affinity is greater in large particles (Sf greater than 100) than in small particles (Sf less than 100); and (3) apoE inhibits binding to the apoB48 R. This ensures sufficient uptake of larger nutrient-rich (lipids and lipid-soluble vitamins) dietary particles by cells responsible for tissue nutrition, immune function and hemopoiesis, cells with high nutritional requirements, and directs smaller apoB lipoproteins to the liver, as observed in vivo. We propose multiple approaches to define the R-binding apoB48 microdomain (Aim 1) and to define modulators of this interaction (Aim 2), using native, modified, and model lipoproteins, monoclonal antibodies, C-terminal truncated apoB, molecularly engineered apoB mutant constructs, and cell and ligand blotting studies. Knowledge of the basic biochemical determinants and molecular mechanisms that govern the interactions of TGRLP with the apoB48 R are crucial to meaningful intervention to prevent excess, atherothrombogenic uptake by this route while preserving sufficient nutrient uptake or, conversely, to enhance uptake in subjects with multiple pathologies due to defective or deficient apoB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF FIBRINOGEN ASSEMBLY IN EXTRACELLULAR MATRIX Principal Investigator & Institution: Simpson-Haidaris, Patricia J.; Associate Professor; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2003 Summary: The process of blood vessel repair following injury is carried out in a temporal and spatial manner by the dynamic interaction of fibrinogen (FBG), fibrin and the extracellular matrix (ECM) with cells of the vessel walls. The long term objectives of
Studies
33
this proposal are to characterize the cellular and molecular mechanisms by which vessel repair occurs. Proteoglycans are essential components of the receptor- growth factor interactions, cell-cell recognition systems, and cell-ECM adhesion processes that interact coordinately to stimulate cell proliferation and migration required for cellular repair. Because cell surface heparan sulfate proteoglycans perform essential functions in these processes, and with the extensive clinical application of heparin in the prevention in the prevention of thrombosis, the potential for heparin binding to fibrin(ogen) has important implications in understanding the mechanisms of heparin modulation of hemostasis, fibrinolysis, angiogenesis and tissue remodeling. Preliminary studies demonstrate that FBG, not fibrin, is incorporated into ECM, resulting in exposure of a cryptic heparin binding domain (HBD). We will test the hypothesis that FBG, through its HBD, plays an active role in heparin and heparin sulfate modulation of cell-cell and cell-matrix interactions involved in vessel repair. The proposed experiments will elucidate the mechanisms by which FBG is assembled into preformed, mature matrices of polarized and interstitial cell types to determine the functional role of matrix-FBG in mediating signal transduction to bring about the ordered process of cell repair and tissue remodeling. Specific Aim 1 of this proposal will be to define the essential structural domains of matrix FBG, and to determine the reciprocal cell-surface receptors and matrix constituents that support assembly of FBG into ECM. The techniques of cell biology, protein biochemistry, confocal scanning laser cytometry, fluorescence microscopy, and immunodetection will be used to characterize the ligands and receptors critical for the assembly of FBG into ECM. Specific Aim 2 will be to examine the cellular responses to FBG deposited and assembled into mature ECM. Modulation of cell proliferation and migration by FBG deposited into ECM, including the signal transduction pathways involved, will be examined using cell and molecular biology techniques. Defining the structure/function relationships involved in FBG, fibrin and the ECM interaction with cells of the vessel wall will provide a new understanding of the host response to injury with implications for treatment of thrombosis and therapeutic manipulation of angiogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF HUMAN MAST CELL TRYPTASE REGULATION Principal Investigator & Institution: Schechter, Norman M.; Research Professor; Dermatology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2004 Summary: The goal of this work is to describe the biochemical mechanism for the functional instability of the serine protease human tryptase and to define the relevance of this mechanism to the regulation of tryptase in vivo. Serine proteases in blood and inflammatory cells play important roles in host defense. The enzymatic activity of these proteases is tightly regulated by other proteins which act as physiological inhibitors; the absence of such regulation can have serious pathological consequences. Enzymatically active tryptase is stored in large amounts within the secretory granules of mast cells, and is released upon stimulation of these cells. However, regulation of tryptase is a mystery because no physiological inhibitor has been identified. Tryptase exhibits many features not seen in other serine protease, namely i) a tetrameric structure composed of four catalytic subunits, ii) rapid and spontaneous activity loss under physiological conditions, and iii) stabilization by interactions with heparin, a highly sulfated glycosaminoglycan also stored in mast cell granules. These features may function in an integrated manner to regulate the activity of the protease. Studies of the properties associated with activity loss suggest that it is a reversible process involving limited
34
Heparin
conformation changes important to the active site structure of all serine proteases, Physical, kinetic and spectral studies of native tryptase and newly produced recombinant/mutant tryptases are proposed to identify more completely the structural changes production the functional instability of tryptase and to establish the contribution of tetramer dissociation to activity loss. Physical studies will be utilized to establish the affinity and rate constraints for the interaction of tryptase with heparin, and mutational studies will be used to identify the heparin binding site. These studies will establish the structural basis for the intrinsic instability of tryptase and the mechanism by which heparin exerts its stabilizing effects. The rate and affinity constants for the interaction with heparin will define the functional life-time of tryptase after secretion from the mast cell. Understanding the structural properties responsible for the functional instability may provide new targets for therapeutic inhibitors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MICROMECHANICS OF THE EXTRACELLULAR MATRIX Principal Investigator & Institution: Fernandez, Julio M.; Professor; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-JAN-2001; Project End 31-JUL-2002 Summary: (From the applicant's abstract) The extracellular matrix (ECM) is the mechanical scaffold that determines the elasticity and tensile strength of organs and tissues and finely regulates their development by controlling cell adhesion and migration. The ECM is formed by modular proteins and polysaccharides knitted together by self-assembly and through interactions with the cell adhesion receptors of a variety of cell types. Mechanical forces play important roles in ECM assembly and function. ECM fibrils are pre-stretched up to four times their resting length and are thought to translate mechanical forces into biological signals through cryptic binding sites that are exposed by mechanical unfolding. However, nothing is known about the molecular basis of the mechanical extensibility and mechanical signaling of the molecules composing the ECM. The long term aim of this proposal is to determine the force driven conformational changes that allow the ECM molecules to extend under an applied force and turn this force into a cellular signal. Towards this aim we will combine cellular and molecular biological techniques together with state of the art force spectroscopy (AFM) techniques and GFP based fluorescence imaging techniques, capable of observing force driven conformational changes in single molecules. During our first grant period we propose to focus on fibronectin and heparin, abundant molecules which are thought to play crucial mechanical roles in the ECM and have a central function in general animal physiology and pathology. We will use force spectroscopy to examine the mechanical unfolding of native fibronectin and of selected fibronectin modules that are known to play important mechanical roles in matrix assembly. We will engineer recombinant fibronectin proteins designed with specific mechanical properties that then will be transfected into CHO cells for fibronectin secretion and matrix assembly. We will use novel GFP based energy transfer probes in order to measure the resting force per molecule and to determine if unfolding occurs in vivo. We will also use force spectroscopy to detect force driven conformations in matrix glycosaminoglycans, in particular of heparin. We will use GFP probes to examine the binding of fibronectin modules to heparin under a stretching force. Mechanical forces play a critical role in ECM assembly and function. The proposed experiments will investigate, for the first time, the molecular basis of matrix mechanics. The findings may be of great importance for organ and tissue engineering and wound repair. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
35
Project Title: MINORITY PREDOCTORAL FELLOWSHIP PROGRAM Principal Investigator & Institution: Garner, Omai B.; Cellular & Molecular Medicine; University of California San Diego La Jolla, Ca 920930934 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2008 Summary: (provided by applicant): Heparan sulfate is a type of glycosaminoglycan (GAG) characterized by alternating uronic acid and D-glucosamine units (Esko and Lindahl, 2001). Heparan sulfate can be found on a number of cell types in a wide range of species from early metazoans to human cells. The chains are assembled while attached to a core protein, and the composite structure is called a proteoglycan. Heparan sulfate proteoglycans can be membrane-intercalated or GPI anchored, secreted, or stored in granules along with other secretory products (Bernfield et al., 1999). Proteoglycans function in a wide array of cellular activities including signaling, cell adhesion, and migration. T cells produce heparan sulfate(Wilson and Rider, 1991) and it is likely that heparan sulfate plays a critical role in their development and activation. This proposal contains a series of experiments that will examine the structure, assembly, and function of heparan sulfate proteoglycans in T cells. One set of experiments examines the composition of heparan sulfate proteoglycans in different T-cell subsets. A second aim focuses on the effect of inactivating a key heparan sulfate biosynthetic enzyme, GIcNAc N-deacetylase/N-sulfotransferase (NDST) on T cell development and activation. The long range goals of this study are to better understand the function of heparan sulfate in cell biology, which may provide novel targets for pharmacologic intervention in T cell mediated immunity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MIP-1B STRUCTURAL FEATURES RESPONSIBLE FOR FUNCTION Principal Investigator & Institution: Liwang, Patricia J.; Associate Professor; Biochemistry and Biophysics; Texas A&M University System College Station, Tx 778433578 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: (provided by applicant):Long-term objective of this proposal is to understand the structural details of the interaction between the chemokine MIP-Ia and its binding partners, particularly CCR5, its natural receptor. CCR5 is a 7- transmembrane helix receptor that is also used as a co-receptor by HIV in order to gain entry to the cell. I MIP1beta has been shown to block HIV entry to the cell by binding to CCR5, thereby suppressing HIV infection. In Specific Aim 1 a binding surface used by MIP-1beta to interact with CCR5 is hypothesized, and experiments to define the details of MIP-IbetaCCR5 interaction are proposed. In order to elucidate specific properties required for inhibition of HIV, MIP-1beta variants with differing quatemary structure and receptor binding capability will be tested as HIV inhibitors. In Specific Aim 2 NMR structural studies of the interaction between MIP- 113and heparin will be carried out to define the glycosaminoglycan binding surface of MIP- 1131 and to define the quaternary arrangement of MIP-1beta as it binds these sugars. In Specific Aim 3, two strategies will be pursued to investigate possible soluble proxies for the CCR5 receptor. First, X-ray crystallography and NMR spectroscopy will be used to determine the structure of the complex between MIP-1beta. and the virally encoded chemokine binding protein, p35. This will allow both an understanding of this particular complex and may also provide insight on modes of chemokine binding used by the natural receptor CCR5. Second, a novel strategy to investigate the structure of CCR5 is proposed, in which portions of CCR5 are grafted onto a stable scaffold. These three Specific Aims will delineate the
36
Heparin
molecular details of MIP-1beta binding to its biological partners, and will allow the design of specific, tight-binding anti-HIV therapeutics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION GLYCOSAMINOGLYCANS
OF
INTEGRIN
FUNCTION
BY
Principal Investigator & Institution: Strand, Kurt B.; Surgery; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2007 Summary: (provided by applicant): In this three-year fellowship, I plan to define the role of heparin in the modulation of the human platelet integrin. Our principal hypothesis is that heparin binds to the platelet integrin receptor GplIblIIa ((IIb(3), and alters its function. Using recombinant protein expression and functional assays with human platelets, as well as the model system of K562 cells expressing that integrin, I propose to define which integrin subunits are modulated by heparin and whether heparin's action depends exclusively on either subunit. Secondly, I plan to define the mechanisms by which heparin modulates integrin function, by examining receptor conformation and signaling. The laboratories of Dr. Sobel and the Vascular Biology Group at the University of Washington will provide excellent resources and environment to accomplish these goals. My mentoring committee includes leaders in each of the specific scientific fields where I will be acquiring new scientific skills. The experiments in the Aims should clearly show if our hypothesis is correct, and will define the precise structure-function relations and signaling pathways of heparin's interactions with the platelet integrin alphaIIb/beta3. Additional experiments are also anticipated to point to alternative hypotheses if our initial ones are not borne out. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR BASIS OF BLOOD COAGULATION REGULATION Principal Investigator & Institution: Olson, Steven T.; Professor; Molecular Biol/Oral Diseases; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 01-JAN-1994; Project End 31-MAR-2006 Summary: (provided by applicant): The plasma protein, antithrombin, and its glycosaminoglycan activator, heparin, act as essential anticoagulant regulators of blood clotting proteinases. Inherited mutations which cause a loss of antithrombin inhibitory function or which block heparin activation of this function are thus associated with an increased risk of thrombosis. Moreover, complete antithrombin deficiency in man is unknown and produces embryonic lethality in mice. The long term goal of this proposal is to provide a complete understanding of the anticoagulant function of antithrombin and heparin at the molecular level and elucidate their contribution to hemostasis. Our hypotheses are: i) antithrombin's specificity for inhibiting multiple procoagulant proteinases with different substrate specificities arises from secondary interaction sites or exosites outside of the main reactive loop region of the inhibitor used for binding proteinases; ii) three basic residues of antithrombin are principally responsible for binding heparin at an allosteric site through an induced-fit mechanism and the action of these residues is coupled to global conformational changes leading to inhibitor activation; iii) limited conformational changes in or near the 325-375 region which are not essential for inhibitor function are responsible for the expression of the antiangiogenic activity of antithrombin. These hypotheses will be tested by the following specific aims: l) We will elucidate the structural determinants of antithrombin's
Studies
37
specificity for different clotting proteinases and assess how these determinants are expressed upon heparin activation; 2) We will determine the relative importance of antithrombin residues responsible for binding heparin and how they cooperate to induce antithrombin into an activated state with high heparin affinity and rapid reactivity with clotting proteinases; and 3) We will characterize the conformational differences between antithrombin forms with and without anti-angiogenic activity and localize the serpin structure which mediates this activity. These studies will utilize sitedirected mutagenesis together with thermodynamic and kinetic characterization of variant antithrombins to elucidate the relationship between antithrombin structure and function. These studies are expected to increase understanding of natural molecular defects in antithrombin and to provide a rational basis for the design of novel antithrombotic and antiangiogenic agents through the engineering of modified antithrombins or heparin mimetics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR THROMBOCYTOPENIA
BIOLOGY
OF
HEPARIN
ASSOCIATED
Principal Investigator & Institution: Poncz, Mortimer; Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-MAR-2002; Project End 31-JAN-2003 Summary: Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy that involves thromboctyopenia and thrombosis. Platelet Factor 4 (PF4)/heparin complexes are involved in the development of HIT. The studies proposed below will further define the molecular basis of the development of HIT. In addition, we believe that these studies may provide insights into other related disorders, such as the Anti-phospholipid Syndrome, which are also immune-based disorders combining thrombocytopenia and a high risk of developing thrombosis. There are 3 specific aims to this application: I. Characterize the antigenic sites on PF4/heparin involved in HIT. We have clearly shown that there are at least two antigenic sites recognized by HIT antibodies. Using mutant forms of PF4, we have defined one as being immediately adjacent to PF4's Cys36. We have also developed a HIT-like murine (m) monoclonal antibody (MoAb) KKO that recognizes a second site and have used a random peptide phage-display library to define a mimetope for KKO. By using mutant PF4/heparin complexes, HIT-like moAbs, further studies with the random peptide phage-display and NMR studies, we plan to fully characterize the antigenic sites on PF4/heparin. We also plan to determine whether either HIT antigenic sites is linked to the clinical course in HIT. II. Define the immune response in HIT patients. We plan to isolate additional MoAbs and characterize them as described above for KKO. We will also have established a phage-display library from a patient with HIT and thrombosis. HIT-like phage-display clones will be isolated from this library and from libraries to be established from HIT patients without thrombosis and from patients with antiPF4/heparin antibodies who do not develop HIT. The hypervariable regions, isotype utilization and antigen affinity and specificity will be compared to each other. Such studies should provide additional insights into how HIT antibodies develop and lead to disease. III. Use a murine HIT model to characterize risk factors and treatment strategies. We have developed a murine passive immunization HIT model in which we have documented thrombocytopenia, but no obvious thrombosis. We plan on maximizing this system, and then test variables, such as the specific nature of the MoAb, the nature of the platelet Fc receptor and the presence of pre- existing vascular disease, on the development of thrombosis. The model may also allow us to test strategies to
38
Heparin
prevent HIT. Thus, we believe that our proposed studies will not only provide insights into the etiology and progression of HIT, but may provide novel new approaches for its prevention and/or its treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR MECHANISM OF THROMBIN INHIBITION Principal Investigator & Institution: Cooper, Scott T.; Biology; University of Wisconsin La Crosse 1725 State St La Crosse, Wi 54601 Timing: Fiscal Year 2003; Project Start 01-JUN-1997; Project End 31-JUL-2006 Summary: (provided by applicant): The regulation of coagulation is central to many diseases, including heart disease and stroke. The objective of this research is to better understand the different mechanisms by which the serpins antithrombin (AT) and protein C inhibitor (PCI) inhibit free thrombin and thrombin bound to thrombomodulin (TM). Specifically the role of the H-helix, and other predicted contact points between the serpin and TM will be investigated. Previously we made the observation that, unlike AT, PCI is a potent inhibitor of thrombin bound to TM. The heparin binding domains of PCI and AT also differ; in AT the D-helix is a major part of the heparin-binding domain, while the H-helix is the heparin-binding domain in PCI. Alignment of the sequences of PCI, AT and heparin cofactor II (HCII) suggests that AT is unique in having a negatively charged H-helix, while the other serpins have positively charged helices. In recent work we demonstrated that changing the charge of the H-helix of AT makes it behave more like PCI in inhibiting thrombin bound to either heparin or thrombomodulin. The crystal structure of thrombin complexed with TM has recently been solved. This structure was used to generate a molecular model of AT complexed with thrombin and TM to explain kinetic data design new experiments. The first aim of this proposal is to continue to explore the roles of the D and H helices of AT in the inhibition of thrombin in the presence and absence of TM or heparin. The molecular model of a complex between thrombin, TM and AT revealed several other potential contact points between AT and TM, which would not be present between PCI and TM. In addition, the amino terminus of AT contains several more amino acids than does PCI, forming a loop which appears to sterically interfere with TM bound to thrombin. The second aim is to explore the importance of this loop by removing amino acid residues from the center of the loop and assaying the ability of these mutants to inhibit thrombin bound to TM. Another contact point in the complex is between AT residues R259 to R262 and three negatively charged amino acids on TM (E357, D398 and EH00). The third aim is to change these residues and measure the impact on inhibition of thrombin bound to TM The outcome of these experiments will provide a clearer understanding of the different mechanisms by which PCI and AT inhibit thrombin complexed with TM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR REGULATION OF CORNEAL WOUND HEALING Principal Investigator & Institution: Yu, Fu-Shin X.; Associate Professor; Cellular Biology and Anatomy; Medical College of Georgia 1120 15Th St Augusta, Ga 30912 Timing: Fiscal Year 2003; Project Start 01-AUG-1995; Project End 31-JUL-2008 Summary: (provided by applicant): Proper healing of corneal wounds is vital to maintaining a clear, healthy cornea and for preserving vision. The long-term goal of the laboratory has been to obtain basic information about the molecular and cellular biology of corneal wound healing. Recent data demonstrated that epithelial injury induces ectodomain shedding of heparin-binding epidermal growth factor (EGF)-like growth
Studies
39
factor (HB-EGF). Shed HB-EGF, in turn, acts as an autocrine ligand to activate EGFreceptor (EGFR) and subsequent intracellular signaling pathways necessary for regulating corneal epithelial wound healing. The current proposal will test the hypothesis that EGFR ligand shedding is catalyzed by an ADAM (a disintegrin and metalloprotease) in a tightly regulated manner and that EGFR activation by shed HBEGF elicits several intracellular signaling pathways that work in concert to regulate corneal epithelial migration and proliferation. (i) The ADAM that is involved in HB-EGF shedding and EGFR activation in corneal epithelial cells in response to wounding will be identified by antisense oligonucleotide inhibition and by expression of dominant negative (dn) and constitutively active (ca) mutants of four ADAMs. (ii) The mechanisms by which wound-induced HB-EGF shedding and sub-sequent EGFR activation is regulated will be elucidated. The protein kinase (PKC) isozyme involved in the PKC-Raf1-MEK-ERK signaling cascade will be identified using enzymatic assays. Its role in EGFR activation and corneal wound healing will be assessed by expression of dn and ca mutants. (iii) The mechanisms by which each EGFR-elicited signaling pathway participates in the regulation of corneal epithelial wound healing will be investigated. Activation of four such pathways, mitogen activated protein kinase, phosphatidylinositol 3-kinase, phospholipase Cg-protein kinase C, as well as focal adhesion kinase, will be determined using biochemical kinase assays; their cross-talk and contribution to regulation of corneal epithelial migration and proliferation will be assessed using pharmacological kinase inhibitors and ca- and dn-mutant expression. An understanding of the molecular events from signal generation to signal transduction during corneal epithelial wound healing should help in the identification of targets for therapeutic interventions of corneal diseases like recurrent erosions and persistent defects of the epithelium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODELS FOR INTERSTITIAL CYSTITIS Principal Investigator & Institution: Schwarz, Edward M.; Associate Professor; Medicine; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 21-SEP-2001; Project End 31-JUL-2005 Summary: Interstitial Cystitis (IC) is a chronic irritable voiding syndrome of unknown etiology. Urinary frequency, urgency, nocturia, suprapubic pressure, and bladder/pelvic pain characterize this condition and there are no predictably effective treatments. Thus, many suffer with incapacitating symptoms for the rest of their lives. We believe that a small animal model will greatly enhance progress since pathophysiologic mechanisms can be dissected and therapeutic strategies developed in a far more controlled environment than the clinic. A model of IC must display features common to the clinical conditions, including chronicity, key elements of the symptom complex, and common pathophysiologic alterations. One etiologic hypothesis is that an urothelial barrier defect exists permitting urinary constituents unusual access to the tissues of the bladder wall. Whether this is an initiating event or the result of other perturbations is controversial, but most lines of evidence support the existence of a barrier deficiency in the clinical syndrome. To generate a small animal model to test the hypothesis that there is a relationship between a barrier defect and irritable voiding patterns, we have developed quantitative methods to evaluate the interplay of bladder permeability with void volume and frequency in mice. We will monitor plasma fluorescein following intravesical administration to assess the integrity of the bladder permeability barrier. We will use computerized balances to measure void volume and frequency within and across days. We will induce chronic cystitis by continuous
40
Heparin
exposure of the urothelium to agents that disrupt the bladder lining by implanting indwelling bladder catheter in each mouse. This will allow us to determine the relationship between altered bladder permeability and micturition frequency and volume. We will attempt to prevent and/or reverse these chronic barrier defects with several drugs (heparin, pentosan polysulfate and hyaluronic acid) and see what effect they have on permeability and voiding patterns. Finally, we will attempt to generate a transgenic mouse model of IC by targeting the expression of a secreted form of mouse protamine-1 (sMP1) to the transitional epithelium and evaluate these animals in our system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NANOPARTICLE TARGETING TO CONTROL ANGIOGENESIS Principal Investigator & Institution: Davidson, Jeffrey M.; Professor of Pathology; Pathology; Vanderbilt University 3319 West End Ave. Nashville, Tn 372036917 Timing: Fiscal Year 2003; Project Start 22-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): The goal of this project is to achieve targeted delivery of angiostatic agents to sites of neovascularization. This is a widely accepted strategy that is limited in part by technologies of delivery and validation. The proposed studies center around a novel, biocompatible delivery device, the nanoparticle (NP), as a means to provide sustained, targeted delivery of angiostatic agents to sites of angiogenesis: wounds and tumors. The key elements of the delivery system are low toxicity and compositional flexibility, based interactions of charged polymer pairs. As a model system, we have utilized novel peptide analogs of thrombospondin-l (TSP-1) previously shown to have angiostatic properties. To provide retention within NP, these peptides have been prepared as polyethylene glycol conjugates that retain both heparin binding and biological activity. NP prepared with TSP-1 peptide conjugates show a markedly different biodistribution than empty NP and localization to sites of neovascularization. This proposal sets out to accomplish three goals: (1) optimization of the NP formulation, including dose-setting and incorporation of other targeting agents; (2) use of imaging and tracer technologies to ascertain biodistribution of targeted NP in mice; (3) validation of the efficacy of targeted delivery of NP containing angiostatic agents to wounds and tumors. In further studies, a peptide sequence derived from apolipoprotein E will be incorporated into the nanoparticle to enhance selective targeting of endothelial cells. Tumor delivery and targeting will be tested by noninvasive imaging using luciferase bioluminescence, 123I-scintigraphic imaging, and magnetic resonance imaging with gadolinium contrast. Conventional tracer technologies and microscopic localization of fluorescently labeled NP will be applied as well. In vivo, real-time image analysis of tumor vascularity will be determined by power Doppler ultrasound, and tumor mass will be determined by magnetic resonance imaging. In addition, conventional morphometric and histological techniques will be used to quantify the efficacy of this novel drug delivery system. The objective is to design drug delivery systems that will specifically target pathological angiogenesis with minimal effects on the normal vasculature. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NANOSCALE ENGINEERING OF ERODIBLE DRUG DELIVERY MATRICES Principal Investigator & Institution: Furst, Eric M.; Chemical Engineering; University of Delaware Newark, De 19716
Studies
41
Timing: Fiscal Year 2003; Project Start 19-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): The paradigm of modern biomaterials research is the design of materials that can respond to specific stimuli and elicit a desired biological response. The revolution in structural biology toward quantitative understanding of biomacromolecular and cellular behavior offers important information for the rational design of materials with desirable bioactivity. One of the primary goals of this proposal is the assembly of novel, noncovalently crosslinked hydrogel matrices via the interaction between biologically important proteins (such as growth factors) and polysaccharides; the thermodynamics and kinetics of the association will be manipulated to control materials properties and release profiles. The interactions used to control assembly will also permit delivery of the proteins by ligand exchange with cell surface receptors. Exploiting ligand exchange mechanisms as a strategy for delivery and erosion will be relevant to many in vivo processes in which cells overexpress certain receptors, and by this unique coordination of activities, the matrices will find application in the targeted delivery of growth factors for chemotherapeutic, tissue engineering, and wound healing applications. In addition to producing novel materials for macromolecular delivery, this work will also utilize new quantitative approaches for characterizing the mechanical response of these biomaterials on length and timescales that are relevant to cells. New quantitative approaches such as tracer particle microrheology and micromanipulation with laser tweezers will be applied to directly measure microscopic mechanics and relaxation timescales of these hydrogels. When coupled with the synthetic strategies above, these investigations will allow us to understand the specific impact of noncovalent molecular interactions on the structure and rheological properties of hydrogel matrices. This will permit the rational design of microscopic mechanical responses, molecular delivery kinetics, and functionality on length and timescales of cellular processes. The proposed strategies will therefore result in materials in which cellular and polymer responses are coupled, and will broadly impact the development of new biomaterials targeted to specific cellular events. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEW BIOMEDICAL INTERFACE MATERIALS Principal Investigator & Institution: Marchant, Roger E.; Professor of Biomedical Engineering; Biomedical Engineering; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-MAR-1988; Project End 31-MAR-2004 Summary: Cardiovascular biomaterials suffer from well-known problems associated with thrombosis and infection. The surface, or interface, of a biomaterial is one of the most important factors that determines its blood compatibility, or its ability to support growth and normal function of endothelial cells (EC). The proposed studies will focus on new interface materials designed to improve the host response to biomaterials. The objectives are to develop new biomimetic materials based on the central hypothesis that non-covalent physical forces created by a cell's glycocalyx provides the major determining factor in the adsorption and functional state of adsorbed proteins, that controls subsequent cell and molecular interactions. To test this hypothesis, we propose to investigate: (1) Biomimetic materials that mimick non- adhesive properties and anticoagulant functions of EC glycocalyx designed to achieve blood compatibility; and (2) biomimetic materials that mimick adhesive glycoproteins in the extracellular matrix (ECM) designed to facilitate endothelization. The biomimetic materials are designed to undergo irreversible assembly on a range of clinically- relevant biomaterials, and consist of surfactant polymers with pendant oligosaccharides, oligopeptides, and hydrophobic
42
Heparin
ligands. Surface modifications will be characterized by spectroscopic and physical methods, and atomic force microscopy that will permit nanoscale imaging and examination of intermolecular forces. EC-like anticoagulant functions will be achieved through pendant heparin oligosaccharides and bioactive oligopeptides derived from thrombomodulin. The effect of biomimetic modifications on interfacial properties and blood compatibility will be determined from spectroscopic, microscopic, and labeling measurements of protein and platelet-surface interactions under well-defined dynamic flow conditions. ECM-like biomimetic materials will incorporate bioactive oligopeptides derived from EC binding proteins and heparin binding oligopeptides from fibronectin. The adhesion, growth, migration, and shear stability of human ECs will be determined using a laminar flow system at physiologic shear stresses. Cell-surface interactions will be studied by analysis of actin stress fibers and focal adhesion proteins using confocal microscopy. From these studies, we shall determine the mechanisms by which alteration in interfacial properties affects adhesive plasma protein and platelet interactions, and how this correlates to blood compatibility or endothelization. If successful, this research will lead to highly effective biomimetic materials that combine protein resistance and anticoagulant functions; or facilitate stable endothelization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NON-ANTICOAGULANT ODS HEPARIN IN MYOCARDIAL INFARCTION Principal Investigator & Institution: Cardin, Alan D.; Celsus Laboratories, Inc. 12150 Best Place Cincinnati, Oh 45241 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-JAN-2004 Summary: Restoration of blood flow to the ischemic coronary bed initiates the inflammatory process of reperfusion injury, progressive necrosis and apoptosis of myocytes, clinically known as myocardial infarction (MI). Although heparin has broad anti-inflammatory properties, its use as a cardioprotectant is limited by its potent anticoagulant action. A simple process has now been devised employing reductive alkalinization during lyophilization that selectively and quantitatively removes the 2-O and 3- O sulfates necessary for binding antithrombin III, critical for heparin's anticoagulant effect. When given at the time of coronary reperfusion, this novel, nonanticoagulant O-desulfated (ODS) heparin prevents neutrophil influx into the ischemicperfused myocardium, blocks myocyte apoptosis and dramatically reduces infarct size. The ultimate objective is to develop ODS heparin for clinical use to prevent myocyte injury and death in MI. The specific aims of Phase I SBIR will focus on the feasibility of producing GMP quality-drug substance. Pending the successful outcome of these studies, a Phase II SBIR will focus on the scale up of 10 kilos of GMP quality ODS heparin to satisfy the toxicology and PK requirements of an IND submission for its use as a cardioprotectant in MI through Phase II clinical trials. PROPOSED COMMERCIAL APPLICATIONS: Intellectual property: USPTO/EPO with claims to composition, methods of production and use to treat/prevent ischemic reperfusion injury in myocardial infarction (AMI), lung injury & stroke. O-DS heparin is non- anticoagulant, broad-acting anti-inflammatory drug shown to be highly effective in protecting against the irreparable tissue damage caused by reperfusion injury. Use in AMI & stroke alone could exceed $4 billion a year annually worldwide. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
43
Project Title: NON-IMMUNOGENIC PEPTIDE ANTICOAGULANT Principal Investigator & Institution: Farrell, David H.; Professor; Barlow Scientific, Inc. 6307 Tamoshan Dr Nw Olympia, Wa 98502 Timing: Fiscal Year 2003; Project Start 20-AUG-2003; Project End 31-JUL-2004 Summary: We have identified a novel heparin-like peptidyl coagulation inhibitor that is a peptide fragment of a naturally-occurring human fibrinogen isoform, gammaA/gamma' fibrinogen. The peptide is active as an anticoagulant in whole plasma, and is unlikely to elicit an immune response, since it is a normal fibrinolytic cleavage product of this fibrinogen isoform. This application focuses on the development of this peptide as a potential pharmacologic anticoagulant. This peptide anticoagulant would have significant advantages over heparin, and could be used as a general replacement for heparin, particularly when heparin is clinically contraindicated, as in cases of heparin-induced thrombocytopenia. The specific aims are therefore to: I) Express the gamma' chain peptide in a recombinant expression system. II) Assay the recombinant gamma1,' peptide for anticoagulant and anti-platelet activities. At the conclusion of these studies, essential milestones will be achieved for Phase II development of the gamma' peptide as a pharmacologic anticoagulant. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF THROMBOSIS IN HIT Principal Investigator & Institution: Arepally, Gowthami M.; Medicine; Duke University Durham, Nc 27710 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2004 Summary: In applying for the mentored clinician scientist development award, the principal investigator is requesting support for an intensive program of laboratory training under the supervision of Dr. Walter Kisiel, Professor of Pathology at the University of New Mexico Health Sciences Center. The objectives of this proposal are designed to strengthen the applicant's scientific background in the biochemical basis of coagulation and endothelial cell biology, areas essential for an understanding of human thrombotic disorders. The award, if funded, will facilitate the long-term goals of the applicant in developing an independent scientific career in the field of hemostasis and thrombosis medicine. The Candidate and her mentor have developed a career development plan which includes a) assurance of protected research time of 80-90 percent b) a training program exposing the Candidate to new areas of scientific investigation in biochemistry, vascular biology, adhesion receptors, and vertebrate biology c) graduate level studies to reinforce the laboratory experience and d) an advisory panel of established investigators with expertise in disciplines related to the proposal. The studies proposed in this application will extend the applicant's previous work on Heparin-induced Thrombocytopenia (HIT) and Thrombosis (HITT). Lifethreatening thromboses occurs in 10-20 percent of patients who develop HIT. The pathogenesis of thrombosis in HIT remains uncertain. Unlike most other immune mediated thrombocytopenic disorders, antibodies to endothelial cells can be demonstrated in HIT/HITT. It is hypothesized that concurrent platelet and endothelial cell activation is critical for the development of thromboses in susceptible individuals. To study the biological basis by which thrombosis develops in HIT, the following specific aims will be studied: 1) Characterizing the interactions of HITT antibodies with endothelial cells. 2) Defining the biological basis of thrombosis in HITT using murine models. 3) Generation of monoclonal antibodies (MoAbs) to PF4/heparin and functional characterization of PF4/heparin MoAbs with respect to thrombosis. It is expected that
44
Heparin
these proposed studies will contribute to a fundamental understanding of pathogenetic mechanisms for thrombosis in HITT, and lead to future investigations addressing therapeutic interventions in HITT. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC PHARMACOLOGY RESEARCH UNIT NETWORK Principal Investigator & Institution: Adamson, Peter C.; Division Chief; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 191044399 Timing: Fiscal Year 2004; Project Start 07-JAN-1999; Project End 31-DEC-2008 Summary: (provided by applicant): The recent advances in our understanding of the molecular basis for a broad range of pediatric diseases, coupled with the legislative changes culminating in the Best Pharmaceuticals for Children Act, has dramatically increased the potential for defining novel therapeutic approaches for a spectrum of childhood diseases. Further, it provides an important opportunity for improving our understanding of how best to utilize medications currently available for children. The Children's Hospital of Philadelphia (CHOP) has the necessary research infrastructure, patient population, and clinical and laboratory expertise to continue its participation and leadership in the Pediatric Pharmacology Research Unit (PPRU) Network. Under the PI leadership of a Board-certified clinical pharmacologist over the past 4 years, the CHOP PPRU experienced impressive growth both in patient accrual to studies and in the development of industry sponsored trials for Network participation. The CHOP PPRU's recruitment of an internationally renowned population pharmacokinetic modeler further increases the depth and strength of this program. The core laboratory has an in depth experience with state-of-the-art analytical techniques allowing for analysis of a broad spectrum of drugs in biologic matrices, each performed according to FDA's Good Laboratory Practices (GLP) specifications. Novel analytical methodologies developed by the CHOP PPRU will allow for ongoing genotype-phenotype correlative studies. The recent establishment of a proteomics core further expands upon these research capabilities. The CHOP PPRU will continue to emphasize clinical pharmacologic trials in the immunocompromised host, the critically ill infant and child, and in pediatric pain management. Two protocols developed for the PPRU Network, "A Pediatric Phase 1 Trial, and Pharmacokinetic, Pharmacogenetic and Pharmacodynamic Study of Dexmedetomidine" and "A Pediatric Population Pharmacokinetic Study of Heparin: Clinical Utility of Exposure and Biomarkers of Anticoagulation" are proposed and highlight CHOP's PPRU scientific focus. Our expertise in drug analytical methods, pharmacokinetic modeling, pharmacogenomics and proteomics, combined with unparalleled pediatric clinical expertise and access to a diverse pediatric population, assure the continued successful participation of the CHOP PPRU in collaborative Network research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FRONTIERS
POLYMER
MEMBRANE
ION/POLYION
SENSORS:
NEW
Principal Investigator & Institution: Meyerhoff, Mark E.; Professor; Chemistry; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-APR-1981; Project End 31-MAR-2006 Summary: (provided by applicant): The continued development, study, and bioanalytical applications of novel polyion and anion selective polymer
Studies
45
membrane/film-based electrochemical and optical sensors are proposed. Research during the next phase of this long-term project will build upon several significant discoveries/advances made during the most recent project period relating to potentiometric polyion sensing and new chemistries for anion-selective sensors. These include dramatically lowering the detection limits toward biomedically important polyions (e.g., heparin, protamine, etc.) via use of a novel rotating potentiometric membrane electrode configuration, and 2) uncovering a unique hydroxide ion bridged dimer/monomer equilibrium that can exist for certain metalloporphyrins when used as ionophores in organic polymer films for devising anion sensing electrodes. Future efforts will include both fundamental and applied studies in both the polyion and anion sensing areas. Specific goals for the polyion sensor efforts include: a) better understanding the nature (size, stoichiometry, etc.) of the ion-exchanger/polyion complexes that form within the polymer membranes used to fabricate such devices; b) demonstrating broader bioanalytical applications of the new, more sensitive rotating polyion sensing membrane electrode configuration; c) investigating the use of polyion sensors (including rotating arrangement) to detect polycationic dendrimers and their interaction with DNA; and d) further development of a completely new and rapid homogeneous immunoassay method for detecting of small, clinically and environmentally important analytes using polyions as labels. In the area of anion sensors, efforts will focus on establishing which metalloporphyrins can spontaneously form hydroxide ion bridged dimer structures within polymeric films, and determining how these reactions affect the response properties of anion selective electrodes formulated with such ionophores. In addition, studies will be undertaken to utilize this novel chemistry to devise completely new polymer film-based optical sensors for anions and neutral species (amines, gases, etc.) based on the ability of such ligating species to break metalloporphyrins dimers into monomers within the organic films, yielding a large shift in the lambdamax of the Soret band. Investigations of electrochemical anion sensors based on a new type of lipophilic dendntic anion-exchanger structure are also proposed. It is anticipated that this research will continue to provide the analytical community with a wide array of new and/or improved chemical sensors as well as novel sensor-based methods that will have immediate applications as tools for basic research and within modem clinical and environmental test instrumentation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITION
POLYURETHANE
CALCIFICATION:MECHANISM
AND
Principal Investigator & Institution: Levy, Robert J.; Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 191044399 Timing: Fiscal Year 2002; Project Start 01-AUG-1997; Project End 31-JUL-2005 Summary: Polyurethane calcification and associated thrombosis remain major obstacles hindering the long term use of polyurethanes in prosthetic valves and ventricular assist systems. Progress in the past three years of this Program has successfully addressed the initial goals of this Program by elucidating the mechanisms of polyurethane calcification and creating synthetic methodology involving hard segment activation to modify (either in bulk or on the surface) already polymerized polyurethanes. Thus, we have created polyurethanes with covalently attached bisphosphonates as effective anticalcification agents. In the Program Continuation, we will address inhibiting thrombus deposition on polyurethane, and thrombus related calcification Aim 1. To derivatize polyurethane with heparin in order to confer relative thrombo-resistance. It is hypothesized that this modification will both reduce platelet-fibrin thrombus build up and retard the
46
Heparin
development of thrombus associated calcification. Aim 2. Polyurethanes modified with tethered gene vectors to provide local fibrinolysis. This aim will be concerned with modifying the polyurethane surfaces to enable gene transfer of an antibody immobilize gene vector encoding for tissue plasminogen activator (tPA), in order to bring about local fibrinolysis. It is hypothesized that fibrinolysis will help to reduce thrombus buildup. Aim 3. Semilunar cusp replacements combining bisphosphonate, heparin, and local gene therapy to over-express tPA. It is hypothesized that our combined therapeutic modifications to prevent polyurethane cuspal calcification and retard thrombosis, will provide optimal pharmacologic synergy in a sheep pulmonary cusp implant model of polyurethane calcification. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING Principal Investigator & Institution: Chung, Leland W.; Professor and Director; Urology; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2003; Project Start 17-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): This multi-institutional Program Project from the Emory University School of Medicine focuses on the elucidation of the biology and molecular pathways involved in the interaction between stromal cells of the bone or the prostate and malignant prostate cancer cells. The overarching theme of this Program Project is that prostate cancer cell interaction with its microenvironment determine tumor growth, invasion, and metastasis in an organ-specific manner. This is manifested in clinical prostate cancer bone metastasis where the proliferation of both tumor epithelium and surrounding bone osteoblasts are accelerated. By understanding the molecular basis of this interaction, novel therapeutic targeting strategies can be developed to treat prostate cancer bone metastasis. This Program Project comprises of 3 Projects and 3 Cores and is organized to achieve synergy among the individual scientists who already have an established track record of prior research collaborations. Specific areas of investigation are: Project 1-Chung: the analysis of extracellular matrix (ECM) and integrin interaction in prostate cancer growth and metastasis; Project 2-FarachCarson: the assessment of the roles of heparan sulfate proteoglycan (HSPG), heparin binding (HB) growth factors and their receptors in prostate cancer bone metastasis; Project 3-Petros: the determination of the effect of mitochondrial DNA (mtDNA) mutations on prostate cancer growth and metastasis, with specific focus on the antiapoptotic function of mtDNA mutations in prostate cancer cells. Each of the projects has its own targeting theme and collaboratively will interact and achieve the goal of developing mechanism-based rational therapeutic approaches for the treatment of prostate cancer bone metastasis. This Program Project is supported by three Cores: the Administrative and Biostatistical Core A-Chung, the Animal and Tissue Culture Core BMartin and the Pathology and Laboratory Support Core C-Amin. The ultimate goal of this Program Project is to develop novel diagnostic, prognostic and treatment modalities based on a mechanistic understanding of prostate tumor and prostate and bone stroma interaction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROSTATE CANCER-BONE INTERACTION--SECRETION OF EGFR Principal Investigator & Institution: Freeman, Michael R.; Director; Children's Hospital (Boston) Boston, Ma 021155737
Studies
47
Timing: Fiscal Year 2002; Project Start 05-JUN-1998; Project End 31-MAR-2004 Summary: A common feature of advanced prostate cancer is metastasis to vertebral bone. Once metastasis to bone is evident, disease progresses rapidly and is almost uniformly fatal. Dissemination of malignant cells frequently occurs prior to diagnosis, and up to 25% of patients have bone metastases at the time of presentation. The mechanisms of tumor cell arrest in bone, proliferation at bony sites, and bone tissue destruction in prostate cancer ar poorly understood. In the proposed experiments, the principal investigator wil use a novel and highly sensitive bioassay, along with other methods, to determine to role of FGF-2 (basic fibroblast growth factor), and possibly othe bone-derived factors, in regulated cleavage-secretion from prostate carcinoma cells of the epidermal growth factor receptor (EGF-R) ligands, heparin-binding EGF-like growth factor (HB-EGF) amphiregulin and transforming growth factor-alpha (TGFalpha). Dr. Freeman presents preliminary data that FGF-2 activation of the extracellular signal-regulated kinase/mitogen activated protein kinase (ERK-MAPK) pathway mediates cleavage-secretion of HB-EGF from prostatic tumor cells. The specific aims are: Specific Aim 1: Determine if FGF-2 increases HB-EGF synthesis and secretion in human prostate adenocarcinoma cells by an extracellular signal-regulated kinase(ERK-MAPK-) dependent mechanism. Specifi Aim 2: Determine if FGF-2 isolated from extracellular bone matrix mediates cleavage-secretion of HB-EFG by an ERK-MAPKdependent mechanism. Determine if FGF-2 is the only heparin-binding factor in bone matrix capable of regulating cleavage-secretion of HB-EGF. Determine if osteoblasts secrete an activity capable of mediating secretion of HB-EGF. Specific Aim 3: Determine if cleavage-secretion of the EGF-R ligands, TGFalpha and amphiregulin, is regulated by FGF-2, factors derived from extracellular bone matrix, and osteoblast secretions in a similar fashion to cleavage-secretion of HB-EGF. Specific Aim 4: Determine the effect of endogenous proHB-EGF, proamphiregulin and proTGFalpha synthesis by Pca cells on metastasis to bone. These studies will expand our understanding of the pathways regulating activation of the EGF-R in prostate adenocarcinoma cells generally, and specifically within the bone microenvironment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEINS AS SIGNALS IN UROTHELIAL CELL PROLIFERATION Principal Investigator & Institution: Bassuk, James A.; Research Scientist; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, Wa 98105 Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Understanding how the urothelium grows and differentiates is central to understanding a number of bladder diseases. Being able to modulate these processes would allow us to improve treatment of urinary tract abnormalities in children and adults. Preliminary evidence in our laboratory suggests that Fibroblast Growth Factor (FGF)-10 plays an important role in regulating DNA synthesis of urothelial cells, a crucial process involved in control of growth, differentiation, and repair of the urothelium. This process is described by a complex network of paracrine action that originates in the mesenchyme but acts on the urothelium. Disruption of this process in FGF10-null mice alters the differentiation of bladder urothelial cells and results in an abnormal transitional epithelium typified by incomplete stratification. Other processes involved in the control of growth and differentiation of the urothelium include cytokines and growth factors of various types. We propose to attack the FGF-10 part of these processes because a) nothing is known about the biology of FGF-10 in the bladder and b) an understanding of how FGF-10
48
Heparin
works in conjunction with these other processes will allow us to develop new and innovative methods to strengthen our translational approach to the problem of bladder and urinary tract disease. In order to achieve these goals, we have established specific aims for this period of support to better understand how FGF-10 functions in the context of a dynamic steady-state interrelationship that stimulates the progression of the urothelial cell cycle. Two mechanisms for how FGF-10 triggers proliferation are hypothesized: 1) the translocation of FGF-10 into urothelial cell nuclei and 2) a signalling cascade that begins with the heparin-dependent phosphorylation of tyrosine residues of surface receptors. We propose that negligible levels of FGF-10 define the normal urothelial phenotype -that of quiescence. During proliferative phases, levels of FGF-10 rise at the urothelial cell surface and/or within urothelial cell nuclei. Since our preparations of recombinant FGF-10 induce urothelial cell proliferation in animals, we eventually plan to evaluate the feasiblity of FGF-10 therapy in repairing the urothelium in clinical settings such as urethral trauma stricture disease and trauma. This study of the basic mechanisms of action will set the stage for later clinical use. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF SEQUENTIAL PROTEIN KINASE PATHWAYS Principal Investigator & Institution: Johnson, Gary L.; Professor and Chair; Pharmacology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-SEP-1988; Project End 31-MAY-2003 Summary: (provided by applicant): Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases that are activated by diverse stimuli ranging from cytokines, neurotransmitters, hormones, cellular stress and cell adherence. The basic assembly of MAPK pathways is a three-component module conserved from yeast to humans. The MAPK module includes three kinases that establish a sequential activation pathway comprising MAPK kinase kinase (MKKK), MAPK kinase (MKK), and MAPK. Currently, the mammalian MAPKs can be subdivided into five families: ERK1/2, p38alpha, Beta, Gamma, delta, JNK1 ,2,3, ERK3/4 and ERK5. Each family of MAPKs has distinct biological regulatory functions. The number of different MKKKs in MAPK modules allows for a diversity of inputs capable of activating specific MAPK pathways. The hypothesis that is the foundation of the research described in this proposal is that multiple MKKKs regulate common MKK/MAPK modules. MKKKs are differentially regulated by upstream signals allowing common MAPK pathways to be selectively regulated by the specific MKKK within the MAPK module. The composition of MAPK modules involves scaffolding proteins and interaction domains encoded in each MKKK, MKK and MAPK. The targeted gene disruption of each MKKK will therefore have a selective loss in the regulation of MAPK pathways in response to a set of specific stimuli. The phenotypic consequence of specific MKKK gene disruptions will therefore have unique defects in cellular regulation. My laboratory first cloned four of the MKKKs referred to as MEKK1, 2, 3 & 4. MEKKs regulate the JNK pathway. MEKK2 and 3 also regulate the ERK5 pathway. Targeted gene disruption of MEKK1, 2, 3 & 4 by homologous recombination has been completed. The MEKK1, 2 and 3 knockouts have unique phenotypes, signaling defects and pathologies. MEKK4 knockout is being characterized. MEKK1-/- animals have defects in cytokine expression, protease regulation and organ homeostasis. MEKK2-/- animals have immune defects with loss of cytokine expression and deficient T cell migration to lymph nodes. MEKK3-/- embryos die at day E4-7 and are postulated to have defects in trophoblast signaling in response to FGF4 or HB-EGF (heparin-binding EGF). Specific aims include: define the
Studies
49
pathophysiology of mice having the targeted disruption of MEKK genes, define the signaling and functional abnormalities in cells deficient for each MEKK, and characterize the function of scaffold proteins we cloned that bind MEKK2 & 3. Cumulatively, the studies are defining the role of MEKKs in the control of physiological processes including wound healing, cardiac hypertrophy, lung inflammation, immune response and signaling controlling embryo development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF SMOOTH MUSCLE PROLIFERATION Principal Investigator & Institution: Patel, Rekha C.; Biological Sciences; University of South Carolina at Columbia Byrnes Bldg., Room 501 Columbia, Sc 29208 Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from Investigator's Abstract): Vascular disease, which is the principal cause of heart attack, stroke and circulatory deficit disorders, is responsible for 50 percent of all mortality in the western world. Proliferation of vascular smooth muscle cells (VSMCs) is a key step in the pathogenesis of atherosclerosis and restenosis after vascular interventions such as angioplasty. Much attention has been focused on the search for an antiproliferative agent to regulate smooth muscle proliferation. Interferons (IFNs), which are cytokines secreted by the immune cells present in the atherosclerotic lesion, have been show to be antiproliferative towards VSMCs. Natural glycosaminoglycans such as heparin are also known to inhibit smooth muscles. Heparin is used widely as one of the local-delivery drugs after invasive procedures. In spite of the well-documented antiproliferative effects of IFNs and heparin on VSMCs, the molecular mechanisms that are involved have not yet been identified. PKR (protein kinase, RNA activated) is an IFN induced, growth inhibitory protein kinase, which is activated by double stranded (ds) RNA in virus-infected cells. PKR's role in regulation of cell proliferation has become clear in recent years. It's over expression or activation has been shown to be growth inhibitory. PKR is also activated by heparin in vitro and our results indicate that treatment of VSMCs with heparin results in activation of PKR. PKR is also induced at the transcriptional level by IFN treatment of VSMCs We hypothesize that, PKR is involved in mediation both heparin and IFN's antiproliferative effect towards VSMCs. We propose to test this with the following specific aims: 1. To investigate the role of PKR in the antiproliferative action of heparin and IFN on VSMCs. 2. To characterize the functional domains of PKR involved in mediating heparin's antiproliferative effect. The long-term goal of this proposal is to elucidate the molecular mechanisms involved in the inhibition of VSMC grown by heparin and IFN thereby offering on opportunity to design better ways of controlling the vascular diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATORY ROLES OF LACTOFERRIN IN HEMOSTASIS Principal Investigator & Institution: Wu, Haifeng M.; Pathology; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2002; Project Start 01-APR-1995; Project End 31-MAR-2004 Summary: Lactoferrin is a prominent component of neutrophil secondary granules and can be released when neutrophils are activated. The concentration of lactoferrin in blood has been demonstrated to be increased in certain inflammatory diseases. In contrast to a well described biochemical characterization of lactoferrin as an iron-binding protein, its physiological role in the regulation of inflammation and other host defense mechanisms is unclear. The current proposed study will test three hypotheses: (i) lactoferrin derived
50
Heparin
from neutrophils is an important physiological mediator in the down-regulation of blood anticoagulation; (ii) the significant elevation of lactoferrin in blood, or at sites of inflammation can contribute significantly to the development of prothrombotic sequelae as seen in the disseminated intravascular coagulation (DIC) associated with bacterial infections; and (iii) the structural determinant(s) of lactoferrin involved in heparin binding is located within a specific sequence (residues 25-31) of the N-terminus. Thus, specific aims of this proposal are: (1) to determine the relationship between the elevation of plasma lactoferrin and the development of prothrombotic complications in patients with bacterial infections. The plasma lactoferrin concentration in patients with DIC resulting from different underlying diseases or with different inflammatory diseases will be examined; (2) to define the structural determinant(s) of lactoferrin involved in heparin binding. Both site- specific and domain-replacement mutagenesis will be used to determine the contribution of N-terminal basic residues (25 to 31) in heparin binding; (3) to study the activity of lactoferrin in the regulation of protein C anticoagulant pathway. Both the effect of lactoferrin on the generation of activated protein C and the specific binding of lactoferrin to chondroitin sulfate moiety of thrombomodulin will be examined. The completion of these studies will enable us to understand the biological role of lactoferrin in the regulation of inflammation and blood coagulation, and will provide new scientific background for the clinical evaluation and management of infectious diseases with thrombotic complications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITY Principal Investigator & Institution: Heit, John A.; Professor; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: This is a study of genetic and environmental determinants of venous thromboembolism (VTE) in the Rochester Minnesota Olmsted County population. The specific aims of the study are: 1) to update the 1966-95 inception cohort to include Olmsted County residents with VTE during the five year period, 1996-2000; 2) to extend the analysis of risk factors for VTE by identifying two Olmsted County residents (controls) without VTE matched by age and gender to each definite or probable case within the 1996-2000 cohort, and to obtain plasma and genomic DNA from all cases and controls and perform a case-control study to test the hypothesis that first specific diseases are related to VTE and mutations of the factor five and prothrombin are independent risk factors for VTE in the community; and interactions between environmental and genetic factors. They will determine the population attributable risk for VTE associated with each risk factor, both individually and collectively for all significant risk factors. They will then compare two Olmsted County residents who received major surgery without developing VTE matched by date and type of surgery to a case with VTE within three months after surgery in order to look at risk factors related to surgery and genetic markers. They will do a similar analysis this time using two Olmsted County residents who were hospitalized for medical illness without developing VTE matched by gender and date of hospitalization to a case who developed VTE within three months after hospitalization and perform a case-control study to test the hypothesis again that risk factors and genetic markers are associated with elevation of risk of VTE. Finally, the investigators will plan to extend their analysis of current VTE in relationship to use of standard heparin and low molecular weight heparin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: RNA APTAMER-DIRECTED ANTICOAGULANT THERAPY Principal Investigator & Institution: Fortenberry, Yolanda M.; Pathology and Lab Medicine; University of North Carolina Chapel Hill Aob 104 Airport Drive Cb#1350 Chapel Hill, Nc 27599 Timing: Fiscal Year 2004; Project Start 01-JAN-2004; Project End 31-DEC-2006 Summary: (provided by applicant): Historically, unfractionated heparin has been used in the treatment and prevention of thromboembolic disorders. However, due to complications associated with heparin (such as bleeding), low molecular weight heparins (LMWHs) have been developed and are being used in place of unfractionated heparin. LMWHs have proven effective as antithrombotic agents; however, the effects of LMWHs cannot be readily reversed while unfractionated heparin can be reversed by protamine sulfate. The overall goal of this proposal is to develop an antithrombin (ATIII)-specific RNA aptamer that will combine the safely and efficacy of LMWH with the reversibility of unfractionated heparin. To accomplish this goal, an oligonucleotide antidote for this aptamer that will be used to rapidly reverse the anticoagulant properties of the aptamer will be developed. Proof of this concept is established by the development of an RNA aptamer and RNA aptamer antidote directed against coagulation factor Xa. In collaboration with this group, an antidote-controlled ATIIIspecific RNA aptamer will be developed. This aptamer will mimic the action of LMWH by binding to the D-helix of ATIII and enhance ATIII inhibition of factor Xa. This aptamer/antidote pair will have advantages over LMWHs because it will not only be able to control thrombosis similar to LMWHs but the availability of an antidote will allow for better therapeutic regulation and intervention. The experiments proposed in this proposal will characterize this family of antithrombin-specific RNA aptamers using both in vitro and in vivo approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE Principal Investigator & Institution: Gallay, Philippe A.; Assistant Professor; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2002; Project Start 15-FEB-2001; Project End 31-JAN-2004 Summary: Host cyclophilin A (CypA) is essential for the replication of the human immunodeficiency virus type 1 (HIV- I) and thus represents an attractive target for the elaboration of new anti-viral therapeutic agents to combat AIDS pathogenesis. Despite intense interest in the involvement of CypA in HIV- I replication, its precise role in the virus life cycle has yet to be elucidated. Our recent work suggests that CypA is exposed at the viral surface and is necessary for the initial step in HIV- I infection - the virus attachment to target cells. We demonstrated that CypA-deficient viruses do not replicate because they fail to attach to target cells. We showed that CypA is exposed at the viral membrane and mediates HIV- I attachment. We identified heparan suiphates (HS) as the exclusive cellular binding partner for CypA. Furthermore, we found that CypA binds directly to heparan via a domain rich in basic residues similar to known heparinbinding motifs. Finally, we showed that this interaction between exposed CypA and cell surface heparans represents the initial step of HIV- I attachment and is a necessary precursor to gp12O-binding to CD4. Our objective is to further understand the precise mechanistic role of CypA in the HIV-l life cycle in order to develop novel anti-HIV-l therapies. We propose to pursue the following aims: 1) to identify and characterize cell surface heparan sulfate proteoglycans necessary for CypA-mediated HIV- I attachment to target cells; 2) to define the events that control both the release of CypA from Gag and
52
Heparin
its relocation to the viral surface; and 3) to determine the direct participation of exposed CypA and/or other virus-associated proteins in HIV- I attachment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF GLYPICAN-1 IN PANCREATIC CANCER Principal Investigator & Institution: Korc, Murray; Chair, Department of Medicine; Medicine; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2004 Summary: (provided by applicant): Pancreatic ductal adenocarcinomas (PDACs) overexpress multiple tyrosine kinase receptors such as the type I FGF receptor (FGFR-1), and their ligands. Many of these ligands are heparin-binding growth factors (HBGFs), whose mitogenic actions are often dependent on interactions with heparan sulfate proteoglycans (HSPGs) that facilitate ligand binding to high affinity receptors. We have determined that PDACs overexpress glypican-1 but de not express high levels of other 5 members of the glypican family, raising the possibility that glypican-1 may have a unique and important role in PDAC. However, the exact role of glypcian-1 in PDAC and its mechanisms of action are not well understood. Therefore, we will use 4 complementary approaches to test the hypothesis that glypican-1 is of paramount importance in PDAC and that it acts by promoting mitogenesis, invasion and/or metastasis. We will first examine whether glypican-1 expression correlates with tumor grade and stage, or patient survival. Second, we will establish pancreatic cancer cell lines that overexpress glypican-1, as well as cell lines whose glypican-1 expression is suppressed by a glypican-1 antisense construct, in order to assess the role of glypican-1 in cancer cell growth, invasion, and metastasis in appropriate in vitro and in vivo model systems. Third, we will determine whether any tumorigenic effects of glypican-1 are enhanced by the presence of the type I fibroblast growth factor receptor (FGFR-1), since this receptor is overexpressed in PDAC and is activated by multiple HBGFs. To this end, we will transfect cultured human pancreatic ductal cells with cDNAs encoding glypican-1 in the absence or presence of the two major FGFR-1 isoforms. Fourth, we will explore the mechanisms whereby glypican-1 confers a growth advantage to cultured pancreatic cancer cells by examining its glycanation status and its interactions with FGFR complexes, and by engineering various glypican-1 chimeric proteins and comparing their actions with the actions of wild type glypican-1. Together, these studies will help to elucidate the role of glypican-1 in PDAC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SMALLPOX VIRULENCE AND COMPLEMENT REGULATORY PROTEINS Principal Investigator & Institution: Atkinson, John P.; Professor of Medicine & Molecular Biolog; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008 Summary: Public health concems have emerged regarding use of smallpox as a bioterrorist weapon since most Americans are no longer immune. Poxviruses subvert the complement system via the expression of regulatory proteins. In variola, vaccinia and ectromelia, the proteins are called SPICE (for smallpox inhibitor of complement enzymes), VCP (vaccinia virus complement control protein) and EMICE (an uncharactedzed analog in ectromelia that we have labeled "ectromelia inhibitor of complement enzymes"). These secreted virulence factors down-regulate complement activation by mimicking the functional repertoire of a family of host proteins called the
Studies
53
Regulators of Complement Activation (RCA). The viral proteins are also structurally related to their host counterparts. Specific Aims: 1. To characterize the complement inhibitory profile of SPICE compared to its human counterparts. We will identify the principal complement-evading activity of SPICE and this will become a target for neutralization. These assessments will take place with the native soluble protein as well as after it attaches to cells via either its heparin-binding site(s) or by addition of an anchor. 2. To determine the complement regulatory sites of SPICE. These experiments will take advantage of the functional profiles (defined in Aim 1) and the sequences of active sites of RCA proteins that are homologous to corresponding regions of SPICE, VCP, and EMICE. These two sets of data provide a logical strategy for a mutational analysis to locate the active sites. 3. To characterize the complement regulatory activity of EMICE. This mousepox protein has not been evaluated for its complement inhibitory (virulence) activity. It is about 90% identical to SPICE and VCP. We will first characterize its regulatory activity for human and mouse complement. Second, we will assess its role in vivo as a virulence factor by infecting sensitive and resistant mouse strains with the ectromelia virus deleted of its complement regulator. The proposed experiments should provide novel information relative to the pathogenesis of poxvirus infections of man and mouse. Additionally, these results will serve as a guide to produce a less toxic small pox vaccine and to identify a viral target for mAb treatment of variola infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL APOLIPOPROTEIN E
BASIS
OF
THE
INTERACTIONS
OF
Principal Investigator & Institution: Lund-Katz, Sissel C.; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 191044399 Timing: Fiscal Year 2002; Project Start 01-JAN-1997; Project End 31-JUL-2005 Summary: (provided by applicant): The overall objective is to gain a more complete understanding of the structure of apolipoprotein (apo) E, especially as it relates to the ability of the protein to bind to heparin, the low density lipoprotein receptor (LDLR), and lipid particles of different size. Point mutations are known to give isoforms of apo E that function abnormally in cholesterol and triglyceride transport. A range of engineered apo E molecules expressed in E. coli is being used to address 3 specific aims. 1) To understand how interaction with phospholipid changes the conformation of apo E so that it can bind to the LDLR. The hypothesis being tested is that changes in alphahelix organization alter the basic residue microenvironment in the LDLR binding domain (residues 136-150) which affects high affinity binding. NMR spectroscopy is used to monitor the microenvironments of lysine residues, and fluorescence and infrared spectroscopic methods are used to monitor the organization of apo E amphipathic alpha-helices in lipid-protein complexes. 2) To determine the type and organization of basic amino acids required in the apo E molecule for binding to heparin as opposed to the LDLR, and to understand why lipidation is required for binding of apo E to the LDLR but not for binding to heparin. The molecular mechanisms underlying changes in the energetics of binding arising from apo E polymorphism will also be investigated. 3) To understand the mechanisms responsible for the differing affinities of apo E isoforms for variously-sized serum lipoprotein particles, the molecular and thermodynamic parameters characterizing the binding of apo E and engineered variants to lipid particles of different sizes will be studied. The hypothesis being tested is that the length and properties (including the hydrophobicity of the nonpolar faces and the distribution of charged residues in the polar faces) of
54
Heparin
amphipathic alpha-helical segments in the C-terminal of the apo E molecule control lipid binding. Overall, achievement of these 3 aims will generate novel quantitative information about the ways in which apo E structure and polymorphism affect the functional properties of the protein in both physiological and pathological conditions. The design of ways to control the aberrant behavior of certain isoforms of apo E will be facilitated by this understanding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDIES OF HERPES SIMPLEX VIRUS GLYCOPROTEINS Principal Investigator & Institution: Cohen, Gary H.; Professor and Chair; Microbiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 30-SEP-1981; Project End 31-MAY-2005 Summary: (Adapted from the Investigator's abstract) For the two herpes simplex viruses (HSV-1 and HSV-2), four glycoproteins designated gB, gD and a complex of gH/gL are essential for virus entry. A fifth glycoprotein, gC, though not essential, is important for facilitating initial attachment by binding to cell surface heparin sulfate proteoglycans. gD triggers entry by interacting with one of several different cellular receptors. gB and gH/gL are necessary for fusion of the envelope with the plasma membrane. The longterm objective of the research efforts of Drs. Cohen and Eisenberg is to understand the mechanism by which these glycoproteins interact with each other and with cell molecules to mediate HSV entry. Within this proposal, they propose three specific aims: 1) to study immunological and biochemical properties of soluble gD, alone or in combination, with two of its receptors, HveA (a TNF receptor) or HveC (an adhesion molecule in the Ig superfamily); 2) to study the gD-receptor interaction when either the ligand or the receptor (or both) is membrane bound; and 3) to study events in virus entry that occur as a consequence of gD-receptor interactions. The investigators suggest that downstream interactions of the virus with the plasma membrane may involve gB and gH/gL of the virus and may additionally involve other cellular molecules. They have cloned the ectodomains of gD, gB, gH/gL, HveA and HveC into a baculovirus expression system and/or mammalian cells and have expressed and obtained purified proteins. In Aim 1, they will use these proteins to solve the structure of gD alone and/or in combination with receptor and/or antibody by X-ray diffraction analysis. They will map antibody and receptor binding domains on gD and look for conformational changes in gD that occur as a result of receptor binding. In Aim 2, they will use quantitative assays that present gD or its receptor in the context of a membrane and study the interaction of the other protein as a soluble form. One approach will be to bind HSV to an ELISA plate and then determine if added soluble receptor inhibits the infection of cells that are added in fluid phase. Such studies will indicate that they are evaluating receptor binding to a viable virus. In a second approach, they will bind virions to a biosensor chip and flow soluble receptor across the chip to measure receptor-virus interactions. A third approach will be to express the receptor in the murine leukemia virus (MuLV)-receptor pseudotype system and use these particles to study binding of gDt. In Aim 3, they will look for interactions among soluble forms of gD, gB and gH/gL in the presence and absence of gD receptors. In addition, they will study a series of gD/gH hybrid molecules for their ability to function in HSV infection in place of gD or gH/gL. Finally, they will study mutant forms of HSV including those that no longer require HveA or HveC for entry. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
55
Project Title: STUDIES ON THROMBIN ALLOSTERY Principal Investigator & Institution: Di Cera, Enrico; Professor; Biochem & Molecular Biophysics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 01-DEC-1994; Project End 31-JAN-2004 Summary: Our laboratory has discovered the Na+-dependent allosteric enhancement of catalytic activity in thrombin and related serine proteases involved in blood coagulation and the complement system, identified the Na+ binding site and elucidated the importance of Na+ binding in the function and evolution of serine proteases. The proposed research project is aimed at gaining a complete functional and structural characterization of thrombin allostery and how it influences recognition of physiological substrates, effectors and inhibitors. We will use a combination of kinetic, mutational and structural studies to identify regions of the enzyme that are under the influence of Na+ binding and constitute the structural scaffold through which the Na+ site communicates changes of functional significance to binding epitopes for physiological ligands. We will determine what regions of the enzyme are involved in recognition of fibrinogen, protein C, the thrombin receptor PAR1, thrombomodulin, heparin and anti- thrombin III with unprecedented detail. The new information to emerged from the proposed studies will broaden our understanding of thrombin interactions in the blood and will enable the identification of molecular targets for new anti-coagulants. We will also exploit the knowledge gained on thrombin allostery to introduce Na+ binding and enhanced catalytic activity in the fibrinolytic enzyme tissue plasminogen activator. These mutational studies will produce more proficient derivatives of the enzyme that may benefit the current treatment of acute myocardial infarction and stroke. Developments from the proposed research plan will impact on the treatment and prevention of thrombotic disorders in which thrombin is directly involved, will have a broad impact on the study of allosteric proteins in general and will demonstrate that proteases with enhanced catalytic activity can be engineered rationally to benefit areas of medical and biotechnological importance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SYNDECAN AND BACTERIAL TRANSLOCATION IN SHOCK AND TRAUMA Principal Investigator & Institution: Wells, Carol L.; Professor; Lab Medicine and Pathology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2007 Summary: (provided by applicant): Normal enteric bacteria, such as Escherichia coli and Enterococcus faecalis, frequently cause complicating infections in patients with shock and trauma. A common finding in these patients is increased intestinal epithelial permeability, and experiments with cultured enterocytes have shown that bacterial adherence to and internalization by enterocytes is increased following opening of enterocyte tight junctions, exposing the enterocyte lateral surface. Syndecan-1, expressed on the basolateral surface of human enterocytes, is a cell surface transmembrane proteoglycan that expresses heparan sulfate (HS) on its extracellular domain. Our working hypothesis is that HS chains of cell surface proteoglycans, and specifically syndecan-1, may act as an enterocyte receptor or co-receptor for a variety of enteric bacteria. Preliminary data indicated that,like human enterocytes, HS and syndecan-1 are prominently expressed on the basolateral surface of cultured HT-29 enterocytes but not Caco-2 enterocytes. Experiments with HT-29 enterocytes (designed to open enterocyte
56
Heparin
tight junctions and interfere with bacterial binding to the HS chains on syndecan-1) suggested that HS may be a receptor for gram-positive but not gram-negative bacteria. The HS analog heparin, and HS itself, inhibited adherence and internalization of grampositive Listeria monocytogenes by HT-29 enterocytes, and experiments with related glycosaminoglycans indicated that this inhibition was specific for HS. Additional preliminary experiments with HT-29 enterocytes indicated that heparin and HS similarly inhibited internalization of gram-positive E. faecalis and Staphylococcus aureus, but not gram-negative Salmonella typhimurium, Proteus mirabilis, and E. coli. Heparin did not have a noticeable effect on internalization of any bacterial species using Caco-2 enterocytes, which express low levels of HS and syndecan-1 Other preliminary experiments indicated that heparin-treated L. monocytogenes was less invasive in orally inoculated mice than was untreated L monocytogenes. In this proposal several experimental tools are used to clarify the interactions of cultured enterocytes with a variety of gram-negative bacteria, while focusing on gram-positive L. monocytogenes, E. faecalis, and S. aureus. These tools include monoclonal antibodies, glycosamino glycans, and heparin disaccharides, and two cell lines transfected to over express syndecan-1, namely ARH-77 myeloma cells and Caco-2 enterocytes. Data from in vitro studies are used to design experiments in mice (outbred and syndecan-1 knockout) to clarify the role of HS and syndecan-1 in intestinal colonization and extra intestinal dissemination of enteric bacteria. Data from these experiments may indicate that enterocytes have a receptor (related to cell surface HS and perhaps syndecan-1) involved in adherence and internalization of a variety of gram-positive bacteria including E. faecalis and S. aureus. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE ROLE OF HEPATIC LIPASE IN CHOLESTEROL HOMEOSTATIS Principal Investigator & Institution: Dichek, Helen L.; Pediatrics; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-MAY-2006 Summary: The enzyme hepatic lipase (HL) is central to cholesterol homeostasis. HL participates in the regulation of plasma cholesterol levels, a major risk factor for atherosclerosis. It also mediates steroid hormone production, by controlling access to exogenous cholesterol in steroid-producing tissues. In turn, increased production of the adrenal steroid cortisol (corticosterone in mice) as occurs in stress, depression and certain tumors of adrenal and pituitary origin, modulates the development of atherosclerosis: increased cortisol levels are linked to an increased risk for atherosclerosis. However, HL's precise role in atherosclerosis is unknown. HL exerts its role via at least two functions. Its catalytic function processes lipoproteins for both receptor-mediated endocytosis and selective cholesterol uptake. Its bridging function facilitates interactions between lipoproteins, receptors, and the plasma membrane, thereby modulating lipoprotein cholesterol flux. This proposal seeks to establish the respective contributions of the catalytic and bridging functions to the cellular uptake of lipoprotein cholesterol and atherosclerosis by generating transgenic mice that express wildtype HL and functional mutants of HL. These mice will be bred with mice deficient in endogenous HL(hl-/-) and with h1-/- mice that are also deficient in the low density lipoprotein (LDL) receptor to generate Ldlr-/-hl-/- mice. (The Ldlr-/- mice serves as a model for diet-induced atherosclerosis). Thus, we will determine the effect of the expression of wildtype and mutant HLs on plasma lipid and lipoprotein concentrations, composition and size, and lipoprotein turnover. The mechanisms of lipoprotein cholesterol uptake will be examined in primary hepatocyte cultures from the livers of these mice by determining the effects of wildtype and mutant HL on cellular binding
Studies
57
and uptake of labeled lipoproteins in the presence of specific inhibitors of cellular receptors. The effect of expression of wildtype and mutant HL on atherosclerosis development will be established in high-fat diet fed wildtype and mutant HL expressing mice on the Ldlr-/-hl-/-background. In addition this proposal seeks to establish the role of HL in regulating the adrenal steroidogenic response to stress and to identify the contribution of the catalytic function of HL to the adrenal steroidogenic response to stress. This will be accomplished by determining plasma corticosterone response, adrenal cholesterol content and adrenal expression of receptors and enzymes involved in cholesterol metabolism, in response to chronic pharmacologic stimulation of corticosterone production in wildtype- and mutant HL-expressing mice and compared to nontransgenic mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TISSUE ENGINEERING OF SMALL DIAMETER VASCULAR GRAFT Principal Investigator & Institution: Chen, Changyi J.; Professor of Surgery; Surgery; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): The aim to produce a truly stable artificial blood vessel containing no synthetic material requires invasion and in growth of endothelial cell and smooth muscle cells as well as fibroblasts into the scaffold. This can be achieved either in vivo from the adjacent tissue or circulating cells after implantation, or in vitro by means of cultivated cells. Such graft should not induce substantial inflammatory reactions that could either damage its wall, setting the scene for long term aneurysm formation or trigger acute thrombosis. Based on such tissue engineering principles and our preliminary data, we propose a central hypothesis that a novel small diameter vascular graft can be tissue-engineered from the porcine carotid artery by decellularization, heparin covalent linkage, and heparin binding growth factors, and endothelial progenitor cell (EPC) seeding; and this graft may maintain its mechanical property and natural compliance; reduce host immune response; provide anticoagulation surface; and accelerate vascular cell growth and remodeling, thereby maintaining a long term potency in vivo. Three specific aims are proposed below to test our central hypothesis: Aim 1: To determine the mechanical property, natural compliance, host immune response, and anticoagulation property of decellularizedheparinized porcine carotid artery grafts (D-H grafts). We will test the hypothesis that D-H grafts may maintain their mechanical property and natural compliance, provide anticoagulation surface, and reduce host immune response. Both in vitro and animal models are included. Carotid artery bypass surgery using D-H grafts will be performed in dogs (xenogenic setting) and in pigs (allogenic setting). Aim 2: To determine the effect of bFGF binding to D-H grafts on vascular cell growth and repopulation of the grafts. We will test the hypothesis that bFGF binding to D-H grafts may promote vascular cell growth and repopulation of the grafts, thereby accelerating vascular healing and remodeling. Characteristics of bFGF binding and release and effect on cell proliferation and anticoagulation will be investigated in vitro. In vivo performance of bFGF bound DH grafts will be studied. Aim 3: To characterize cell proliferation and differentiation of EPC and its application with bFGF bound D-H grafts. We will test the hypothesis that bFGF bound D-H grafts may enhance EPC proliferation and differentiation, and EPC seeded bFGF bound D-H grafts may have better healing and remodeling characteristics as compared to un-seeded grafts. EPC will be isolated and characterized from dog or pig peripheral blood. The effect of bFGF and hemodynamics on EPC differentiation and proliferation will be investigated. In vivo performance of EPC seeded bFGF bound D-H
58
Heparin
grafts will be studied. This study represents a multidisciplinary approach including tissue engineering, cellular and molecular biology, and animal models. Success of this proposal will directly indicate the clinical applications of tissue engineered small diameter vascular grafts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRIGGERED LOCAL RELEASE OF ACTIVE THROMBOLYTIC AGENTS Principal Investigator & Institution: Yang, Victor C.; Albert B. Prescott Professor of Pharmace; Pharmaceutical Sciences; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-SEP-1996; Project End 31-JAN-2004 Summary: Cardiovascular diseases which result from thrombosis of blood vessels are a leading cause of deaths. At present, the treatment is dissolution of the thrombus using a thrombolytic agent, namely a plasminogen activator (PA). Activation of plasminogen produces plasmin which degrades fibrin. Plasmin, however, also degrades clotting factors. Thrombolytic therapy which introduces systemic generation of plasmin, therefore, carries the risk of hemorrhage. Previously, we proposed a novel, pro-drug and triggered release approach which could permit targeted thrombolysis without the bleeding risk. The approach consists of two components: [i] a fibrin- targeting antibody linked to an anionic heparin (termed Ab-Hep); and [ii] a cation-modified PA (termed mPA+). These two components are linked via an electrostatic interaction. Since the used cations are small, m-PA+ would retain its catalytic activity. This activity, however, would be inhibited after binding to Ab-Hep due to blockage of the PA's active site by the appended macromolecules. Since protamine is a clinical heparin- binding antidote, it can be used safely to trigger the release of m-PA+ from the Ab-Hep-m-PA+ complex. Thus, the approach would permit injection of a fibrin-targeting but inactive PA drug (thereby alleviating the bleeding risk by aborting systemic generation of plasmin), and subsequently a triggered release of the active m-PA+ in close proximity of a fibrin deposit. Although it was a brand new project with minimal data, the previous application received full support from NIH shortly after submission based on its scientific merits and clinical significance. For reasons not clearly stated, however, the overall grant period was cut by NIH from 4 to 3 years. Despite being handicapped by a shortened time for renewal, our group has made remarkable progress and outstanding productivity. In a short 2-year period, 20 manuscripts and 10 abstracts have been published or submitted. The in vitro feasibility of the project, particularly on the prodrug and triggered-release features, have been demonstrated in plasma. In this new application, we plan to build upon those promising findings and further establish the project. Our integrated specific aims are: [i] develop analytical methods essential to the project; [ii] produce the desired m-PA+ by biological or chemical means; [iii] produce the Ab-Hep conjugates; [iv] test the functions of the final Ab-Hep-m-PA+ products in vitro; [v] examine their pharmacokinetic properties in rats; and [vi] test their functions in vivo using a rabbit jugular vein model and a clinically- simulated canine intracoronary thrombosis model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CYSTITIS
URINE
ANTIPROLIFERATIVE
PEPTIDE
IN
INTERSTITIAL
Principal Investigator & Institution: Keay, Susan F.; Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201
Studies
59
Timing: Fiscal Year 2002; Project Start 30-SEP-1997; Project End 31-MAR-2006 Summary: (Adapted from the Applicant's Abstract): Interstitial cystitis (IC) is a chronic bladder disease with often devastating effects on the lives of approximately 450,000 people in the U.S. The etiology of IC is unknown, and there is currently no reliably effective treatment. It is therefore important to continue to search for a cause of this debilitating disorder in order to systematically devise an effective therapy. The applicants report discovering two, specific and significant abnormalities in the urine of IC patients as compared to controls, which may be linked to the pathogenesis of this disease - the presence of a low molecular weight urine peptide that inhibits the proliferation of bladder epithelial cells in vitro (antiproliferative factor, or APF) and complex changes in the levels of specific urine epithelial cell growth factors, including significantly decreased urine levels of heparin-binding epidermal growth factor-like growth factor. Because a damaged bladder epithelium is a central finding in IC, it is possible that the APF and the growth factor abnormalities are directly involved in the pathogenesis of this disease. The proposed research is designed to determine the mechanisms by which the APF regulates bladder epithelial cell proliferation. In addition, specific effects of HPLC-purified APF on bladder epithelial cell physiology in vitro will be confirmed in vivo using a mouse model. The applicants suggest data from these studies should yield valuable information regarding the regulation of bladder epithelial proliferation and the pathogenesis of IC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VASCULAR DRUG DELIVERY Principal Investigator & Institution: Edelman, Elazer R.; Professor and Director; Health Sciences Technology; Massachusetts Institute of Technology Room E19-750 Cambridge, Ma 02139 Timing: Fiscal Year 2003; Project Start 01-AUG-1994; Project End 31-MAR-2007 Summary: (provided by applicant): NIH RO1 funding has enabled us to contribute to understanding the interplay between local drug delivery and arterial disease. We demonstrated the importance of directionality and site of drug administration, and arterial anatomic ultrastructure and disease. We completed a three-dimensional model of vascular drug delivery capable of predicting point-to-point drug concentrations throughout the arterial wall from delivery devices of any geometry and with any form of release. Having developed a rigorous quantitative framework for characterizing drug distribution, we will now correlate drug distribution with ultimate biological effect. Although we can predict where drug deposits, the importance of this next step, knowing where drug acts, cannot be overstated. The prevailing assumption is that biological effect maps directly with drug distribution, and while this may prove true for some drugs, the relationship between localization of drug and effect remains poorly understood. Preliminary data show that response to vasoactive compounds may depend more on cell interconnectivity than on local drug concentration. Moreover, response to many drugs may be affected by local injury, inflammatory processes or even changes in local mechanical state. Indeed, characterizing drug distribution may only be the starting point, i.e. one component of a vastly more complicated biological circuitry which ultimately determines how the distribution of biologic response evolves. In this revised grant application we now propose to therefore (a) examine whether drug distribution correlates with localization of ultimate biologic response, (b) delineate how cell interconnectivity and local tissue state modulate this correlation, (c) define how local pharmacokinetics dictates biologic response in vascular tissues, and (d) characterize how modifications of cell communications can enhance response to drug in injured
60
Heparin
tissue. Studies in cell culture in which cell connectivity, cell state, and drug administration can be easily defined and controlled, will be extended to whole arteries wherein local pharmacokinetics are defined, and in the myocardium, in which neither the mechanical nor pharmacokinetic factors influencing drug distribution are known. A range of drugs will be considered based on physicochemical properties, biological activity, clinical performance and mechanism of cell responsiveness. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VISUALIZING SYNAPTIC CIRCUITRY IN THE RETINA Principal Investigator & Institution: Breakefield, Xandra O.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2004; Project Start 09-FEB-2004; Project End 31-JAN-2007 Summary: (provided by applicant): This research effort will focus on gene delivery of fluorescent proteins to neurons in the retina using HSV vectors in order to elucidate details of synaptic circuitry. In Aim 1, targeted gene delivery to specific neuronal subtypes will be undertaken by selective infection and by placing transgene expression under a cell specific promoter. The major heparin sulfate binding domain of the virion will be replaced with BDNF to increase infection of retinal ganglion cells that express high levels of the TrkB receptor on their cell surface. Transcriptional targeting will be undertaken by using the Thy-1 promoter, specifically expressed in this same neuronal population, either to drive expression of a reporter gene in HSV amplicon vectors, or by blocking expression of a reporter under a strong promoter in the vector through insertion of a IoxP-flanked stop codon between these sequences with subsequent infection of Thy-1-Cre transgenic mice to activate transgene expression. In Aim 2, we will attempt to label specific synaptic pathways by vector-mediated delivery of informative fluorescent fusion proteins. A GFP-tetanus toxin heavy chain fusion protein will be used to selectively label presynaptic contacts of the infected neurons. A BDNFGFP fusion protein will be used to label synaptic partners of the infected cell which are enriched for TrkB-BDNF receptors. Aim 3 will undertake labeling of synaptically connected neurons by expression of reporter genes carried in a replicating vector system intended to have minimal-to-no toxicity for the host neurons. Vector propagation will be controlled by placing an essential viral gene for ICP4 under a tight tetracycline regulated (tet-on) promoter in an HSV amplicon vector and coupling infection with a mutant helper virus deleted for this gene. Both vector and helper virus will express reporter genes, and co-infection with both will allow drug-dependent regulation of the levels of virions produced and passed onto synaptically connected neurons. The proposed targeting and labeling methods should be adaptable to other types of receptors and synaptic connections throughout the nervous system and should be very useful in dissecting and monitoring synaptic circuitry in living and fixed preparations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National
3
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
Studies
61
Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “heparin” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for heparin in the PubMed Central database: •
A heparin-binding synthetic peptide of heparin /heparan sulfateinteracting protein modulates blood coagulation activities. by Liu S, Zhou F, Hook M, Carson DD.; 1997 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19986
•
A strategy for rapid sequencing of heparan sulfate and heparin saccharides. by Turnbull JE, Hopwood JJ, Gallagher JT.; 1999 Mar 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15832
•
Activation of the calcium release channel (ryanodine receptor) by heparin and other polyanions is calcium dependent. by Bezprozvanny IB, Ondrias K, Kaftan E, Stoyanovsky DA, Ehrlich BE.; 1993 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=300932
•
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. by Visentin GP, Ford SE, Scott JP, Aster RH.; 1994 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=293737
•
Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III. by Mattsson C, Hoylaerts M, Holmer E, Uthne T, Collen D.; 1985 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=425441
•
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation? by Farquhar D.; 2001 Feb 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=80756
•
Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials. by Randolph AG, Cook DJ, Gonzales CA, Andrew M.; 1998 Mar 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28499
•
Binding to Heparan Sulfate or Heparin Enhances Neutrophil Responses to Interleukin 8. by Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A.; 1993 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47095
4
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
62
Heparin
•
Characterization of a cDNA encoding the heparin and collagen binding domains of human thrombospondin. by Dixit VM, Hennessy SW, Grant GA, Rotwein P, Frazier WA.; 1986 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=386304
•
Characterization of an amyloid beta precursor protein that binds heparin and contains tyrosine sulfate. by Schubert D, LaCorbiere M, Saitoh T, Cole G.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=286848
•
Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. by Shriver Z, Sundaram M, Venkataraman G, Fareed J, Linhardt R, Biemann K, Sasisekharan R.; 2000 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27030
•
Comparison of heparin and EDTA transport tubes for detection of cytomegalovirus in leukocytes by shell vial assay, pp65 antigenemia assay, and PCR. by Storch GA, Gaudreault-Keener M, Welby PC.; 1994 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264108
•
Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense. by Smith SA, Mullin NP, Parkinson J, Shchelkunov SN, Totmenin AV, Loparev VN, Srisatjaluk R, Reynolds DN, Keeling KL, Justus DE, Barlow PN, Kotwal GJ.; 2000 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112054
•
Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. by Nicholson T, McGuire A, Milne R.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59676
•
Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. by Herold BC, Gerber SI, Belval BJ, Siston AM, Shulman N.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190219
•
Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. by Edelman ER, Adams DH, Karnovsky MJ.; 1990 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=53985
•
Effect of Heparin and Heparin Fractions on Platelet Aggregation. by Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L.; 1980 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371340
•
Effect of Heparin on the Inactivation of Serum Lipoprotein Lipase by the Liver in Unanesthetized Dogs. by Whayne TF Jr, Felts JM, Harris PA.; 1969 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322346
Studies
63
•
Enzymic Depolymerization of Macromolecular Heparin as a Factor in Control of Lipoprotein Lipase Activity. by Horner AA.; 1972 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=389795
•
Evaluation of critical groups required for the binding of heparin to antithrombin. by Atha DH, Stephens AW, Rosenberg RD.; 1984 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=344757
•
Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. by Hogg PJ, Jackson CM.; 1989 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=287189
•
Fractionation of heparin by chromatography on a tissue plasminogen activatorSepharose column. by Andrade-Gordon P, Strickland S.; 1990 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=53584
•
Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. by Fryer AD, Jacoby DB.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443381
•
Further Characterization of a Factor From Endotoxin-Treated Serum which Releases Histamine and Heparin from Mast Cells. by Hook WA, Snyderman R, Mergenhagen SE.; 1972 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=422462
•
Growth-Inhibitory Effect of Heparin on Babesia Parasites. by Bork S, Yokoyama N, Ikehara Y, Kumar S, Sugimoto C, Igarashi I.; 2004 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=310193
•
Hepatic uptake of a modified low molecular weight heparin in rats. by Stehle G, Friedrich EA, Sinn H, Wunder A, Harenberg J, Dempfle CE, Maier-Borst W, Heene DL.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443279
•
Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode [alpha]1,4- N-acetylglucosaminyltransferases that likely are involved in heparan sulfate / heparin biosynthesis. by Kim BT, Kitagawa H, Tamura JI, Saito T, KuscheGullberg M, Lindahl U, Sugahara K.; 2001 Jun 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34642
•
Identification and Characterization of Heparin Binding Regions of the Fim2 Subunit of Bordetella pertussis. by Geuijen CA, Willems RJ, Hoogerhout P, Puijk WC, Meloen RH, Mooi FR.; 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108189
•
Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G. by Feldman SA, Hendry RM, Beeler JA.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112745
64
Heparin
•
Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. by Stevens RL, Fox CC, Lichtenstein LM, Austen KF.; 1988 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=279975
•
Identification of Receptor and Heparin Binding Sites in Fibroblast Growth Factor 4 by Structure-Based Mutagenesis. by Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Basilico C, Mohammadi M.; 2001 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87313
•
Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. by Tsai M, Takeishi T, Thompson H, Langley KE, Zsebo KM, Metcalfe DD, Geissler EN, Galli SJ.; 1991 Jul 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=52087
•
Inhibition of chymotrypsin by heparin cofactor II. by Church FC, Noyes CM, Griffith MJ.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=390730
•
Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. by Lindner V, Olson NE, Clowes AW, Reidy MA.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443269
•
Inhibitory Effect of Heparin on Gentamicin Concentrations in Blood. by Regamey C, Schaberg D, Kirby WM.; 1972 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=444216
•
Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. by Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K.; 1985 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423436
•
Involvement of cell surface heparin sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells. by Shimada K, Gill PJ, Silbert JE, Douglas WH, Fanburg BL.; 1981 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370886
•
Isolation and Characterization of Heparin from Human Lung. by Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF.; 1979 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371305
•
Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. by Sampath TK, Muthukumaran N, Reddi AH.; 1987 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=299239
Studies
65
•
Isolation of rabbit reticulocyte initiation factors by means of heparin bound to sepharose. by Waldman AA, Marx G, Goldstein J.; 1975 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=432756
•
Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity. by Beg OU, Meng MS, Skarlatos SI, Previato L, Brunzell JD, Brewer HB Jr, Fojo SS.; 1990 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=53923
•
Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass. A preliminary report. by von Segesser LK, Garcia E, Turina MI.; 1993; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=325049
•
Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases. by Yaryura R, Doucet J, Mathur VS.; 1997; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=325487
•
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. by Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E.; 1988 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=281919
•
Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. by Tollefsen DM, Pestka CA.; 1985 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423524
•
Multiple functional domains of the heparin molecule. by Oosta GM, Gardner WT, Beeler DL, Rosenberg RD.; 1981 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=319896
•
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. by Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF.; 2003 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152934
•
N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. by Purkerson ML, Tollefsen DM, Klahr S.; 1988 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=442474
•
On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. by Lantz M, Thysell H, Nilsson E, Olsson I.; 1991 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=295793
66
Heparin
•
Oral heparin results in the appearance of heparin fragments in the plasma of rats. by Larsen AK, Lund DP, Langer R, Folkman J.; 1986 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=323427
•
Preferential Self-Association of Basic Fibroblast Growth Factor is Stabilized by Heparin during Receptor Dimerization and Activation. by Venkataraman G, Sasisekharan V, Herr AB, Ornitz DM, Waksman G, Cooney CL, Langer R, Sasisekharan R.; 1996 Jan 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40145
•
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser. by Borg JY, Owen MC, Soria C, Soria J, Caen J, Carrell RW.; 1988 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=329661
•
Purification of genomic DNA using heparin to remove nuclear proteins. by Koller CA, Kohli V.; 1993 Jun 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=309703
•
Receptor-like function of heparin in the binding and uptake of neutral lipids. by Bosner MS, Gulick T, Riley DJ, Spilburg CA, Lange LG 3rd.; 1988 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=282206
•
Resolution of Experimental Pulmonary Emboli with Heparin and Streptokinase in Different Dosage Regimens. by Cade JF, Hirsh J, Regoeczi E, Gent M, Buchanan MR, Hynes DM.; 1974 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301618
•
Response of Plasma Histaminase Activity to Small Doses of Heparin in Normal Subjects and Patients with Hyperlipoproteinemia. by Baylin SB, Beaven MA, Krauss RM, Keiser HR.; 1973 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302481
•
Role of cysteines in Plasmodium falciparum circumsporozoite protein: Interactions with heparin can rejuvenate inactive protein mutants. by Rathore D, McCutchan TF.; 2000 Jul 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26982
•
Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. by Shriver Z, Raman R, Venkataraman G, Drummond K, Turnbull J, Toida T, Linhardt R, Biemann K, Sasisekharan R.; 2000 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27029
•
Structural Determinants of the Capacity of Heparin to Inhibit the Formation of the Human Amplification C3 Convertase. by Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF.; 1981 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=371591
Studies
67
•
Structural specificity of heparin binding in the fibroblast growth factor family of proteins. by Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R.; 2003 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151345
•
Structure-function relationships of heparin species. by Rosenberg RD, Armand G, Lam L.; 1978 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=392714
•
The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. by Konkle BA, Ginsburg D.; 1988 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303551
•
The Interaction of Heparin with an Apoprotein of Human Very Low Density Lipoprotein. by Shelburne FA, Quarfordt SH.; 1977 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=372443
•
The nucleotide sequence of rat heparin binding growth factor 1 (HBGF-1). by Goodrich SP, Yan GC, Bahrenburg K, Mansson PE.; 1989 Apr 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=317675
•
The use of heparin as a simple cost-effective means of controlling background in nucleic acid hybridization procedures. by Singh L, Jones KW.; 1984 Jul 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=320019
•
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. by Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191746
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with heparin, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “heparin” (or synonyms) 6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
68
Heparin
into the search box, and click “Go.” The following is the type of output you can expect from PubMed for heparin (hyperlinks lead to article summaries): •
A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Author(s): Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. Source: Obstetrics and Gynecology. 2003 June; 101(6): 1307-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12798541
•
A positive in vitro assay is required to diagnose heparin-induced thrombocytopenia. Author(s): Kottke-Marchant K, Bontempo FA. Source: The Medical Clinics of North America. 2003 November; 87(6): 1215-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14680302
•
A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. Author(s): Hidalgo-Ovejero AM, Garcia-Mata S, Martinez-Grande M, Otermin-Maya I. Source: The Journal of Bone and Joint Surgery. British Volume. 2003 May; 85(4): 619-20; Author Reply 620. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12793576
•
Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia. Author(s): Mims MP, Manian P, Rice L. Source: European Journal of Haematology. 2004 May; 72(5): 366-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15059074
•
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Author(s): Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S. Source: Thrombosis Research. 2003 March 15; 109(5-6): 333-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12818259
•
Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. Author(s): Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, Lahav J, Battler A, Badimon JJ, Kornowski R. Source: Journal of the American College of Cardiology. 2004 March 17; 43(6): 966-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15028351
Studies
69
•
Allergy to heparin: a new in vitro diagnostic technique. Author(s): Caballero MR, Fernandez-Benitez M. Source: Allergologia Et Immunopathologia. 2003 November-December; 31(6): 324-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14670287
•
Analysis of heparin binding to human leukocytes using a fluorescein-5isothiocyanate labeled heparin fragment. Author(s): Harenberg J, Malsch R, Piazolo L, Huhle G, Heene DL. Source: Cytometry : the Journal of the Society for Analytical Cytology. 1996 January 1; 23(1): 59-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14650442
•
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Author(s): Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA. Source: Chest. 2004 March; 125(3): 856-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15006942
•
Anticoagulation of pregnant women with mechanical heart valves using lowmolecular-weight heparin. Author(s): Bauersachs R, Lindhoff-Last E. Source: Archives of Internal Medicine. 2003 December 8-22; 163(22): 2788-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14662636
•
Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. Author(s): Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Source: Progress in Cardiovascular Diseases. 2004 May-June; 46(6): 506-23. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15224257
•
Anticoagulation with low-molecular-weight heparin in patients with heart diseases. Author(s): Bechtold H, Janssen D. Source: European Journal of Medical Research. 2004 April 30; 9(4): 186-98. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15210399
•
Antimicrobial activities of heparin-binding peptides. Author(s): Andersson E, Rydengard V, Sonesson A, Morgelin M, Bjorck L, Schmidtchen A. Source: European Journal of Biochemistry / Febs. 2004 March; 271(6): 1219-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15009200
70
Heparin
•
Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor in men with interstitial cystitis versus chronic pelvic pain syndrome. Author(s): Keay S, Zhang CO, Chai T, Warren J, Koch K, Grkovic D, Colville H, Alexander R. Source: Urology. 2004 January; 63(1): 22-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14751340
•
Antithrombin and heparin may limit the activation of Protein C. Author(s): Macias W, Yan SB. Source: Acta Anaesthesiologica Scandinavica. 2004 March; 48(3): 385. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14982578
•
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Author(s): Jeske WP, Walenga JM. Source: Methods in Molecular Medicine. 2004; 93: 61-82. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14733328
•
Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Author(s): Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Source: Thrombosis and Haemostasis. 2002 November; 88(5): 733-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428086
•
Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves. Author(s): Izaguirre R, De La Pena A, Ramirez A, Cortina E, Huerta M, Salazar E. Source: Proc West Pharmacol Soc. 2002; 45: 127-8. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12434554
•
Argatroban, a new treatment option for heparin-induced thrombocytopenia. Author(s): Cleveland KW. Source: Critical Care Nurse. 2003 December; 23(6): 61-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14692173
Studies
71
•
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Author(s): Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM; Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Source: Circulation. 2001 December 4; 104(23): 2772-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11733393
•
Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. Author(s): Tenke P, Riedl CR, Jones GL, Williams GJ, Stickler D, Nagy E. Source: International Journal of Antimicrobial Agents. 2004 March; 23 Suppl 1: S67-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15037330
•
Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. Author(s): Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Source: Journal of Hepatology. 2002 October; 37(4): 463-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12217599
•
Bedside coagulometry during intravenous heparin therapy after coronary angioplasty. Author(s): Schroeder AP, Knudsen LL, Husted SE, Knudsen L, Ingerslev J. Source: Journal of Thrombosis and Thrombolysis. 2001 October; 12(2): 157-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11729367
•
Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. Author(s): Klenner AF, Fusch C, Rakow A, Kadow I, Beyersdorff E, Eichler P, Wander K, Lietz T, Greinacher A. Source: The Journal of Pediatrics. 2003 December; 143(6): 741-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14657819
•
Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Author(s): Messmore H, Jeske W, Wehrmacher W, Walenga J. Source: Drug Safety : an International Journal of Medical Toxicology and Drug Experience. 2003; 26(9): 625-41. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12814331
72
Heparin
•
Bilateral posterior segment intraocular hemorrhage after heparin therapy in a diabetic patient. Author(s): Levartovsky S, Reisin I, Reisin L, Leibowitz E. Source: Isr Med Assoc J. 2003 January; 5(1): 77. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12592970
•
Bilateral posterior segment intraocular hemorrhage in a diabetic patients after therapy with heparin. Author(s): Levartovsky S, Reisin I, Reisin L, Leibowitz E. Source: Isr Med Assoc J. 2003 August; 5(8): 605. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12929308
•
Bimodal expression of heparin-binding EGF-like growth factor in colonic neoplasms. Author(s): Ito Y, Higashiyama S, Takeda T, Okada M, Matsuura N. Source: Anticancer Res. 2001 March-April; 21(2B): 1391-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11396220
•
Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Author(s): Gruel Y, Pouplard C, Nguyen P, Borg JY, Derlon A, Juhan-Vague I, Regnault V, Samama M; French Heparin-Induced Thrombocytopenia Study Group. Source: British Journal of Haematology. 2003 June; 121(5): 786-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12780795
•
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. Author(s): Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Source: Jama : the Journal of the American Medical Association. 2003 February 19; 289(7): 853-63. Erratum In: Jama. 2003 April 2; 289(13): 1638. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12588269
•
Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-STelevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Author(s): Antman EM, McCabe CH, Braunwald E. Source: American Heart Journal. 2002 February; 143(2): 229-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11835024
Studies
73
•
Bivalirudin as alternative to both danaparoid and heparin in off-pump coronary artery bypass grafting. Author(s): Baciewicz FA Jr. Source: The Journal of Thoracic and Cardiovascular Surgery. 2003 December; 126(6): 2108-9; Author Reply 2109. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14688746
•
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Author(s): Merry AF, Raudkivi PJ, Middleton NG, McDougall JM, Nand P, Mills BP, Webber BJ, Frampton CM, White HD. Source: The Annals of Thoracic Surgery. 2004 March; 77(3): 925-31; Discussion 931. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14992900
•
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Author(s): Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Source: American Heart Journal. 2002 May; 143(5): 847-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12040347
•
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures. Author(s): Chew DP. Source: Hamostaseologie. 2002 August; 22(3): 60-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12215763
•
Bleeding and thrombosis in high-risk renal transplantation candidates using heparin. Author(s): Mathis AS, Dave N, Shah NK, Friedman GS. Source: The Annals of Pharmacotherapy. 2004 April; 38(4): 537-43. Epub 2004 February 06. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14766999
•
Bleeding following coronary surgery after preoperative low-molecular-weight heparin. Author(s): Myhre U, Stenseth R, Karevold A, Bjella L, Lingaas PS, Olsen PO, Haaverstad R, Kirkeby-Garstad I, Levang OW. Source: Asian Cardiovascular & Thoracic Annals. 2004 March; 12(1): 3-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14977732
74
Heparin
•
Bone marrow biopsy related haemorrhage and low molecular weight heparin. Author(s): Morley NJ, Makris M. Source: British Journal of Haematology. 2003 November; 123(3): 562. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14617026
•
Building a better heparin. Author(s): Caughey GH. Source: American Journal of Respiratory Cell and Molecular Biology. 2003 February; 28(2): 129-32. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12540478
•
Can heparin prevent adverse pregnancy outcome? Author(s): Romero R, Dekker G, Kupferminc M, Saade G, Livingston J, Peaceman A, Mazor M, Yoon BH, Espinoza J, Chaiworapongsa T, Gomez R, Arias F, Sibai B. Source: J Matern Fetal Neonatal Med. 2002 July;12(1):1-8. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12422903
•
Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial. Author(s): Norgren L; Swedish EnoxaVasc Study Group. Source: Journal of Vascular Surgery : Official Publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2004 May; 39(5): 977-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15111848
•
Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to non-heparin-bonded circuits. Author(s): Mongero LB, Beck JR, Manspeizer HE, Heyer EJ, Lee K, Spanier TA, Smith CR. Source: Perfusion. 2001 March; 16(2): 107-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11334193
•
Case reports on emergency treatment of cardiovascular syndromes through heparinmediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage. Author(s): Jaeger BR, Kreuzer E, Knez A, Leber A, Uberfuhr P, Borner M, Milz P, Reichart B, Seidel D. Source: Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis. 2002 October; 6(5): 394-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12423536
Studies
75
•
Catheter-drawn blood cultures: is withdrawing the heparin lock beneficial? Author(s): Everts R, Harding H. Source: Pathology. 2004 April; 36(2): 170-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15203754
•
Changes in blood viscosity by heparin and argatroban. Author(s): Hitosugi M, Niwa M, Takatsu A. Source: Thrombosis Research. 2001 December 1; 104(5): 371-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11738080
•
Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system. Author(s): Jensen E, Andreasson S, Bengtsson A, Berggren H, Ekroth R, Larsson LE, Ouchterlony J. Source: The Annals of Thoracic Surgery. 2004 March; 77(3): 962-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14992907
•
Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. Author(s): Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Source: The Journal of Biological Chemistry. 2004 March 26; 279(13): 12346-54. Epub 2004 January 05. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14707131
•
Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors. Author(s): Umehara Y, Yamada S, Nishimura S, Shioi J, Robakis NK, Sugahara K. Source: Febs Letters. 2004 January 16; 557(1-3): 233-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14741373
•
Comparing methods of establishing the aPTT therapeutic range of heparin. Author(s): Liepman CI, Koerber JM, Mattson JC, Westley SJ, Smythe MA. Source: The Annals of Pharmacotherapy. 2003 June; 37(6): 794-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12773063
•
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Author(s): Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, White HD, Van de Werf F, Armstrong PW, Ellis SG, Califf RM, Topol EJ. Source: The American Journal of Cardiology. 2001 December 15; 88(12): 1403-6, A6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11741559
76
Heparin
•
Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Author(s): Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ. Source: The American Journal of Cardiology. 2004 January 15; 93(2): 247-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14715362
•
Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent. Author(s): Semiz E, Ermis C, Yalcinkaya S, Sancaktar O, Deger N. Source: Japanese Heart Journal. 2003 November; 44(6): 889-98. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711184
•
Comparison of outcomes up to six months of Heparin-Coated with noncoated stents after percutaneous coronary intervention for acute myocardial infarction. Author(s): Lev EI, Assali AR, Teplisky I, Rechavia E, Hasdai D, Sela O, Shor N, Battler A, Kornowski R. Source: The American Journal of Cardiology. 2004 March 15; 93(6): 741-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15019881
•
Comparison of serum and heparin-plasma samples in different generations of dimension troponin I assay. Author(s): Dorizzi RM, Caputo M, Ferrari A, Lippa L, Rizzotti P. Source: Clinical Chemistry. 2002 December; 48(12): 2294-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12446498
•
Connective tissue activation XXXVIII: heparin/heparanase activity of human platelets resides in a high molecular weight protein, not in connective tissue activating peptide III. Author(s): Castor CW, Kotlyar A, Edwards BE. Source: The Journal of Rheumatology. 2002 November; 29(11): 2337-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12415589
•
Continuous administration of heparin in patients with deep vein thrombosis can increase plasma levels of diamine oxidase. Author(s): Klocker J, Perkmann R, Klein-Weigel P, Morsdorf G, Drasche A, Klingler A, Fraedrich G, Schwelberger HG. Source: Vascular Pharmacology. 2004 January; 40(6): 293-300. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15063833
Studies
77
•
Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Author(s): Amorosi SL, Tsilimingras K, Thompson D, Fanikos J, Weinstein MC, Goldhaber SZ. Source: The American Journal of Cardiology. 2004 February 15; 93(4): 509-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14969639
•
Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective. Author(s): Orlewska E, Budaj A, Tereszkowski-Kaminski D. Source: Pharmacoeconomics. 2003; 21(10): 737-48. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12828495
•
Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Author(s): Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Source: Chest. 2004 May; 125(5): 1642-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15136371
•
Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Author(s): Kodityal S, Manhas AH, Udden M, Rice L. Source: European Journal of Haematology. 2003 August; 71(2): 109-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12890149
•
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient. Author(s): Igaki N, Matsuda T, Yatani H, Kawaguchi T, Kida A, Yanase K, Moriguchi R, Sakai M, Tamada F, Goto T. Source: Clinical and Experimental Nephrology. 2003 December; 7(4): 306-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14712362
•
Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin. Author(s): Tapson VF. Source: Manag Care. 1999 December; 8 Suppl: 2-6. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11729399
78
Heparin
•
Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarction. Author(s): Ferguson JJ. Source: Clin Cardiol. 2002 November; 25(11 Suppl 1): I16-22. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428815
•
Delayed systemic reactions with flare-ups of previously negative intradermal skin tests to heparin. Author(s): Garcia Robaina JC, Sanchez Machin I, Fernandez-Caldas E, de la Torre Morin F. Source: Allergy. 2003 July; 58(7): 685-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12823138
•
Delayed-onset heparin-induced thrombocytopenia. Author(s): Kane R. Source: Annals of Internal Medicine. 2003 November 4; 139(9): 790. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14597468
•
Delayed-onset heparin-induced thrombocytopenia. Author(s): De Palma JR. Source: Annals of Internal Medicine. 2003 November 4; 139(9): 790; Author Reply 790-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14597467
•
Dendritic polyglycerol sulfates as new heparin analogues and potent inhibitors of the complement system. Author(s): Turk H, Haag R, Alban S. Source: Bioconjugate Chemistry. 2004 January-February; 15(1): 162-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14733596
•
Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Author(s): Money SR, York JW. Source: Cardiovascular Surgery (London, England). 2001 June; 9(3): 211-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11336843
•
Differential expression of heparin-binding EGF-like growth factor (HB-EGF) mRNA in normal human keratinocytes induced by a variety of natural and synthetic retinoids. Author(s): Yoshimura K, Uchida G, Okazaki M, Kitano Y, Harii K. Source: Experimental Dermatology. 2003; 12 Suppl 2: 28-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14756521
Studies
79
•
Differential tyrosine phosphorylation of fibroblast growth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin. Author(s): Lundin L, Ronnstrand L, Cross M, Hellberg C, Lindahl U, Claesson-Welsh L. Source: Experimental Cell Research. 2003 July 1; 287(1): 190-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12799194
•
Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Author(s): Sarris E, Tsele E, Bagiatoudi G, Salpigidis K, Stavrianaki D, Kaklamanis L, Siakotos M. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2003 May; 41(5): E15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12778433
•
Direct stenting with 3000 i.u. heparin. Author(s): Caussin C, Fsihi A, Ohanessian A, Jacq L, Rahal S, Lancelin B. Source: International Journal of Cardiovascular Interventions. 2003; 5(4): 206-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14630564
•
Does my patient have heparin-induced thrombocytopenia? Author(s): King JE. Source: Nursing. 2003 November; 33(11): 24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14650380
•
Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia? Author(s): Fohlen-Walter A, De Maistre E, Mulot A, Marchand-Arvier M, Lecompte T. Source: Journal of Thrombosis and Haemostasis : Jth. 2003 August; 1(8): 1844-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12911605
•
Don't miss HIT (heparin induced thrombocytopenia). Author(s): Horner BM, Myers SR. Source: Burns : Journal of the International Society for Burn Injuries. 2004 February; 30(1): 88-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14693093
•
Dosing and timing of low-molecular-weight heparin thromboprophylaxis in total hip arthroplasty. Author(s): Colwell CW Jr. Source: Orthopedics. 2003 November; 26(11): 1155-61; Quiz 1162-3. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14627117
80
Heparin
•
Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Author(s): Malhotra S, Bhasin D, Shafiq N, Pandhi P. Source: Expert Opinion on Pharmacotherapy. 2004 February; 5(2): 329-34. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14996629
•
Drugs for the prevention and treatment of thrombosis in patients with heparininduced thrombocytopenia. Author(s): Lubenow N, Greinacher A. Source: American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. 2001; 1(6): 429-43. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14728002
•
Early onset of heparin-induced thrombocytopenia with thrombosis after open heart surgery: importance of an early diagnosis and Lepirudin treatment. Author(s): Paparella D, Galeone A, Micelli M, Memmola C, de Luca Tupputi Schinosa L. Source: Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 2004 March; 15(2): 183-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15091006
•
Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Author(s): Lappegard KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, Mollnes TE. Source: The Annals of Thoracic Surgery. 2004 March; 77(3): 932-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14992902
•
Effect of intravenous heparin administration on duration of hospitalization. Author(s): Dunn A, Bioh D, Beran M, Capasso M, Siu A. Source: Mayo Clinic Proceedings. 2004 February; 79(2): 159-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14959908
•
Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Author(s): Fenyvesi T, Jorg I, Harenberg J. Source: Pathophysiology of Haemostasis and Thrombosis. 2002 July-August; 32(4): 1749. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12759518
Studies
81
•
Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors. Author(s): East MA, Landis DI, Thompson MA, Annex BH. Source: The American Journal of Cardiology. 2003 May 15; 91(10): 1234-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12745108
•
Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells. Author(s): Martinez-Sales V, Vila V, Reganon E, Oms JG, Aznar J. Source: Haematologica. 2003 June; 88(6): 694-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12801846
•
Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Author(s): Koster A, Spiess B, Chew DP, Krabatsch T, Tambeur L, DeAnda A, Hetzer R, Kuppe H, Smedira NG, Lincoff AM. Source: The American Journal of Cardiology. 2004 February 1; 93(3): 356-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14759391
•
Effectivity of heparin in assisted reproduction. Author(s): Fiedler K, Wurfel W. Source: European Journal of Medical Research. 2004 April 30; 9(4): 207-14. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15210401
•
Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Author(s): Brown RA, Lever R, Jones NA, Page CP. Source: British Journal of Pharmacology. 2003 June; 139(4): 845-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12813008
•
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. Author(s): Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Source: Jama : the Journal of the American Medical Association. 2004 July 7; 292(1): 8996. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15238596
82
Heparin
•
Emergency department-based atrial fibrillation treatment strategy with lowmolecular-weight heparin. Author(s): Wakai A. Source: Annals of Emergency Medicine. 2003 May; 41(5): 757-8; Author Reply 758-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12744251
•
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and thirdgeneration fibrinolytic agents. Author(s): Schroeder WS, Gandhi PJ. Source: Current Cardiology Reports. 2003 July; 5(4): 310-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12801451
•
Endogenous heparin activity deficiency: the 'missing link' in atherogenesis? Author(s): Engelberg H. Source: Atherosclerosis. 2001 December; 159(2): 253-60. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11730804
•
Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Author(s): Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J. Source: Cancer Research. 2004 April 15; 64(8): 2743-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15087389
•
Enoxaparin and unfractionated heparin in acute coronary syndromes without STsegment elevation. Author(s): Cohen M, Antman EM. Source: Thrombosis and Haemostasis. 2002 November; 88(5): 884-6; 886-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428118
•
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. Author(s): Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Source: Jama : the Journal of the American Medical Association. 2004 July 7; 292(1): 4554. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15238590
Studies
83
•
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Author(s): Wallock M, Jeske WP, Bakhos M, Walenga JM. Source: Perfusion. 2001 March; 16(2): 147-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11334198
•
Exaggerated postprandial lipaemia and lower post-heparin lipoprotein lipase activity in middle-aged men. Author(s): Jackson KG, Knapper-Francis JM, Morgan LM, Webb DH, Zampelas A, Williams CM. Source: Clinical Science (London, England : 1979). 2003 October; 105(4): 457-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12812518
•
Exaggerated response to heparin in a post-operative renal transplant recipient with lupus anticoagulant undergoing plasmapheresis. Author(s): Mathis AS, Shah NK. Source: Transplantation. 2004 March 27; 77(6): 957-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15077052
•
Excretion of low molecular weight heparin in human milk. Author(s): Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Source: British Journal of Clinical Pharmacology. 2001 December; 52(6): 708-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11736885
•
Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. Author(s): Mahesh B, Evans S, Bryan AJ. Source: J Heart Valve Dis. 2002 September; 11(5): 745-50. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12358414
•
Fibrillin-1 and -2 contain heparin-binding sites important for matrix deposition and that support cell attachment. Author(s): Ritty TM, Broekelmann TJ, Werneck CC, Mecham RP. Source: The Biochemical Journal. 2003 October 15; 375(Pt 2): 425-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12837131
•
Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Author(s): Delehedde M, Lyon M, Gallagher JT, Rudland PS, Fernig DG. Source: The Biochemical Journal. 2002 August 15; 366(Pt 1): 235-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12000311
84
Heparin
•
Filter anticoagulation is accomplished through the administration of dilute heparin. Author(s): Michaud D, Komant T, Pfefferle P. Source: Dynamics. 2000 Winter; 11(4): 10. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11982053
•
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. Author(s): Harenberg J. Source: Current Opinion in Pulmonary Medicine. 2002 September; 8(5): 383-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12172440
•
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Author(s): Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S; TH-4 Study Group. Source: Thrombosis and Haemostasis. 2003 August; 90(2): 252-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12888872
•
Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies. Author(s): Donohoe S, Quenby S, Mackie I, Panal G, Farquharson R, Malia R, Kingdom J, Machin S. Source: Lupus. 2002; 11(1): 11-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11898913
•
Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Author(s): Maetzke J, Hinrichs R, Staib G, Scharffetter-Kochanek K. Source: Allergy. 2004 February; 59(2): 237-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14763948
•
Fondaparinux sodium lacks immunomodulatory effects of heparin. Author(s): Heinzelmann M, Bosshart H. Source: American Journal of Surgery. 2004 January; 187(1): 111-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14706599
•
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Author(s): Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Source: Expert Opinion on Investigational Drugs. 2002 March; 11(3): 397-407. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11866668
Studies
85
•
Food deprivation increases post-heparin lipoprotein lipase activity in humans. Author(s): Ruge T, Svensson A, Eriksson JW, Olivecrona T, Olivecrona G. Source: European Journal of Clinical Investigation. 2001 December; 31(12): 1040-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11903489
•
Formation of polymerized mixed heparin/albumin surface layer and cellular adhesional responses. Author(s): Magoshi T, Matsuda T. Source: Biomacromolecules. 2002 September-October; 3(5): 976-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12217043
•
Fractionation of cytosolic proteins on an immobilized heparin column. Author(s): Shefcheck K, Yao X, Fenselau C. Source: Analytical Chemistry. 2003 April 1; 75(7): 1691-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12705604
•
Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Author(s): O'Shea SI, Sands JJ, Nudo SA, Ortel TL. Source: American Journal of Hematology. 2002 January; 69(1): 72-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11835336
•
Frequency of heparin-induced thrombocytopenia in critical care patients. Author(s): Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Source: Pharmacotherapy. 2003 June; 23(6): 745-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12820817
•
Full heparin anticoagulation should not be used in acute ischemic stroke. Author(s): Sandercock P. Source: Stroke; a Journal of Cerebral Circulation. 2003 January; 34(1): 231-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12511780
•
Functional differences between integrin alpha4 and integrins alpha5/alphav in modulating the motility of human oral squamous carcinoma cells in response to the V region and heparin-binding domain of fibronectin. Author(s): Zhang Y, Lu H, Dazin P, Kapila Y. Source: Experimental Cell Research. 2004 April 15; 295(1): 48-58. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15051489
86
Heparin
•
Furin proteolytically processes the heparin-binding region of extracellular superoxide dismutase. Author(s): Bowler RP, Nicks M, Olsen DA, Thogersen IB, Valnickova Z, Hojrup P, Franzusoff A, Enghild JJ, Crapo JD. Source: The Journal of Biological Chemistry. 2002 May 10; 277(19): 16505-11. Epub 2002 February 22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11861638
•
Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Author(s): Islam T, Butler M, Sikkander SA, Toida T, Linhardt RJ. Source: Carbohydrate Research. 2002 November 19; 337(21-23): 2239-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12433488
•
Gabexate mesilate and heparin responsiveness in coronary patients. Author(s): Ranucci M. Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2004 March; 10(3): Pi40-3. Epub 2004 March 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14976449
•
Gastrin regulates the heparin-binding epidermal-like growth factor promoter via a PKC/EGFR-dependent mechanism. Author(s): Sinclair NF, Ai W, Raychowdhury R, Bi M, Wang TC, Koh TJ, McLaughlin JT. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2004 June; 286(6): G992-9. Epub 2004 February 05. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14764442
•
Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population. Author(s): Kobayashi J, Maruyama T, Watanabe H, Kudoh A, Tateishi S, Sasaki T, Murano S, Watanabe M. Source: Diabetes Research and Clinical Practice. 2003 October; 62(1): 39-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14581156
•
Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Author(s): Chu Y, Iida S, Lund DD, Weiss RM, DiBona GF, Watanabe Y, Faraci FM, Heistad DD. Source: Circulation Research. 2003 March 7; 92(4): 461-8. Epub 2003 January 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12600899
Studies
87
•
Glucosamine sulfate does not crossreact with the antibodies of patients with heparininduced thrombocytopenia. Author(s): Weimann G, Lubenow N, Selleng K, Eichler P, Albrecht D, Greinacher A. Source: European Journal of Haematology. 2001 March; 66(3): 195-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11350488
•
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. Author(s): Vernon SM. Source: Cardiology Clinics. 2001 May; 19(2): 235-52, Vi. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11407108
•
Glycosaminoglycan structures required for strong binding to midkine, a heparinbinding growth factor. Author(s): Zou P, Zou K, Muramatsu H, Ichihara-Tanaka K, Habuchi O, Ohtake S, Ikematsu S, Sakuma S, Muramatsu T. Source: Glycobiology. 2003 January; 13(1): 35-42. Epub 2002 October 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12634322
•
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Author(s): Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Source: Cancer Research. 2001 July 15; 61(14): 5562-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11454708
•
Gordon Murray: heparin, hemodialysis and hubris. Author(s): Fellner SK, Purkerson ML. Source: American Journal of Nephrology. 2002 July; 22(2-3): 271-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12097752
•
Group IID heparin-binding secretory phospholipase A(2) is expressed in human colon carcinoma cells and human mast cells and up-regulated in mouse inflammatory tissues. Author(s): Murakami M, Yoshihara K, Shimbara S, Sawada M, Inagaki N, Nagai H, Naito M, Tsuruo T, Moon TC, Chang HW, Kudo I. Source: European Journal of Biochemistry / Febs. 2002 June; 269(11): 2698-707. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12047378
88
Heparin
•
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Author(s): Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Source: Circulation. 2001 June 19; 103(24): 2994-3018. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11413093
•
Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Author(s): Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Pittino S, Filoni M, Bressan F, Sarti E, Cinotti S, Morfini M. Source: Minerva Anestesiol. 2001 October; 67(10): 693-703. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11740417
•
Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding. Author(s): Lee KB, Kim B, Lee YH, Yoon SJ, Kang WH, Huh W, Kim DJ, Oh HY, Kim YG. Source: Nephron. Clinical Practice [electronic Resource]. 2004; 97(1): C5-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15153761
•
Heparin cofactor II deficiency. Author(s): Tollefsen DM. Source: Archives of Pathology & Laboratory Medicine. 2002 November; 126(11): 1394400. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12421148
•
Heparin dose, transfusion rates, and intraoperative graft patency in minimally invasive direct coronary artery bypass. Author(s): Donias HW, D'Ancona G, Pande RU, Schimpf D, Kawaguchi AT, Karamanoukian HL. Source: Heart Surg Forum. 2003; 6(3): 176-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12821433
•
Heparin for pregnant women with acquired or inherited thrombophilias. Author(s): Walker MC, Ferguson SE, Allen VM. Source: Cochrane Database Syst Rev. 2003; (2): Cd003580. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12804477
•
Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Author(s): Mason HR, Nowak RA, Morton CC, Castellot JJ Jr. Source: American Journal of Pathology. 2003 June; 162(6): 1895-904. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12759246
Studies
89
•
Heparin solution locked in acute hemodialysis catheters: impact on activated partial thromboplastin time. Author(s): Sombolos KI, Fragia TK, Bamichas GI, Christidou FP, Stangou MI, Karagianni AC, Natse TA, Georgoulis IE. Source: Asaio Journal (American Society for Artificial Internal Organs : 1992). 2003 MayJune; 49(3): 287-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12790377
•
Heparin therapy for mistaken cardiac diagnosis in Boerhaave's syndrome. Author(s): Vyas H, Desal D, Abraham P, Joshi A. Source: Indian J Gastroenterol. 2004 March-April; 23(2): 72-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15176542
•
Heparin thromboprophylaxis in gastric bypass surgery. Author(s): Shepherd MF, Rosborough TK, Schwartz ML. Source: Obesity Surgery : the Official Journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand. 2003 April; 13(2): 249-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12740133
•
Heparin/aspirin therapy for implantation failure in IVF cycles. Author(s): Prakash A, Ola B. Source: Fertility and Sterility. 2004 May; 81(5): 1431; Author Reply 1431-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15136130
•
Heparin-bonded lines reduce hospital-acquired bacteraemia. Author(s): Gilbert R, Howard R, Mok Q. Source: The Journal of Hospital Infection. 2003 June; 54(2): 163-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12818593
•
Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. Author(s): Ovrum E, Tangen G, Oystese R, Ringdal MA, Istad R. Source: Journal of Cardiac Surgery. 2003 March-April; 18(2): 140-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12757341
•
Heparin-coated hemodialyzers--the holy grail for patients at risk of bleeding? Author(s): Evenepoel P. Source: Nephron. Clinical Practice [electronic Resource]. 2004; 97(1): C1-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15153759
90
Heparin
•
Heparin-induced hyperkalemia after cardiac surgery. Author(s): Day JR, Chaudhry AN, Hunt I, Taylor KM. Source: The Annals of Thoracic Surgery. 2002 November; 74(5): 1698-700. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12440638
•
Heparin-induced thrombocytopenia in children. Author(s): Newall F, Barnes C, Ignjatovic V, Monagle P. Source: Journal of Paediatrics and Child Health. 2003 May-June; 39(4): 289-92. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12755937
•
Heparin-induced thrombocytopenia: molecular pathogenesis. Author(s): Lee SH, Liu CY, PaoloVisentin G. Source: International Journal of Hematology. 2002 August; 76 Suppl 1: 346-51. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12430880
•
Heparin-induced thrombocytopenia: pathogenesis and management. Author(s): Warkentin TE. Source: British Journal of Haematology. 2003 May; 121(4): 535-55. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12752095
•
Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Author(s): Lindhoff-Last E, Bauersachs R. Source: Seminars in Thrombosis and Hemostasis. 2002 October; 28(5): 439-46. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12420239
•
Hirudin in heparin-induced thrombocytopenia. Author(s): Lubenow N, Greinacher A. Source: Seminars in Thrombosis and Hemostasis. 2002 October; 28(5): 431-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12420238
•
Histidine-rich glycoprotein plus zinc reverses growth inhibition of vascular smooth muscle cells by heparin. Author(s): Mori S, Shinohata R, Renbutsu M, Takahashi HK, Fang YI, Yamaoka K, Okamoto M, Yamamoto I, Nishibori M. Source: Cell and Tissue Research. 2003 June; 312(3): 353-9. Epub 2003 May 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12764609
Studies
91
•
Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C. Author(s): Jang JH, Hwang JH, Chung CP, Choung PH. Source: The Journal of Biological Chemistry. 2004 June 11; 279(24): 25562-6. Epub 2004 April 06. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15069070
•
Impact of heparin management on release of tissue factor pathway inhibitor during cardiopulmonary bypass. Author(s): Fischer T, Kuppe H, Koster A. Source: Anesthesiology. 2004 April; 100(4): 1040. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15087657
•
Improving cardiopulmonary bypass: heparin-coated circuits. Author(s): Vocelka C, Lindley G. Source: J Extra Corpor Technol. 2003 December; 35(4): 312-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14979422
•
Improving the laboratory diagnosis of heparin-induced thrombocytopenia. Author(s): Rodgers GM. Source: The American Journal of Medicine. 2003 May; 114(7): 609-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12753887
•
Increased pre-operative platelet counts are a possible predictor for reduced sensitivity to heparin. Author(s): Vuylsteke A, Mills RJ, Crosbie AE, Burns TI, Latimer RD. Source: British Journal of Anaesthesia. 2000 December; 85(6): 896-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11732526
•
Induction of apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin. Author(s): Karti SS, Ovali E, Ozgur O, Yilmaz M, Sonmez M, Ratip S, Ozdemir F. Source: Hepatogastroenterology. 2003 November-December; 50(54): 1864-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14696420
•
Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Author(s): Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Source: Blood. 2001 May 15; 97(10): 3300-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11342462
92
Heparin
•
Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits). Author(s): Hazama S, Eishi K, Yamachika S, Noguchi M, Ariyoshi T, Takai H, Odate T, Matsukuma S, Onohara D, Yanatori M. Source: Ann Thorac Cardiovasc Surg. 2004 April; 10(2): 90-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15209550
•
Influence of heparin dosage on hemostasis under combined use of Nafamostat mesilate during deep hypothermic circulatory arrest. Author(s): Nakamura K, Onitsuka T, Yano M, Yano Y, Matsuyama M, Niina K. Source: Jpn J Thorac Cardiovasc Surg. 2003 May; 51(5): 186-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12776949
•
Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Author(s): Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich JE. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2002 December; 17(12): 2231-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12454238
•
Inherited and acquired thrombophilias and poor pregnancy outcome: should we be treating with heparin? Author(s): Gebhardt GS, Hall DR. Source: Current Opinion in Obstetrics & Gynecology. 2003 December; 15(6): 501-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14624217
•
Inhibition of neointimal proliferation in balloon-injured arteries using nonanticoagulant heparin-carrying polystyrene. Author(s): Fujita M, Ishihara M, Ono K, Matsumura K, Saito Y, Yura H, Morimoto Y, Shimizu M, Takase B, Ozaki S, Kikuchi M, Maehara T. Source: Journal of Cardiovascular Pharmacology. 2004 January; 43(1): 31-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14668565
•
Inhibition of NF-kappa B activation and its target genes by heparin-binding epidermal growth factor-like growth factor. Author(s): Mehta VB, Besner GE. Source: Journal of Immunology (Baltimore, Md. : 1950). 2003 December 1; 171(11): 601422. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14634113
Studies
93
•
Interactions of heparin with human skin cells: binding, location, and transdermal penetration. Author(s): Parisel C, Saffar L, Gattegno L, Andre V, Abdul-Malak N, Perrier E, Letourneur D. Source: Journal of Biomedical Materials Research. 2003 November 1; 67A(2): 517-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14566793
•
Intralipid/heparin infusion suppresses serum leptin in humans. Author(s): Garcia-Lorda P, Nash W, Roche A, Pi-Sunyer FX, Laferrere B. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2003 June; 148(6): 669-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12773140
•
Intra-operative heparin release during lung surgery. Author(s): Ashour M, Hajjar W, Al-Kattan K, Essa M, Al-Motrafi AA, Al-Saddique A, ElBakry A. Source: European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery. 2004 May; 25(5): 839-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15082291
•
Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Author(s): Sifil A, Mermut C, Yenicerioglu Y, Cavdar C, Gumustekin M, Celik A, Yuksel F, Camsari T. Source: Adv Perit Dial. 2003; 19: 28-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14763030
•
Intravenous heparin did not prevent exacerbations of hereditary angioedema in a patient on maintenance hemodialysis. Author(s): Perricone R, De Carolis C, Fontana L. Source: The Journal of Allergy and Clinical Immunology. 2003 May; 111(5): 1137; Reply 1137. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12743585
•
Involvement of CD44 in induction of matrix metalloproteinases by a COOH-terminal heparin-binding fragment of fibronectin in human articular cartilage in culture. Author(s): Yasuda T, Poole AR, Shimizu M, Nakagawa T, Julovi SM, Tamamura H, Fujii N, Nakamura T. Source: Arthritis and Rheumatism. 2003 May; 48(5): 1271-80. Erratum In: Arthritis Rheum. 2003 June; 48(6): 1763. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12746900
94
Heparin
•
Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Author(s): Caine GJ, Lip GY. Source: Archives of Internal Medicine. 2003 May 26; 163(10): 1243-4; Author Reply 1244. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12767973
•
Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Author(s): Rabe C, Gramann T, Sons X, Berna M, Gonzalez-Carmona MA, Klehr HU, Sauerbruch T, Caselmann WH. Source: Intensive Care Medicine. 2002 August; 28(8): 1172-6. Epub 2002 July 05. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12185445
•
Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. Author(s): Rux AH, Lou H, Lambris JD, Friedman HM, Eisenberg RJ, Cohen GH. Source: Virology. 2002 March 15; 294(2): 324-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12009874
•
Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation. Author(s): Dager WE, Gosselin RC, Yoshikawa R, Owings JT. Source: The Annals of Pharmacotherapy. 2004 April; 38(4): 598-601. Epub 2004 February 24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14982973
•
Localization of the laminin alpha4 chain in the skin and identification of a heparindependent cell adhesion site within the laminin alpha4 chain C-terminal LG4 module. Author(s): Matsuura H, Momota Y, Murata K, Matsushima H, Suzuki N, Nomizu M, Shinkai H, Utani A. Source: The Journal of Investigative Dermatology. 2004 March; 122(3): 614-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15086543
•
Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. Author(s): Unver B, Sunder-Plassmann G, Horl WH, Apsner R. Source: Acta Medica Austriaca. 2002; 29(4): 146-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12424942
Studies
95
•
Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Author(s): Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O'Morain C, Lowson D, Orm S. Source: Alimentary Pharmacology & Therapeutics. 2004 April 15; 19(8): 871-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15080848
•
Low molecular weight heparin and neuraxial anesthesia. Author(s): Horlocker TT. Source: Thrombosis Research. 2001 January 1; 101(1): V141-54. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11342094
•
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen. Author(s): Cook C, Callaway M. Source: European Radiology. 2001; 11(12): 2536-8. Epub 2001 May 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11734955
•
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Author(s): Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Source: Bone Marrow Transplantation. 2003 June; 31(12): 1143-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796794
•
Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery. Author(s): Sawczuk IS, Williams D, Chang DT. Source: Cancer Investigation. 2002; 20(7-8): 889-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12449719
•
Low molecular weight heparin induced priapism. Author(s): Lin PH, Bush RL, Lumsden AB. Source: The Journal of Urology. 2004 July; 172(1): 263. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15201790
•
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Author(s): Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2004 May 15; 22(10): 1944-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15143088
96
Heparin
•
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. Author(s): Chang LC, Lee HF, Yang Z, Yang VC. Source: Aaps Pharmsci [electronic Resource]. 2001; 3(3): E17. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11741268
•
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. Author(s): Chang LC, Liang JF, Lee HF, Lee LM, Yang VC. Source: Aaps Pharmsci [electronic Resource]. 2001; 3(3): E18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11741269
•
Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. Author(s): Ahmed S, Karim A, Patel D, Siddiqui R, Mattana J. Source: The American Journal of the Medical Sciences. 2002 November; 324(5): 279-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12449450
•
Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Author(s): Holzheimer RG. Source: European Journal of Medical Research. 2004 April 30; 9(4): 225-39. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15210403
•
Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Author(s): Douketis JD, Johnson JA, Turpie AG. Source: Archives of Internal Medicine. 2004 June 28; 164(12): 1319-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15226166
•
Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Author(s): Quinlan DJ, McQuillan A, Eikelboom JW. Source: Annals of Internal Medicine. 2004 February 3; 140(3): 175-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14757615
•
Low-molecular-weight heparin during pregnancy. Author(s): Bazzan M, Donvito V. Source: Thrombosis Research. 2001 January 1; 101(1): V175-86. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11342097
Studies
97
•
Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Author(s): Hull RD, Pineo GF, MacIsaac S. Source: Thrombosis Research. 2001 January 1; 101(1): V155-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11342095
•
Low-molecular-weight heparin to prevent pre-eclampsia: there is no evidence and potential harm. Author(s): Middeldorp S. Source: The Netherlands Journal of Medicine. 2004 March; 62(3): 69-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15209469
•
Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Author(s): Heit JA. Source: Thrombosis Research. 2001 January 1; 101(1): V163-73. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11342096
•
Management dilemma of cardiopulmonary bypass in patients with type II heparininduced thrombocytopenia. Author(s): Saad RA, Horn L, Mankad PS. Source: British Journal of Haematology. 2002 December; 119(3): 880. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12437678
•
Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. Author(s): Koster A, Fischer T, Gruendel M, Mappes A, Kuebler WM, Bauer M, Kuppe H. Source: Journal of Cardiothoracic and Vascular Anesthesia. 2003 April; 17(2): 171-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12698397
•
Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Author(s): Warkentin TE. Source: Thrombosis Research. 2003 May 1; 110(2-3): 73-82. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12893020
•
Management of phlegmasia alba dolens using hirudin in a neurosurgical patient with heparin-induced thrombocytopenia. Author(s): Darwish RS, Amiridze NS, James RF, Schreibman D. Source: Journal of Neurosurgical Anesthesiology. 2004 April; 16(2): 171-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15021290
98
Heparin
•
Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Introduction. Author(s): Spinler SA. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 October 15; 60 Suppl 5: S2-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14593976
•
Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin. Author(s): Badmanaban B, Sachithanandan A, Hunter I, Graham A, Sarsam M. Source: Journal of Cardiac Surgery. 2003 July-August; 18(4): 316-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12869178
•
Mechanism of activation of heparin cofactor II by calcium spirulan. Author(s): Hayakawa Y, Hirashima Y, Yamamoto H, Kurimoto M, Hayashi T, Lee JB, Endo S. Source: Archives of Biochemistry and Biophysics. 2003 August 1; 416(1): 47-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12859981
•
Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. Author(s): Wiebe EM, Stafford AR, Fredenburgh JC, Weitz JI. Source: The Journal of Biological Chemistry. 2003 September 12; 278(37): 35767-74. Epub 2003 June 27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12832413
•
Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces. Author(s): Kopp R, Mottaghy K, Kirschfink M. Source: Asaio Journal (American Society for Artificial Internal Organs : 1992). 2002 November-December; 48(6): 598-605. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12455769
•
Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. Author(s): Paredes N, Wang A, Berry LR, Smith LJ, Stafford AR, Weitz JI, Chan AK. Source: The Journal of Biological Chemistry. 2003 June 27; 278(26): 23398-409. Epub 2003 April 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12695507
Studies
99
•
Mechanisms responsible for the failure of protamine to inactivate low-molecularweight heparin. Author(s): Crowther MA, Berry LR, Monagle PT, Chan AK. Source: British Journal of Haematology. 2002 January; 116(1): 178-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11841415
•
Mice expressing only covalent dimeric heparin binding-deficient lipoprotein lipase: muscles inefficiently secrete dimeric enzyme. Author(s): Lutz EP, Kako Y, Yagyu H, Heeren J, Marks S, Wright T, Melford K, BenZeev O, Radner H, Merkel M, Bensadoun A, Wong H, Goldberg IJ. Source: The Journal of Biological Chemistry. 2004 January 2; 279(1): 238-44. Epub 2003 October 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14570890
•
Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Author(s): Inoh K, Muramatsu H, Ochiai K, Torii S, Muramatsu T. Source: Biochemical and Biophysical Research Communications. 2004 April 23; 317(1): 108-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15047154
•
Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Author(s): Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T. Source: Arthritis and Rheumatism. 2004 May; 50(5): 1420-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15146411
•
Miscellaneous treatments, II: niacin and heparin: unapproved uses, dosages, or indications. Author(s): Wolf R, Orion E, Matz H, Tuzun Y, Tuzun B. Source: Clinics in Dermatology. 2002 September-October; 20(5): 547-57. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12435525
•
Multimerization of the Toxoplasma gondii MIC2 integrin-like A-domain is required for binding to heparin and human cells. Author(s): Harper JM, Hoff EF, Carruthers VB. Source: Molecular and Biochemical Parasitology. 2004 April; 134(2): 201-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15003840
•
Multiple heparin binding domains of respiratory syncytial virus G mediate binding to mammalian cells. Author(s): Shields B, Mills J, Ghildyal R, Gooley P, Meanger J. Source: Archives of Virology. 2003 October; 148(10): 1987-2003. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14551820
100
Heparin
•
Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin. Author(s): Rezaie AR, Yang L, Manithody C. Source: Biochemistry. 2004 March 16; 43(10): 2898-905. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15005625
•
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Author(s): Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. Source: The Journal of Clinical Investigation. 2003 April; 111(8): 1181-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12697737
•
N-desulfated heparin improves concanavalin A-induced liver injury partly through inhibiting T lymphocyte adhesion. Author(s): Yuan L, Geng JG, Xu Q. Source: Inflammation Research : Official Journal of the European Histamine Research Society. [et Al.]. 2003 September; 52(9): 383-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14504666
•
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Author(s): Wan JG, Mu JS, Zhu HS, Geng JG. Source: Inflammation Research : Official Journal of the European Histamine Research Society. [et Al.]. 2002 September; 51(9): 435-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12365716
•
Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin. Author(s): Geisbrecht BV, Dowd KA, Barfield RW, Longo PA, Leahy DJ. Source: The Journal of Biological Chemistry. 2003 August 29; 278(35): 32561-8. Epub 2003 June 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12810718
•
Neuropeptide-induced transactivation of a neuronal epidermal growth factor receptor is mediated by metalloprotease-dependent formation of heparin-binding epidermal growth factor. Author(s): Shah BH, Farshori MP, Catt KJ. Source: The Journal of Biological Chemistry. 2004 January 2; 279(1): 414-20. Epub 2003 October 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14573593
Studies
101
•
New heparin dosing recommendations for patients with acute coronary syndromes. Author(s): Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS. Source: The American Journal of Medicine. 2001 June 1; 110(8): 641-50. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11382373
•
New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding. Author(s): Chanard J, Lavaud S, Randoux C, Rieu P. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2003 February; 18(2): 252-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12543877
•
No influence of heparin plasma and other (pre)analytic variables on D-dimer determinations. Author(s): Schutgens RE, Haas FJ, Ruven HJ, Spannagl M, Horn K, Biesma DH. Source: Clinical Chemistry. 2002 September; 48(9): 1611-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12194950
•
Non-anticoagulant effects of heparin in carcinoma metastasis and Trousseau's syndrome. Author(s): Borsig L. Source: Pathophysiology of Haemostasis and Thrombosis. 2003; 33 Suppl 1: 64-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12955009
•
Novel concatameric heparin-binding peptides reverse heparin and low-molecularweight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Author(s): Schick BP, Maslow D, Moshinski A, San Antonio JD. Source: Blood. 2004 February 15; 103(4): 1356-63. Epub 2003 October 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14576044
•
Novel drug development opportunities for heparin. Author(s): Lever R, Page CP. Source: Nature Reviews. Drug Discovery. 2002 February; 1(2): 140-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12120095
•
Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy. Author(s): Sakai K, Oda H, Honsako A, Takahashi K, Miida T, Higuma N. Source: Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 2003 July; 59(3): 351-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12822157
102
Heparin
•
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Author(s): Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2003 October; 18(10): 2097-104. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=13679486
•
Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. Author(s): Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R. Source: Journal of Biomedical Materials Research. 2003 November 1; 67A(2): 458-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14566786
•
Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Author(s): Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, Mismetti P. Source: Thrombosis and Haemostasis. 2003 October; 90(4): 654-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14515186
•
Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin. Author(s): Brieger D. Source: Clin Cardiol. 2004 January; 27(1): 3-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14743848
•
Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. Author(s): Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. Source: Journal of Thrombosis and Haemostasis : Jth. 2003 September; 1(9): 1914-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12941031
•
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. Author(s): Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, Lopez-Sendon JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Source: Journal of the American College of Cardiology. 2003 October 1; 42(7): 1178-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14522476
Studies
103
•
Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Author(s): Segal JB, Bolger DT, Jenckes MW, Krishnan JA, Streiff MB, Eng J, Tamariz LJ, Bass EB. Source: The American Journal of Medicine. 2003 September; 115(4): 298-308. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12967695
•
Overview of heparin-induced thrombocytopenia. Author(s): Spinler SA, Dager W. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 October 15; 60 Suppl 5: S5-11. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14593977
•
Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Author(s): Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Source: Molecular and Cellular Biology. 2004 June; 24(12): 5172-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15169883
•
Pathophysiology, epidemiology, diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Author(s): Picker SM, Gathof BS. Source: European Journal of Medical Research. 2004 April 30; 9(4): 180-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15210398
•
Pericardial fluid and serum VEGF in response to different types of heparin treatment. Author(s): Gerrah R, Tshori S, Gilon D. Source: International Journal of Cardiology. 2004 April; 94(2-3): 193-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15093980
•
Pharmacotherapy of heparin- induced thrombocytopenia. Author(s): Dager WE, White RH. Source: Expert Opinion on Pharmacotherapy. 2003 June; 4(6): 919-40. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12783589
•
Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants. Author(s): Boning A, Scheewe J, Ivers T, Friedrich C, Stieh J, Freitag S, Cremer JT. Source: The Journal of Thoracic and Cardiovascular Surgery. 2004 May; 127(5): 1458-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15116008
104
Heparin
•
Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Author(s): Breddin HK. Source: Archives of Pathology & Laboratory Medicine. 2003 July; 127(7): 782-3; Author Reply 783. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12823032
•
Pre-heparin lipoprotein lipase mass. Author(s): Kobayashi J. Source: J Atheroscler Thromb. 2004; 11(1): 1-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15067192
•
Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. Author(s): Spinal Cord Injury Thromboprophylaxis Investigators. Source: The Journal of Trauma. 2003 June; 54(6): 1116-24; Discussion 1125-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12813332
•
Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. Author(s): Spinal Cord Injury Thromboprophylaxis Investigators. Source: The Journal of Trauma. 2003 June; 54(6): 1111-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12813331
•
Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Author(s): Piepkorn M, Predd H, Underwood R, Cook P. Source: Archives of Dermatological Research. 2003 July; 295(3): 93-101. Epub 2003 May 27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12768307
•
P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment. Author(s): Papalambros E, Sigala F, Travlou A, Bastounis E, Mirilas P. Source: Journal of the American College of Surgeons. 2004 July; 199(1): 69-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15217633
Studies
105
•
Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Author(s): Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Source: British Journal of Clinical Pharmacology. 2002 December; 54(6): 627-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12492611
•
R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells through fibrin glue. Author(s): Erzurum VZ, Bian JF, Husak VA, Ellinger J, Xue L, Burgess WH, Greisler HP. Source: Journal of Vascular Surgery : Official Publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2003 May; 37(5): 1075-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12756357
•
Randomized clinical trial of low molecular weight heparin with thigh-length or kneelength antiembolism stockings for patients undergoing surgery. Author(s): Howard A, Zaccagnini D, Ellis M, Williams A, Davies AH, Greenhalgh RM. Source: The British Journal of Surgery. 2004 July; 91(7): 842-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15227689
•
Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Author(s): Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK, Hekmatpanah J, Frim D. Source: Surgical Neurology. 2003 May; 59(5): 363-72; Discussion 372-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12765806
•
Recurrence rate of pre-eclampsia in women with thrombophilia influenced by lowmolecular-weight heparin treatment? Author(s): Kalk JJ, Huisjes AJ, de Groot CJ, van Beek E, van Pampus MG, Spaanderman ME, van Eyck J, Oei SG, Bezemer PD, de Vries JI. Source: The Netherlands Journal of Medicine. 2004 March; 62(3): 83-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15209472
•
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Author(s): O'Donnell M, Linkins LA, Kearon C, Julian J, Hirsh J. Source: Archives of Internal Medicine. 2003 June 9; 163(11): 1362-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796074
106
Heparin
•
Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a largescale, real world registry. Author(s): Gupta V, Aravamuthan BR, Baskerville S, Smith SK, Gupta V, Lauer MA, Fischell TA. Source: J Invasive Cardiol. 2004 June; 16(6): 304-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15155999
•
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Author(s): Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J; Organization to Assess Strategies for Ischemic Syndromes Investigators. Source: Circulation. 2003 June 17; 107(23): 2884-8. Epub 2003 Jun 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796128
•
Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice. Author(s): McGarry LJ, Thompson D. Source: Clinical Therapeutics. 2004 March; 26(3): 419-30. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15110135
•
Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Author(s): Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, Mann MJ, Achorn NL, Moskalik WF, Hoopes CW. Source: Anesthesia and Analgesia. 2004 June; 98(6): 1635-9, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15155316
•
Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Author(s): Opatrny L, Warner MN. Source: American Journal of Hematology. 2004 July; 76(3): 240-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15224359
•
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-STsegment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. Author(s): Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; A to Z Investigators. Source: Jama : the Journal of the American Medical Association. 2004 July 7; 292(1): 5564. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15238591
Studies
107
•
Safety of heparin reversal with protamin and immediate sheath removal after coronary angioplasty. Author(s): Lohne F, Klow NE, Stavnes S, Brekke M, Hoffmann P, Stensaeth KH, Sovik E, Pettersen MS. Source: Acta Radiologica (Stockholm, Sweden : 1987). 2004 April; 45(2): 171-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15191101
•
Spontaneous splenic rupture following the administration of intravenous heparin: case report and retrospective case review. Author(s): Ghobrial MW, Karim M, Mannam S. Source: American Journal of Hematology. 2002 December; 71(4): 314-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12447963
•
Stenosis of the hepatic vein anastomosis after liver transplantation: treatment with a heparin-coated metal stent. Author(s): Frazer CK, Gupta A. Source: Australasian Radiology. 2002 December; 46(4): 422-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12452917
•
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Author(s): LaMonte MP, Brown PM, Hursting MJ. Source: Critical Care Medicine. 2004 April; 32(4): 976-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15071388
•
Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecularweight heparin in the initial treatment of venous thromboembolism. Author(s): Prandoni P, Carnovali M, Marchiori A; Galilei Investigators. Source: Archives of Internal Medicine. 2004 May 24; 164(10): 1077-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15159264
•
Suboptimal monitoring and dosing of unfractionated heparin. Author(s): Chung KK, Tofferi JK, Browne WT. Source: Annals of Internal Medicine. 2004 April 6; 140(7): 582; Author Reply 582-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15068994
•
Successful pregnancy with low molecular weight heparin in two women with recurrent miscarriage of unknown etiology. Author(s): Miyashita Y, Waguri M, Nakanishi I, Suehara N, Fujita T. Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989). 2003 February; 49(2): 90-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12765347
108
Heparin
•
Successful treatment of left atrial disk thrombus on an Amplatzer atrial septal defect occluder with abciximab and heparin. Author(s): Willcoxson FE, Thomson JD, Gibbs JL. Source: Heart (British Cardiac Society). 2004 May; 90(5): E30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15084578
•
Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Author(s): Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ, ter Wee PM. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2002 December; 17(12): 2189-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12454232
•
The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura). Author(s): Blessing F, Wang Y, Nagel D, Seidel D. Source: Ther Apher Dial. 2004 February; 8(1): 33-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15128017
•
The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Author(s): de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA, Hack CE, van Barneveld L, Eijsman L, Wildevuur CR. Source: Anesthesia and Analgesia. 2004 June; 98(6): 1586-94, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15155310
•
The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Author(s): Haas S. Source: Semin Vasc Med. 2003 May; 3(2): 139-46. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15199477
•
The ShdA adhesin binds to the cationic cradle of the fibronectin 13FnIII repeat module: evidence for molecular mimicry of heparin binding. Author(s): Kingsley RA, Keestra AM, de Zoete MR, Baumler AJ. Source: Molecular Microbiology. 2004 April; 52(2): 345-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15066025
•
The value of heparin concentration monitoring in off-pump coronary bypass surgery. Author(s): Baykut D, Weichelt K, Wehrle J, Zerkowski HR, Bernet F. Source: European Journal of Medical Research. 2003 April 30; 8(4): 161-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12765862
Studies
109
•
Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. Author(s): Kitchens CS. Source: American Journal of Hematology. 2004 May; 76(1): 69-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15114601
•
Thromboprophylaxis with low molecular weight heparin in thrombophiliacomplicated pregnancy. Author(s): Ebina Y, Yamada H, Kato EH, Yamamoto R, Sakuragi N, Fujimoto S. Source: The Journal of Obstetrics and Gynaecology Research. 2002 October; 28(5): 251-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428694
•
Treatment of acute pulmonary embolism during pregnancy with low molecular weight heparin: three case reports. Author(s): Kaaja RJ, Ulander VM. Source: Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 2002 October; 13(7): 637-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12439150
•
Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews. Author(s): Krishnan JA, Segal JB, Streiff MB, Bolger DT, Eng J, Jenckes MW, Tamariz LJ, Bass EB. Source: Respiratory Medicine. 2004 May; 98(5): 376-86. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15139566
•
Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini. Author(s): Myers JC, Li D, Amenta PS, Clark CC, Nagaswami C, Weisel JW. Source: The Journal of Biological Chemistry. 2003 August 22; 278(34): 32047-57. Epub 2003 June 03. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12788917
•
Unfractionated heparin and other antithrombin mediated anticoagulants. Author(s): Adler BK. Source: Clin Lab Sci. 2004 Spring; 17(2): 113-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15168893
110
Heparin
•
Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy. Author(s): Opal SM. Source: Critical Care Medicine. 2004 March; 32(3): 874-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15090975
•
Up-regulation of heparin binding epidermal growth factor-like growth factor and amphiregulin expression in Helicobacter pylori-infected human gastric mucosa. Author(s): Tuccillo C, Manzo BA, Nardone G, D'Argenio G, Rocco A, Di Popolo A, Della VN, Staibano S, De Rosa G, Ricci V, Del Vecchio BC, Zarrilli R, Romano M. Source: Dig Liver Dis. 2002 July; 34(7): 498-505. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12236483
•
Use of a centrifugal vortex blood pump and heparin-bonded circuit for extracorporeal rewarming of severe hypothermia in acutely injured and coagulopathic patients. Author(s): Kirkpatrick AW, Garraway N, Brown DR, Nash D, Ng A, Lawless B, Cunningham J, Chun R, Simons RK. Source: The Journal of Trauma. 2003 September; 55(3): 407-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14501879
•
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. Author(s): Cochran K, DeMartini TJ, Lewis BE, O Brien J, Steen LH, Grassman ED, Leya F. Source: J Invasive Cardiol. 2003 November; 15(11): 617-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14608129
•
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Author(s): Streif W, Goebel G, Chan AK, Massicotte MP. Source: Archives of Disease in Childhood. Fetal and Neonatal Edition. 2003 September; 88(5): F365-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12937038
•
Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. Author(s): Kajitani M, Aguinaga M, Johnson CE, Scott MA, Antakli T. Source: Journal of Cardiac Surgery. 2001; 16(4): 313-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11833705
•
Use of the low-molecular-weight heparin nadroparin during pregnancy. A review. Author(s): Makatsaria AD, Bitsadze VO, Dolgushina NV. Source: Current Medical Research and Opinion. 2003; 19(1): 4-12. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12661774
Studies
111
•
Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. Author(s): Kim MH, Decena BF, Bruckman D, Eagle KA. Source: American Heart Journal. 2003 April; 145(4): 665-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12679763
•
Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Author(s): Zimmermann AT, Jeffries WS, McElroy H, Horowitz JD. Source: Internal Medicine Journal. 2003 January-February; 33(1-2): 18-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12534874
•
Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Author(s): Toth C, Voll C. Source: Stroke; a Journal of Cerebral Circulation. 2002 March; 33(3): 670-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11872885
•
Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Author(s): Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M. Source: European Journal of Clinical Pharmacology. 2003 September; 59(5-6): 373-7. Epub 2003 July 08. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12851802
•
Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes. Author(s): Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crepin M. Source: The Journal of Biological Chemistry. 2001 October 26; 276(43): 39748-54. Epub 2001 August 20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11514538
•
Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia. Author(s): Tokuda Y, Matsumoto M, Sugita T, Nishizawa J, Matsuyama K, Yoshida K, Matsuo T. Source: Circulation Journal : Official Journal of the Japanese Circulation Society. 2003 October; 67(10): 889-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14578626
112
Heparin
•
VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. Author(s): Lange T, Guttmann-Raviv N, Baruch L, Machluf M, Neufeld G. Source: The Journal of Biological Chemistry. 2003 May 9; 278(19): 17164-9. Epub 2003 February 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12598527
•
Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Author(s): Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC. Source: American Journal of Hematology. 2002 September; 71(1): 50-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12221676
•
Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Author(s): Cesarone MR, Belcaro G, Nicolaides AN, Incandela L, De S, Geroulakos G, Lennox A, Myers KA, Moia M, Ippolito E, Winford M. Source: Angiology. 2002 January-February; 53(1): 1-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11863301
•
Venous thrombosis prophylaxis with low-molecular-weight heparin in hip and knee arthroplasty. Author(s): Colwell CW Jr. Source: Instr Course Lect. 2002; 51: 487-9. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12064138
•
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Author(s): van der Heijden JF, Hutten BA, Buller HR, Prins MH. Source: Cochrane Database Syst Rev. 2002; (1): Cd002001. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11869618
•
von Willebrand factor binding to heparin in various types of von Willebrand disease. Author(s): Rastegar-Lari G, Legendre P, Ajzenberg N, Warszawski J, Meyer D, Baruch D. Source: The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 2000; 1(3): 190-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11920189
Studies
113
•
Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Author(s): Warkentin TE, Whitlock RP, Teoh KH. Source: American Journal of Hematology. 2004 January; 75(1): 56-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14695634
•
Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparininduced thrombocytopenia. Author(s): Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, Murphy S, Baker KR. Source: Archives of Internal Medicine. 2004 January 12; 164(1): 66-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14718324
•
What is the incidence of heparin-induced thrombocytopenia (HIT) in children? Author(s): Martchenke J, Pate MF, Cruz M, Phromsivarak S. Source: Critical Care Nurse. 2004 February; 24(1): 66-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15007896
•
When can unfractionated heparin really be useful in the treatment of ulcerative colitis? Author(s): Papa A, Danese S, Gasbarrini G, Gasbarrini A. Source: Gastroenterology. 2001 April; 120(5): 1306-7; Author Reply 1307-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11288745
•
When should heparin preferably be administered during radiofrequency catheter ablation? Author(s): Anfinsen OG, Gjesdal K, Aass H, Brosstad F, Orning OM, Amlie JP. Source: Pacing and Clinical Electrophysiology : Pace. 2001 January; 24(1): 5-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11227969
•
Which heparin is best. When cardiac catheterization is needed, know your heparins. Author(s): Knight D. Source: The American Journal of Nursing. 2003 December; 103(12): 81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14702571
•
Wounding induces motility in sheets of corneal epithelial cells through loss of spatial constraints: role of heparin-binding epidermal growth factor-like growth factor signaling. Author(s): Block ER, Matela AR, SundarRaj N, Iszkula ER, Klarlund JK. Source: The Journal of Biological Chemistry. 2004 June 4; 279(23): 24307-12. Epub 2004 March 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15039441
114
•
Heparin
Zinc ions promote the interaction between heparin and heparin cofactor II. Author(s): Eckert R, Ragg H. Source: Febs Letters. 2003 April 24; 541(1-3): 121-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12706831
115
CHAPTER 2. NUTRITION AND HEPARIN Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and heparin.
Finding Nutrition Studies on Heparin The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “heparin” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
116
Heparin
The following is a typical result when searching for recently indexed consumer information on heparin: •
New heparin is no heavyweight. Source: Feinberg, A W Health-News. 2000 August; 6(8): 5-6 1081-5880
The following information is typical of that found when using the “Full IBIDS Database” to search for “heparin” (or a synonym): •
Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Author(s): Departments of Anaesthesiology and Intensive Care B, University of Vienna, School of Medicine, Vienna, Austria.
[email protected] Source: Kozek Langenecker, S A Spiss, C K Gamsjager, T Domenig, C Zimpfer, M WienKlin-Wochenschr. 2002 February 15; 114(3): 96-101 0043-5325
•
Contribution of basic residues of the A helix of heparin cofactor II to heparin- or dermatan sulfate-mediated thrombin inhibition. Author(s): Department of Neurosurgery, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Japan.
[email protected] Source: Hayakawa, Yumiko Hirashima, Yutaka Kurimoto, Masanori Hayashi, Nakamasa Hamada, Hideo Kuwayama, Naoya Endo, Shunro FEBS-Lett. 2002 July 3; 522(1-3): 147-50 0014-5793
•
Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Author(s): Departments of Cardiology and Lab Medicine Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA.
[email protected] Source: Chandy, T Rao, G H Wilson, R F Das, G S Drug-Delivolume 2002 Apr-June; 9(2): 87-96 1071-7544
•
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Author(s): Sanofi-Synthelabo Recherche, Toulouse, France. Source: Herault, J P Bernat, A Gaich, C Herbert, M Thromb-Haemost. 2002 February; 87(2): 238-44 0340-6245
•
Facilitation of learning and modulation of frontal cortex acetylcholine by ventral pallidal injection of heparin glucosaminoglycan. Author(s): Institute of Physiological Psychology, University of Dusseldorf, 40225, Dusseldorf, Germany. Source: De Souza Silva, M A Jezek, K Weth, K Muller, H W Huston, J P Brandao, M L Hasenohrl, R U Neuroscience. 2002; 113(3): 529-35 0306-4522
•
Hydration effects of heparin on antithrombin probed by osmotic stress. Author(s): Wake Forest University Medical School, Medicine Department, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA.
[email protected] Source: McGee, Maria P Liang, Jie Luba, James Biophys-J. 2002 February; 82(2): 1040-9 0006-3495
•
Inhibition of human angiogenesis with heparin and hydrocortisone. Author(s): Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA. Source: Jung, S P Siegrist, B Wade, M R Anthony, C T Woltering, E A Angiogenesis. 2001; 4(3): 175-86 0969-6970
Nutrition
117
•
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Author(s): Department of Medicine E, Sheba Medical Center, Sackler School of Medicine and School of Engineering, Tel-Aviv University, Israel.
[email protected] Source: Pauzner, R Dulitzki, M Langevitz, P Livneh, A Kenett, R Many, A ThrombHaemost. 2001 December; 86(6): 1379-84 0340-6245
•
Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Author(s): The Department of Obstetrics and Gynecology, Lis Maternity Hospital, TelAviv University, Tel-Aviv, Israel.
[email protected] Source: Kupferminc, M J Fait, G Many, A Lessing, J B Yair, D Bar Am, A Eldor, A Hypertens-Pregnancy. 2001; 20(1): 35-44 1064-1955
•
Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Author(s): Institute of Pharmacy, University of Regensburg, Regensburg, Germany.
[email protected] Source: Alban, S Semin-Thromb-Hemost. 2001 October; 27(5): 503-11 0094-6176
•
Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity. Author(s): Department of Radiation Oncology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
[email protected] Source: Hosoi, Y Matsumoto, Y Tomita, M Enomoto, A Morita, A Sakai, K Umeda, N Zhao, H J Nakagawa, K Ono, T Suzuki, N Br-J-Cancer. 2002 April 8; 86(7): 1143-9 00070920
•
The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Author(s): Department of Medicine, Massachusetts General Hospital, Boston 02114, USA.
[email protected] Source: Brown, J R Kuter, D J Thromb-Haemost. 2001 June; 85(6): 979-85 0340-6245
•
The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. Author(s): Pharmacology Group, Research & Development Division, Nippon Organon K. K., Osaka, Japan. Source: Miyake, Y Yokota, K Fujishima, Y Sukamoto, T Blood-Coagul-Fibrinolysis. 2001 July; 12(5): 349-57 0957-5235
•
Use of enzyme and heparin paste in acute haemorrhoids. Author(s): Gupta Nursing Home, Nagpur, India. Source: Gupta, P J Rom-J-Gastroenterol. 2002 September; 11(3): 191-5 1221-4167
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
118
Heparin
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to heparin; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Vitamin C Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin D Source: Healthnotes, Inc.; www.healthnotes.com
Nutrition
119
Vitamin D Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin E Source: Prima Communications, Inc.www.personalhealthzone.com •
Minerals Chondroitin Alternative names: chondroitin sulfate, sodium chondroitin sulfate Source: Integrative Medicine Communications; www.drkoop.com Chondroitin Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10017,00.html Potassium Source: Healthnotes, Inc.; www.healthnotes.com Potassium Source: Integrative Medicine Communications; www.drkoop.com Vanadium Alternative names: Vanadate Source: Integrative Medicine Communications; www.drkoop.com Vinpocetine Source: Prima Communications, Inc.www.personalhealthzone.com
•
Food and Diet Garlic Source: Prima Communications, Inc.www.personalhealthzone.com Omega-3 Fatty Acids Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,992,00.html
121
CHAPTER 3. ALTERNATIVE MEDICINE AND HEPARIN Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to heparin. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to heparin and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “heparin” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to heparin: •
A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats. Author(s): Abrial D, Blanc A, Rehailia M, Mismetti P, Bouchut C, Laporte-Simitsidis S, Decousus H, Buisson B. Source: Haemostasis. 2000 September-October; 30(5): 233-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11251330
•
A protocol for coadministration of i.v. iron dextran and heparin in chronic hemodialysis patients. Author(s): Davis P, Bednarz D, Briglia A, Paganini EP. Source: Anna J. 1998 October; 25(5): 533-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9887705
122
Heparin
•
A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent. Author(s): Brancaccio V, Ames PR, Glynn J, Iannaccone L, Mackie IJ. Source: Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 1997 April; 8(3): 155-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9167015
•
A sensitive and specific functional flow cytometric assay for the diagnosis of heparininduced thrombocytopenia. Author(s): Tomer A. Source: British Journal of Haematology. 1997 September; 98(3): 648-56. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9332321
•
Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. Author(s): Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Source: Ophthalmology. 2001 July; 108(7): 1179-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11425671
•
Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Author(s): Narita T, Kawakami-Kimura N, Sato M, Matsuura N, Higashiyama S, Taniguchi N, Kannagi R. Source: Oncology. 1996 September-October; 53(5): 374-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8784471
•
Antithrombin increases pulmonary endothelins: inhibition by heparin and Ca2+ channel antagonism. Author(s): Stangl K, Dschietzig T, Alexiou K, Brunner F. Source: European Journal of Pharmacology. 1999 April 1; 370(1): 57-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10323280
•
BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparinbinding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. Author(s): Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR. Source: The Journal of Biological Chemistry. 2001 August 10; 276(32): 30127-32. Epub 2001 May 04. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11340068
Alternative Medicine 123
•
Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. Author(s): Talts JF, Andac Z, Gohring W, Brancaccio A, Timpl R. Source: The Embo Journal. 1999 February 15; 18(4): 863-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10022829
•
Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. Author(s): Rezaie AR. Source: The Journal of Biological Chemistry. 1998 July 3; 273(27): 16824-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9642241
•
Characterization of a 30-kDa peripheral nerve glycoprotein that binds laminin and heparin. Author(s): Saito F, Yamada H, Sunada Y, Hori H, Shimizu T, Matsumura K. Source: The Journal of Biological Chemistry. 1997 October 17; 272(42): 26708-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9334255
•
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Author(s): Balthasar JP. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 1999 September 15; 56(18): 1891. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10511236
•
Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures. Author(s): Chen C, Li J, Micko CJ, Pierce GF, Cunningham MR, Lumsden AB. Source: The Journal of Surgical Research. 1998 February 15; 75(1): 35-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9614854
•
Delayed cutaneous reactions to heparin in antiphospholipid syndrome during pregnancy. Author(s): Kim J, Smith KJ, Toner C, Skelton H. Source: International Journal of Dermatology. 2004 April; 43(4): 252-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15090006
•
Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Author(s): Tomer A, Masalunga C, Abshire TC. Source: American Journal of Hematology. 1999 May; 61(1): 53-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10331512
124
Heparin
•
Development of poly(Lactic acid)/chitosan co-matrix microspheres: controlled release of taxol-heparin for preventing restenosis. Author(s): Chandy T, Rao GH, Wilson RF, Das GS. Source: Drug Delivery. 2001 April-June; 8(2): 77-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11400866
•
Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. Author(s): Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Source: The Journal of Clinical Investigation. 1998 February 15; 101(4): 877-89. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9466983
•
Differentiation between the complement modulating effects of an arabinogalactanprotein from Echinacea purpurea and heparin. Author(s): Alban S, Classen B, Brunner G, Blaschek W. Source: Planta Medica. 2002 December; 68(12): 1118-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12494341
•
Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Author(s): Day JR, Malik IS, Weerasinghe A, Poullis M, Nadra I, Haskard DO, Taylor KM, Landis RC. Source: Heart (British Cardiac Society). 2004 July; 90(7): 794-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15201252
•
Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex. Author(s): Kan M, Wang F, To B, Gabriel JL, McKeehan WL. Source: The Journal of Biological Chemistry. 1996 October 18; 271(42): 26143-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8824259
•
EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Author(s): Lam NY, Rainer TH, Chiu RW, Lo YM. Source: Clinical Chemistry. 2004 January; 50(1): 256-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14709670
•
Effect of glycemic control on plasma plant sterol levels and post-heparin diamine oxidase activity in type 1 diabetic patients. Author(s): Kojima H, Hidaka H, Matsumura K, Fujita Y, Yamada S, Haneda M, Yasuda H, Kikkawa R, Kashiwagi A.
Alternative Medicine 125
Source: Atherosclerosis. 1999 August; 145(2): 389-97. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10488968 •
Effects of anticoagulants in amino acid analysis: comparisons of heparin, EDTA, and sodium citrate in vacutainer tubes for plasma preparation. Author(s): Chuang CK, Lin SP, Lin YT, Huang FY. Source: Clinical Chemistry. 1998 May; 44(5): 1052-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9590384
•
Effects of heparin on polymerase chain reaction for blood white cells. Author(s): Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I. Source: Journal of Clinical Laboratory Analysis. 1999; 13(3): 133-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10323479
•
Effects of hyperbaric oxygen treatment and heparin on the survival of unipedicled venous flaps: an experimental study in rats. Author(s): Yucel A, Bayramicli M. Source: Annals of Plastic Surgery. 2000 March; 44(3): 295-303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10735222
•
Effects of lithium heparin and tripotassium EDTA on hematologic values of Hermann's tortoises (Testudo hermanni). Author(s): Muro J, Cuenca R, Pastor J, Vinas L, Lavin S. Source: J Zoo Wildl Med. 1998 March; 29(1): 40-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9638624
•
Endpoint-attached heparin blocks neutrophil sticking and spreading. Author(s): Videm V. Source: Biomaterials. 2004 January; 25(1): 43-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14580907
•
Ethylenediaminetetraacetic acid (EDTA) in heparin. Author(s): Coyne E, Messmore HL, Walenga JM, Fareed J, Wehrmacher WH. Source: Thrombosis Research. 1998 June 1; 90(5): 245-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9694247
•
Fine mapping of the sequences in domain 5 of high molecular weight kininogen (HK) interacting with heparin and zinc. Author(s): Pixley RA, Lin Y, Isordia-Salas I, Colman RW. Source: Journal of Thrombosis and Haemostasis : Jth. 2003 August; 1(8): 1791-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12911595
126
Heparin
•
Hematologic evaluation of normal and anemic lambs with the Technicon H*1 using EDTA or heparin as anticoagulants. Author(s): Vatn S, Framstad T, Torsteinbo WO. Source: Vet Clin Pathol. 2000; 29(2): 62-68. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12070814
•
Heparin in plasma samples causes nonspecific binding to histones on Western blots. Author(s): Alcantara FF, Iglehart DJ, Ochs RL. Source: Journal of Immunological Methods. 1999 June 24; 226(1-2): 11-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10410967
•
Heparin modulates integrin function in human platelets. Author(s): Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, Kusumoto S, Blystone SD, Suda Y. Source: Journal of Vascular Surgery : Official Publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter. 2001 March; 33(3): 587-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11241131
•
Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine. Author(s): Tevaearai HT, Jegger D, Mueller XM, Horisberger J, von Segesser LK. Source: The Thoracic and Cardiovascular Surgeon. 1998 October; 46(5): 303-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9885123
•
Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells. Author(s): Maia RC, Wagner K, Cabral RH, Rumjanek VM. Source: Cancer Letters. 1996 August 23; 106(1): 101-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8827053
•
Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Author(s): Liu JJ, Zhang J, Ramanan S, Julian J, Carson DD, Hooi SC. Source: Carcinogenesis. 2004 June; 25(6): 873-9. Epub 2004 January 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14729579
•
Heparin-binding EGF-like growth factor regulates elastin and FGF-2 expression in pulmonary fibroblasts. Author(s): Liu J, Rich CB, Buczek-Thomas JA, Nugent MA, Panchenko MP, Foster JA. Source: American Journal of Physiology. Lung Cellular and Molecular Physiology. 2003 November; 285(5): L1106-15. Epub 2003 July 25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882762
Alternative Medicine 127
•
Heparin-binding epidermal-growth-factor-like growth factor gene expression is induced by scrape-wounding epithelial cell monolayers: involvement of mitogenactivated protein kinase cascades. Author(s): Ellis PD, Hadfield KM, Pascall JC, Brown KD. Source: The Biochemical Journal. 2001 February 15; 354(Pt 1): 99-106. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11171084
•
Heparinoids: structure, biological activities and therapeutic applications. Author(s): Gunay NS, Linhardt RJ. Source: Planta Medica. 1999 May; 65(4): 301-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10364832
•
Heparin-platelet factor (PF) 4 antibodies in patients with pseudothrombocytopenia: coincidence or association? Author(s): Schwarzinger I, Speiser W, Lubenow N, Greinacher A, Panzer S. Source: Thrombosis and Haemostasis. 2000 December; 84(6): 1123-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11154128
•
Heterogeneity of the chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for pleiotrophin/heparin binding growth-associated molecule. Author(s): Maeda N, He J, Yajima Y, Mikami T, Sugahara K, Yabe T. Source: The Journal of Biological Chemistry. 2003 September 12; 278(37): 35805-11. Epub 2003 July 02. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12840014
•
High-dose heparin impairs nitric oxide pathway and vasomotion in rats. Author(s): Bachetti T, Pasini E, Clini E, Cremona G, Ferrari R. Source: Circulation. 1999 June 8; 99(22): 2861-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10359728
•
Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia. Author(s): Reilly MP, Weiss R, Askenase A, Tuite C, Soulen M, Mohler ER 3rd. Source: Vascular Medicine (London, England). 2000; 5(4): 239-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11213236
•
Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Author(s): Hall MW, Goodman PD, Alston SM, Solen KA. Source: American Journal of Hematology. 2002 January; 69(1): 45-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11835331
128
Heparin
•
Identification of a major heparin and cell binding site in the LG4 module of the laminin alpha 5 chain. Author(s): Nielsen PK, Gho YS, Hoffman MP, Watanabe H, Makino M, Nomizu M, Yamada Y. Source: The Journal of Biological Chemistry. 2000 May 12; 275(19): 14517-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10799535
•
Influence of EDTA and heparin on lipopolysaccharide binding and cell activation, evaluated at single-cell level in whole blood. Author(s): Brunialti MK, Kallas EG, Freudenberg M, Galanos C, Salomao R. Source: Cytometry : the Journal of the Society for Analytical Cytology. 2002 February 15; 50(1): 14-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11857593
•
Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. Author(s): Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A. Source: The Journal of Allergy and Clinical Immunology. 1999 June; 103(6): 1143-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10359897
•
Interaction between the carboxyl-terminal heparin-binding domain of fibronectin and (-)-epigallocatechin gallate. Author(s): Sazuka M, Isemura M, Isemura S. Source: Bioscience, Biotechnology, and Biochemistry. 1998 May; 62(5): 1031-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9648240
•
Laminin E8 alveolarization site: heparin sensitivity, cell surface receptors, and role in cell spreading. Author(s): Chen L, Shick V, Matter ML, Laurie SM, Ogle RC, Laurie GW. Source: The American Journal of Physiology. 1997 March; 272(3 Pt 1): L494-503. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9124607
•
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies? Author(s): White HD. Source: J Invasive Cardiol. 2000 February; 12 Suppl A: 6A-13A. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10731290
•
Low-molecular-weight heparin as a multipurpose anticoagulant for laboratory testing. Author(s): Kawamoto T, Hiino M, Takubo T, Tatsumi N.
Alternative Medicine 129
Source: Osaka City Med J. 2000 June; 46(1): 37-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10983466 •
Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism. Author(s): Tsimoyiannis EC, Floras G, Antoniou N, Papanikolaou N, Siakas P, Tassis A. Source: World Journal of Surgery. 1996 October; 20(8): 968-71; Discussion 972. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8798349
•
Matrix metalloproteinase production by COOH-terminal heparin-binding fibronectin fragment in rheumatoid synovial cells. Author(s): Yasuda T, Shimizu M, Nakagawa T, Julovi SM, Nakamura T. Source: Laboratory Investigation; a Journal of Technical Methods and Pathology. 2003 February; 83(2): 153-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12594231
•
Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan. Author(s): Heinzelmann M, Polk HC Jr, Miller FN. Source: Infection and Immunity. 1998 December; 66(12): 5842-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9826363
•
Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. Author(s): Kouretas PC, Hannan RL, Kapur NK, Hendrickson R, Redmond EM, Myers AK, Kim YD, Cahill PA, Sitzmann JV. Source: Journal of Molecular and Cellular Cardiology. 1998 December; 30(12): 2669-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9990538
•
Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. Author(s): Smith BS, Gandhi PJ. Source: Journal of Thrombosis and Thrombolysis. 2001 February; 11(1): 39-48. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11248789
•
Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. Author(s): Reimann JD, Modi NB, Novotny W. Source: Journal of Clinical Pharmacology. 2000 May; 40(5): 488-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10806602
•
Post-heparin serum lecithinase in man and its positional specificity. Author(s): Vogel WC, Bierman EL.
130
Heparin
Source: Journal of Lipid Research. 1967 January; 8(1): 46-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14564704 •
Reversal of RT-PCR inhibition observed in heparinized clinical specimens. Author(s): Jung R, Lubcke C, Wagener C, Neumaier M. Source: Biotechniques. 1997 July; 23(1): 24, 26, 28. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9232220
•
Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. Author(s): Whinna HC, Lesesky EB, Monroe DM, High KA, Larson PJ, Church FC. Source: Journal of Thrombosis and Haemostasis : Jth. 2004 July; 2(7): 1127-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15219196
•
Seasonal variation in the effect of a fixed dose of heparin on activated clotting time in patients prepared for open-heart surgery. Author(s): Hodoglugil U, Gunaydin B, Yardim S, Zengil H, Smolensky MH. Source: Chronobiology International. 2001 September; 18(5): 865-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11763993
•
Simpler technique for measuring oxidative susceptibility by heparin affinity column isolation of lipoproteins. Author(s): Kaplan IV, Hobbs GA, Levinson SS. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 1999 May; 283(1-2): 89-103. Erratum In: Clin Chim Acta 1999 September; 287(1-2): 173. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10404734
•
Sulfated polysaccharide from the leaves of Artemisia Princeps activates heparin cofactor II independently of the Lys173 and Arg189 residues of heparin cofactor II. Author(s): Hayashi T, Hayakawa Y, Hayashi T, Sasaki H, Sakuragawa N. Source: Thrombosis Research. 1997 July 1; 87(1): 105-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9253805
•
The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass. Author(s): Muriithi EW, Belcher PR, Rao JN, Chaudhry MA, Nicol D, Wheatley DJ. Source: The Journal of Thoracic and Cardiovascular Surgery. 2000 September; 120(3): 538-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10962416
•
The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Author(s): Park M, Lee ST.
Alternative Medicine 131
Source: Biochemical and Biophysical Research Communications. 1999 November 2; 264(3): 730-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10544000 •
The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components. Author(s): Wallon UM, Overall CM. Source: The Journal of Biological Chemistry. 1997 March 14; 272(11): 7473-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9054449
•
The heparin-binding 10 kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. Author(s): Ball DK, Rachfal AW, Kemper SA, Brigstock DR. Source: The Journal of Endocrinology. 2003 February; 176(2): R1-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12553878
•
The HepG2 extracellular matrix contains separate heparinase- and lipid-releasable pools of ApoE. Implications for hepatic lipoprotein metabolism. Author(s): Burgess JW, Gould DR, Marcel YL. Source: The Journal of Biological Chemistry. 1998 March 6; 273(10): 5645-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9488694
•
The medicinal plant Porana volubilis contains polysaccharides with anticoagulant activity mediated by heparin cofactor II. Author(s): Yoon SJ, Pereira MS, Pavao MS, Hwang JK, Pyun YR, Mourao PA. Source: Thrombosis Research. 2002 April 1; 106(1): 51-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12165289
•
Therapeutic uses of heparinoids in renal disease patients. Author(s): Striker GE. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 1999 March; 14(3): 540-3. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10193791
•
Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat. Author(s): Fischer M, Bottiger BW, Popov-Cenic S, Hossmann KA. Source: Intensive Care Medicine. 1996 November; 22(11): 1214-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9120116
132
•
Heparin
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Author(s): Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, Trowbridge AA, Elliott CG, Green D, Feinglass J. Source: Archives of Internal Medicine. 1997 February 10; 157(3): 289-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9040295
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to heparin; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Angina Source: Integrative Medicine Communications; www.drkoop.com Atherosclerosis and Heart Disease Prevention Source: Prima Communications, Inc.www.personalhealthzone.com Cyclic Mastalgia Alternative names: Cyclic Mastitis, Fibrocystic Breast Disease Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 133
Dermatitis Herpetiformis Source: Healthnotes, Inc.; www.healthnotes.com Dysmenorrhea Alternative names: Painful Menstruation Source: Prima Communications, Inc.www.personalhealthzone.com Heart Attack Source: Healthnotes, Inc.; www.healthnotes.com Heart Attack Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Prima Communications, Inc.www.personalhealthzone.com Migraine Headaches Source: Prima Communications, Inc.www.personalhealthzone.com Miscarriage Source: Integrative Medicine Communications; www.drkoop.com Myocardial Infarction Source: Integrative Medicine Communications; www.drkoop.com Nausea Source: Prima Communications, Inc.www.personalhealthzone.com Prostate Cancer Source: Healthnotes, Inc.; www.healthnotes.com Psoriasis Source: Prima Communications, Inc.www.personalhealthzone.com Rheumatoid Arthritis Source: Prima Communications, Inc.www.personalhealthzone.com Spontaneous Abortion Source: Integrative Medicine Communications; www.drkoop.com Stroke Source: Healthnotes, Inc.; www.healthnotes.com Varicose Veins Source: Prima Communications, Inc.www.personalhealthzone.com •
Herbs and Supplements Aesculus Alternative names: Horse Chestnut; Aesculus hippocastanum L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
134
Heparin
Aloe Alternative names: Aloe vera L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Aortic Glycosaminoglycans Source: Prima Communications, Inc.www.personalhealthzone.com Bromelain Source: Prima Communications, Inc.www.personalhealthzone.com Coleus Forskohlii Source: Prima Communications, Inc.www.personalhealthzone.com Devil's Claw Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,970,00.html Eleuthero Alternative names: Siberian Ginseng, Eleuthero; Acanthopanax/Eleutherococcus senticosus Rupr. & Maxim. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Eugenia Clove Alternative names: Cloves; Eugenia sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Feverfew Source: Prima Communications, Inc.www.personalhealthzone.com Ginger Source: Prima Communications, Inc.www.personalhealthzone.com Ginkgo Source: Prima Communications, Inc.www.personalhealthzone.com Ginkgo Biloba Source: Healthnotes, Inc.; www.healthnotes.com Ginkgo Biloba Alternative names: Maidenhair Tree Source: Integrative Medicine Communications; www.drkoop.com Heparin Source: Healthnotes, Inc.; www.healthnotes.com Heparin Alternative names: Hep-Lock Source: Prima Communications, Inc.www.personalhealthzone.com Horse Chestnut Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 135
Maidenhair Tree Alternative names: Ginkgo Biloba Source: Integrative Medicine Communications; www.drkoop.com OPCS (Oligomeric Proanthocyanidins) Source: Prima Communications, Inc.www.personalhealthzone.com Phosphatidylserine Source: Prima Communications, Inc.www.personalhealthzone.com Red Clover Source: Prima Communications, Inc.www.personalhealthzone.com Reishi Source: Prima Communications, Inc.www.personalhealthzone.com Tetracycline Source: Healthnotes, Inc.; www.healthnotes.com Vanadate Alternative names: Vanadium Source: Integrative Medicine Communications; www.drkoop.com Vanadyl Alternative names: Vanadium Source: Integrative Medicine Communications; www.drkoop.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
137
CHAPTER 4. DISSERTATIONS ON HEPARIN Overview In this chapter, we will give you a bibliography on recent dissertations relating to heparin. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “heparin” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on heparin, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Heparin ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to heparin. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
Efficacy of 4% trisodium citrate compared to saline or diluted heparin solution in patency of central venous triple lumen catheters in critically ill patients by Michaud, Dominique Camille Yvon, MN from University of Alberta (Canada), 2003, 105 pages http://wwwlib.umi.com/dissertations/fullcit/MQ82239
•
Manipulating the surface active and anticoagulant properties of heparin through amphiphilic molecular constructs by Mintz, Rosita Candida, PhD from Case Western Reserve University, 2004, 221 pages http://wwwlib.umi.com/dissertations/fullcit/3118146
138
Heparin
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
139
CHAPTER 5. PATENTS ON HEPARIN Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “heparin” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on heparin, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Heparin By performing a patent search focusing on heparin, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We
8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
140
Heparin
will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on heparin: •
Biocompatible medical articles and process for their production Inventor(s): Al-Lamee; Kadam Gayad (Yorkshire, GB) Assignee(s): Polybiomed Limited (Sheffield, GB) Patent Number: 6,756,125 Date filed: September 23, 2002 Abstract: An article of metal, glass, ceramics or plastics having a surface for contact with tissue or with circulating blood, has a surface coating of an organopolysiloxane and heparin, in which coating the organopolysiloxane is adherent to the surface of the article and has cationic groups that form ionic bonds with anionic groups of the heparin. The surface for contact with circulating blood may be an interior surface of a cannula or tubing or of a blood oxygenator or it may be a working surface of a blood filter. The polymer may be poly-[dimethylsiloxane-co-methyl-(3-hydroxypropyl)siloxane]-graftpoly(eth ylene glycol) [3-(trimethylammonio) propyl chloride] ether. A method is also provided for forming a coated article as aforesaid, said method comprising contacting said surface with a solution in a volatile organic solvent of an organopolysiloxane and with heparin, the organopolysiloxane being adherent to the surface of the article and having cationic groups that form ionic bonds with the anionic groups of the heparin, and removing said volatile solvent. Excerpt(s): This invention relates to medical articles that can be placed in contact with a stream of blood or other tissue and which have surfaces that are anti-thrombogenic. It also relates to a process for treating a medical article to impart anti-thrombogenic properties to a surface thereof. Articles for contact with circulating blood, whether intracorporeally or during extracorporeal blood circulation, can give rise to coagulation. In particular, plastics materials have been found to be thrombogenic, even in the case of relatively blood-compatible materials such as polytetrafluoroethylene and silicone rubber. In order to minimize trauma in blood circulating in contact with articles having non-biological surfaces, bonding of heparin to such surfaces has been disclosed, the heparin imparting anti-thrombogenic properties. Bonding of heparin to surfaces was first described by V. I. Gott et. Al., Science, 142, 1297 (1963), the surfaces being graphitized, treated with benzalkonium chloride and then with heparin. Subsequently a simpler surface treatment was developed based on coating the surface e.g. by simple immersion with a thin layer of tridodecylmethyl ammonium heparinate, see V. I. Gott et. al., Ann. Thoracic Surg., 14, 219 (1972) and A. H. Krause et. al, Ann. Thoracic Surg., 14, 123 (1972). According to a data sheet issued by Polysciences Limited of Northampton, England in 1984 the process was used to make shunts for use in artery bypass. Greater stability to washing can be achieved by cross-linking the bonded heparin molecules with dialdehydes, see U.S. Pat. No. 3,810,781 (Eriksson), and an increased level of heparin uptake can be achieved in the case of plastics articles by glowor corona-treating the surface of the article, see U.S. Pat. No. 4,613,517. The use of socalled "Duraflo II heparin" coatings to reduce blood trauma in extracorporeal circuits e.g. of cardiopulmonary bypass machines is disclosed by Li-Chien Hsu, Cardiac Surgery: state of the art reviews-Vol. 7, No. 2, 265 (1993). The effectiveness of so-called "heparin bonded circuits" in reducing the need for blood transfusion during coronary artery bypass surgery is disclosed by G. M. Mahoney et. al., European Journal of Cardiothoracic Surgery.
Patents 141
Web site: http://www.delphion.com/details?pn=US06756125__ •
Biocompatible metallic materials grafted with biologically active compounds and preparation thereof Inventor(s): Goo; Hyun Chul (Seoul, KR), Kim; Soo Hyun (Seoul, KR), Kim; Young Ha (Seoul, KR), Lee; Won Kyu (Daejeon, KR), Park; Ki Dong (Seoul, KR) Assignee(s): Korea Institute of Science and Technology (Seoul, KR) Patent Number: 6,617,027 Date filed: March 26, 2001 Abstract: Disclosed are surface-modified medical metallic materials and preparation thereof. The medical metallic material is prepared by coating a gold or silver thin layer onto a base metal, adsorbing a polyfunctional sulfur compound onto the gold or silver thin layer, and chemically bonding a biologically active material such as heparin or estradiol to the functional group of the sulfur compound. The biologically active material is firmly bonded to the base metal via the sulfur compound. Being significantly improved in antithrombogenicity and biocompatibility, the metallic materials are suitable for use in various implants, including stents, artificial cardiac valves and catheters. Excerpt(s): The present invention relates to medical metallic materials, especially medical tools for use in circulatory systems, whose surface is modified to improve antithrombogenicity and biocompatibility. More particularly, the present invention relates to the reliable introduction of a biologically active compound onto the surface of a base metal via a linker, thereby bringing about a great improvement in the antithrombogenicity and biocompatibility of the base metal. Also, the present invention is concerned with a method for preparing such a medical metallic material and with the use of the metallic material in the medical field. For use in substituting for congenitally or postnatally defective valves of the heart, artificial cardiac valves are generally classified into two groups: valves made of tissues and mechanical valves, which are made of metallic materials. Tissue values show excellent biocompatibility, but poor internal durability due to calcification. On the other hand, mechanical valves endure for extended periods in vivo, but have the disadvantage of forcing the patients to take anticoagulants throughout their lifetime because they are likely to generate thrombus. In spite of extensive research, satisfactory advance has not been yet achieved in the antithrombogenicity of mechanical valves. Indeed, not only is it virtually impossible to prevent thrombogenesis, a normal physiological function of the body, but also its mechanism has not been disclosed completely. Extensively conducted for the treatment of coronary stenosis is percutaneous transluminal coronary angioplasty in which an intraaortic balloon catheter is inserted within the coronary artery to expand the blood vessel. This operation brings about relatively good results, and development has been and continues to be ongoing in the processes and tools for percutaneous transluminal coronary angioplasty. However, such problems as acute closure and restenosis still remain unsolved. Web site: http://www.delphion.com/details?pn=US06617027__
142
•
Heparin
Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof Inventor(s): Cardin; Alan D. (Cincinnati, OH), Van Gorp; Cornelius L. (Springboro, OH) Assignee(s): IntimaX Corporation (Cincinnati, OH) Patent Number: 6,518,244 Date filed: March 9, 2001 Abstract: Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation. Excerpt(s): The present application relates to combinations of a heparin cofactor II agonist and a platelet glycoprotein IIb/IIIa receptor (GPIIb/IIIa) antagonist that are useful in inhibiting both platelet aggregation and thrombin generation resulting from disease, or injury responses to wound repairs. The present application particularly relates to the use of subtherapeutic amounts of a heparin cofactor II agonist and subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist that, in combination, are therapeutically effective in inhibiting both platelet aggregation and thrombin generation. Cardiovascular disease is the primary cause of death in the USA. According to the American Heart Association, 2.5 million individuals suffer from venous thrombosis and 600,000 suffer from pulmonary embolism each year. In 1996, approximately 830,000 cardiac surgeries and 700,000 cardiac catheterization procedures were performed in the USA as a result of arterial and venous thromboses. Usually, anticoagulant therapy is implemented either alone or in combination with anti-platelet and/or anti-fibrinolytic therapies, particularly in acute care settings where the immediate reopening of a blocked vessel becomes imperative. The drugs used in these therapies, however, have certain dose-limiting side effects, the foremost being hemorrhagic (i.e., prolonged bleeding) and when used in combination, these side effects can become potentiated, further limiting effective dosing and duration of the needed drug treatment. See Fareed, "Drug Interactions with Antiplatelet Agents" IBC 3.sup.rd Annual Mini-Symposium on Advances in Antiplatelet Therapies (Waltham, Mass. 2000). With current anticoagulants, the bleeding effects are due to an action on one or more of the enzymes that regulate hemostasis in the global circulation, versus their action in a more specific and limited sense on enzymes of the hemostatic mechanism that promote the disease process at the vascular wall, e.g., low selectivity. Likewise, antiplatelet drugs exhibit strong interactions with the anticoagulants (such as heparin), antithrombin drugs and thrombolytic agents, and safety considerations, for example, preclude their administration to patients at high risk for intracranial hemorrhage, particularly elderly patients with poorly controlled hypertension and previous manifestations of cerebrovascular disease. Web site: http://www.delphion.com/details?pn=US06518244__
Patents 143
•
Compliant dehyrated tissue for implantation and process of making the same Inventor(s): Cheung; David T. (Arcadia, CA), Duran; Carlos M. G. (Missoula, MT), Pang; David C. (Missoula, MT) Assignee(s): International Heart Institute of Montana Foundation (Missoula, MT) Patent Number: 6,630,001 Date filed: June 24, 1998 Abstract: A process for preparing pliable soft tissue specimen which are resistant to cracking and devoid of viable cells includes the steps of treating native soft tissue obtained from a donor by a gradually increasing gradient of aliphatic alcohol or other suitable water miscible polar organic solvent until the last alcohol (or other solvent) solution has at least 25% by volume of the organic liquid. Thereafter, the tissue specimen is treated with a solution containing glycerol or low molecular weight (<1000 D) polyethylene glycol, and polyethylene glycol of a molecular weight between approximately 6,000 to 15,000 D and heparin. Thereafter, the tissue specimen is briefly immersed in aqueous heparin solution, frozen and lyophilized. The tissue specimen is suitable for implantation as a homograft or xenograft, with or without rehydration. Excerpt(s): The present invention is in the field of implant materials. More particularly, the present invention is directed to compliant dehydrated implant materials which have no viable cells, and can be stored and transported without being immersed in liquid. The present invention is also directed to the process of producing said implant materials. The use of autografts, homografts and xenografts for augmenting or replacing defective tissues in humans and animals has been known for a long time. From the standpoint of providing suitable materials for implantation, augmenting or replacing hard tissues, such as bone, presents a different type of problem than augmenting or replacing soft tissues. In the selection of substitute materials for hard tissue graft, the strength and hardness of the graft are important whereas compliance and flexibility are, generally speaking, less crucial. On the other hand, in the selection of soft tissue materials for implantation, compliance and flexibility of the graft material are usually of utmost importance because the soft tissue replacement material usually must closely match the healthy functional tissue that will be replaced. In this regard it must be remembered that natural soft tissue containing collagen is strong and able to withstand repeated three-dimensional stress as well as bending and deformation. Often natural soft tissue acts as a physical barrier that must maintain its structural integrity. Ideally, replacement or augmentation soft tissue that is utilized in implantation should have the same characteristics as the natural soft tissue that it replaces, and should be easy to obtain, store and transport. These, however are difficult goals that the prior art has been striving to attain, and up to the present invention only with moderate success. Web site: http://www.delphion.com/details?pn=US06630001__
•
Composition comprising heparin as a non-thrombogenic surface coating agent Inventor(s): Holmer; Erik (Stockholm, SE) Assignee(s): Carmeda AB (Stockholm, SE) Patent Number: 6,559,132 Date filed: February 27, 2001
144
Heparin
Abstract: The present invention relates to a composition comprising heparin to be used as a non-thrombogenic surface when in contact with arterial blood flow. It also relates to a device treated on the surface thereof with such a composition. Excerpt(s): This application is a 371 of PCT/NO99/00278, filed Sep. 9, 1999. The present invention relates to a composition comprising heparin to be used as a nonthrombogenic surface coating agent when in contact with arterial blood flow. It also relates to a device treated on the surface thereof with such a composition. Thrombosis is a major health problem in the industrialized world. Thrombosis related diseases cause the death of several millions of people every year and the health care costs have been estimated to be over 90 billion US dollars just for the USA. Web site: http://www.delphion.com/details?pn=US06559132__ •
Controlled release of non heparin-binding growth factors from heparin-containing matrices Inventor(s): Hubbell; Jeffrey A. (Zurich, CH), Sakiyama-Elbert; Shelly E. (Zurich, CH) Assignee(s): Eidgenossische Technische Hochschule (Zurich, CH), Universitat Zurich (Zurich, CH) Patent Number: 6,723,344 Date filed: May 3, 2001 Abstract: Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or non-covalently bound heparin or heparin-like polymers, which serve to sequester the low heparin-binding affinity growth factor protein peptides within the matrix. The controlled release of some low heparin-binding affinity growth factor or peptides thereof occurs by degradation of some matrix component or dissociation of the low heparin-binding affinity growth factor protein peptides from the bound heparin. This differs from many controlled delivery devices in that release is not controlled solely by diffusion, and the rate of release may therefore be regulated by altering the rate of degradation of the matrix component or the amount of heparin bound within the matrix. The controlled release of such low heparin-binding affinity growth factor proteins such as NGF-.beta., NT-3 and BDNF, is demonstrated. The invention also identifies basic domains that can be utilized to identify other low heparin-binding affinity growth factor protein peptides useful in delivery as part of the matrices described herein. Excerpt(s): The present invention relates to the field of three-dimensional matrices that contain pharmacologically active molecules, particularly growth factors. The invention also relates to the use of growth factors or proteins in a matrix designed to promote cell and tissue growth. The invention further relates to the use of growth factors with low heparin-binding affinity. In addition, the invention relates to the field of articles of manufacture useful as implantable devices and wound dressings as the matrix of the invention is designed to be used in conjunction with such devices to provide protracted and controlled release of growth factor, thus promoting wound healing in the patient. Many growth factors are thought of as "heparin-binding" growth factors. Families with one or more members that bind heparin include fibroblast growth factors and bone morphogenetic proteins (BMPs) (1, 2). Additional growth factors that bind heparin include transforming growth factor.beta.1 (TGF-.beta.1), interleukin-8, neurotrophin-6, vascular endothelial cell growth factor, heparin-binding epidermal growth factor,
Patents 145
hepatocyte growth factor, connective tissue growth factor, midkine, and heparinbinding growth associate molecule (3-11). These factors have shown the potential to enhance healing in many different types of tissue including vasculature, skin, nerve, and liver. Controlled delivery devices based on heparin-affinity of these growth factors have been designed previously (12-14). These drug delivery devices have previously been used to deliver "heparin-binding" growth factors. Such "heparin-binding" growth factors are typically considered to be those which bind to heparin with a relatively high affinity, often characterized by elution from heparin-affinity columns at NaCl concentrations well above physiological levels (>140 mM). In such delivery systems, the heparin-binding affinity of the growth factor is usually used to sequester the growth factors to immobilized heparin of some form. For example, Edelman et al. have used heparin-conjugated Sepharose beads to bind basic fibroblast growth factor (bFGF) and then encapsulated the beads with alginate (12, 19). These beads serve as reservoirs that release bFGF slowly based on the binding and dissociation constants of bFGF and heparin. Web site: http://www.delphion.com/details?pn=US06723344__ •
Fast-acting pharmaceutical compositions and methods of use Inventor(s): McKay; Douglas William (450 Moosa Blvd., Suite C, Eunice, LA 70535) Assignee(s): none reported Patent Number: 6,569,839 Date filed: November 30, 1999 Abstract: A pharmaceutical composition comprising at least one local anesthetic, at least one anti-inflammatory agent and at least one antibiotic are disclosed. The local anesthetic has a peak effect no later than about 10 minutes after administration to a mammal, and the anesthetic and anti-inflammatory have a half-life of no greater than about 36 hours after administration. The pharmaceutical composition, thus, advantageously provides rapid relief of pain with a substantially low residual accumulation of active components so that the pharmaceutical composition can be repeatedly or continuously administered to a wound. Embodiments include preparing a medicinal solution including Lidocaine as the local anesthetic, Hydrocortisone sodium succinate as the anti-inflammatory agent, Chloramphenicol as the antibiotic agent and, optionally, Heparin as an anticoagulant. The medicinal solution is continuously administered to treat a wound of a mammal to maintain a constant positive physiological pressure in the treated wound at a pressure to enable permeation of the medicinal solution and fluids from the wound with concomitant periodical suctioning of debris from the wound. Excerpt(s): The present invention relates to pharmaceutical compositions useful for the treatment of a wound or joint, with particular applicability to post operative closed muscular skeletal wounds. The pharmaceutical composition provides alleviation of pain, while promoting healing of the wound and early rehabilitation. Of major concern in the care of wounds, such as incurred in joint surgery, are relief of post-operative pain, avoidance of infection, hastening of healing, early joint motion, and a decrease in the length of necessary hospital services. Traditional post-operative management of orthopaedic wounds or traumatic wounds have varied in approach. However, an important consideration in the management of wounds is to prevent the painful accumulation of blood and debris and to prevent infection following the formation of an open wound. Pain relief and reduced swelling can be minimized by leaving a surgical
146
Heparin
wound or traumatic wound open thereby encouraging the free flow of debris and accumulated fluid out of the wound. Irrigation of the open wound with a sterile solution further promotes the removal of debris, blood, extra-cellular fluid, etc. The same debris and blood in an open wound, however, provide an excellent culture medium for bacterial growth and, hence, such techniques invite infection and promote contamination. Wound closure, conversely, prevents the beneficial flow of debris and fluid from the wound with concomitant pain relief but advantageously reduces the occurrence of bacterial infection and otherwise exterior contamination. Web site: http://www.delphion.com/details?pn=US06569839__ •
Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates Inventor(s): Andrew; Maureen (Oakville, CA), Berry; Leslie (Burlington, CA) Assignee(s): Hamilton Civic Hospitals Research Development Inc. (Ontario, CA) Patent Number: 6,562,781 Date filed: November 30, 1995 Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome are also described. Excerpt(s): This invention relates to new chemical compounds comprising covalent conjugates of glycosaminoglycans, particularly heparins, methods for their preparation, their pharmaceutical compositions and therapeutic uses thereof. Heparin is a sulfated polysaccharide which consists largely of an alternating sequence of hexuronic acid and 2-amino-2-deoxy-D-glucose. Heparin and a related compound, dermatan sulfate, are of great importance as anticoagulants for clinical use in the prevention of thrombosis and related diseases. They are members of the family of glycosaminoglycans, (GAGs), which are linear chains of sulfated repeating disaccharide units containing a hexosamine and a uronic acid. Anticoagulation using GAGs (such as heparin and dermatan sulfate) proceeds via their catalysis of inhibition of coagulant enzymes (the critical one being thrombin) by serine protease inhibitors (serpins) such as antithrombin III (ATIII) and heparin cofactor II (HCII). Binding of the serpins by the catalysts is critical for their action and occurs through specific sequences along the linear carbohydrate chain of the glycosaminoglycan (GAG). Heparin acts by binding to ATIII via a pentasaccharide sequence, thus potentiating inhibition of a variety of coagulant enzymes (in the case of thrombin, heparin must also bind to the enzyme). Heparin can also potentiate inhibition of thrombin by binding to the serpin HCII. Dermatan sulfate acts by specifically binding to HCII via a hexasaccharide sequence, thus potentiating only the inhibition of thrombin. Since glycosaminoglycans (particularly heparin) can bind to other molecules in vivo or be lost from the site of action due to a variety of mechanisms, it would be advantageous to keep the GAG permanently associated with the serpin by a covalent bond. Covalent complexes between ATIII and heparin have been produced previously; see, e.g., Bjork et al., (1982) FEBS Letters 143(1):96-100, and by Collen et al., U.S. Pat. No. 4,623,718. These conjugates required covalent modification of the heparin prior to its conjugation. The product by Bjork et al. (produced by reduction of the Schiff base between the aldehyde of a 2,5-D-anhydromannose terminus of heparin, produced by
Patents 147
partial depolymerization of heparin to heparin fragments with nitrous acid, and a lysyl amino of ATIII) had undetectable antithrombin activity. The product by Collen et al. (produced by conjugation of carboxyl groups within the chain of the heparin molecule and lysyl amino groups of ATIII through amino-hexyl tolyl spacer arms) had a random attachment to the carboxyls of the uronic acids of the heparin moiety that might affect the ATIII binding sequence and in fact the specific anti-Xa (a coagulation protease which activates prothrombin to thrombin) activity was approximately 65% of the starting noncovalently linked unmodified heparin (J. Biol. Chem. 257:3401-3408 (1982)). The specific anti-thrombin activity would also be, therefore, 65% or less since both Xa and thrombin require heparin binding to ATIII. The bimolecular rate constant of the product by Collen et al. for inhibition of thrombin was claimed to be comparable to that of non-covalent mixtures of heparin saturated with ATIII (J. Biol. Chem. 259:5670-5677 (1984)). However, large molar excesses of heparin or covalent complex over thrombin (>10:1) were used to simplify the kinetics, which would mask the effect of any subpopulation of molecules with low activity. Specific antithrombin activities were not given. Web site: http://www.delphion.com/details?pn=US06562781__ •
Heparin delivery method Inventor(s): Chan; Randy (San Jose, CA), Yan; John Y. (Los Gatos, CA) Assignee(s): Advanced Cardiovascular Systems, Inc. (Santa Clara, CA) Patent Number: 6,605,114 Date filed: October 29, 1999 Abstract: A method for delivering heparin, wherein an implantable stent is coated with a material that attracts heparin and with which heparin forms a bond. The stent is exposed to a heparin containing solution just prior to implantation or is first implanted and then exposed to heparinized blood. As heparin becomes detached from the stent, the implantation site is exposed to heparin to restore an effective level and thereby prevent thrombosis. Excerpt(s): The present invention relates to endovascular stents and more particularly pertains to coatings that are applied to stents in order to reduce thrombogenicity. Stents are implanted within blood vessels in an effort to maintain their patency by preventing collapse of the lumen and/or by impeding restenosis. Unfortunately, the presence of a foreign object within the blood flow may have a thrombogenic effect. It has therefore been found to be desirable to use various anti-coagulant drugs in an effort to reduce the likelihood of the development of restenosis and provide an antithrombogenic effect. A drug that has been found to be particularly effective for such purpose is heparin. By maintaining an effective concentration of the drug in and about the implantation site until the stent is encapsulated by tissue, the risk of thrombogenesis is substantially mitigated. To that end, various approaches have been employed in the administration of heparin. Web site: http://www.delphion.com/details?pn=US06605114__
148
•
Heparin
Inhibition of L-selectin and P-selection mediated binding using heparin Inventor(s): Koenig; Andrea (La Jolla, CA), Varki; Ajit (Del Mar, CA) Assignee(s): The Regents of the University of California (Oakland, CA) Patent Number: 6,596,705 Date filed: February 8, 1999 Abstract: The present invention provides methods of inhibiting L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial anticoagulant activity or undesirable bleeding in the subject. In addition, the invention provides methods of treating a subject having a pathology characterized, at least in part, by abnormal L-selectin or P-selectin mediated binding by administering heparin to the subject in an amount that results in attaining a concentration of less than about 0.2-0.4 units heparin per ml of plasma in the subject. Excerpt(s): The present invention relates generally to molecular biology and, more specifically, to methods of modulating L-selectin and P-selectin mediated binding in a subject by administering heparin to the subject in an amount that does not produce substantial anticoagulation activity or undesirable bleeding. L-selectin, E-selectin and Pselectin mediate the initial adhesive events directing the homing of lymphocytes into lymphoid organs, as well as the interactions of leukocytes and other inflammatory cells with endothelium at sites of inflammation. L-selectin is expressed on leukocytes, Eselectin is expressed on endothelium and P-selectin is expressed on platelets and endothelium. The three selectins bind to specific carbohydrate structures on opposing cells, for example, L-selectin binds to platelets and endothelium, whereas P-selectin and E-selectin bind to leukocytes. Selectin adhesion is involved in disorders such as pathologic reperfusion injury, inflammatory disorders and autoimmune disorders. Selectin interactions also can mediate primary adhesive mechanisms involved in the metastasis of certain epithelial cancers. Thus, selectins are potential therapeutic targets for the treatment of pathologies characterized by undesirable or abnormal interactions mediated by selecting. Web site: http://www.delphion.com/details?pn=US06596705__
•
Inhibition of TNF activity Inventor(s): Aderka; Dan (Tel Aviv, IL), Eshed (Englender); Talma (Givatayim, IL) Assignee(s): Applied Research Systems ARS Holding N.V. (Curacao, AN) Patent Number: 6,608,044 Date filed: November 20, 2000 Abstract: The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity. Excerpt(s): The present application is the national stage under 35 U.S.C. 371 of PCT/IL99/00709, filed Dec. 30, 1999. The present invention is directed to a method and pharmaceutical compositions for inhibiting activity of tumor necrosis factor (TNF).
Patents 149
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine produced by a wide spectrum of cells. It has a key role in defending the host, mediating complex cellular responses of different, and even contrasting, nature (Aggarwal et al, 1996). In excess, TNF may have detrimental systemic effects. Two specific high affinity cell surface receptors, the p55 TNF-receptor (p55 TNF-R) and the p75 TNF-receptor (p75 TNF-R), function as transducing elements, providing the intracellular signal for cell responses to TNF. The extracellular parts of the TNF-Rs, known as soluble TNF-Rs, were formerly referred to as TBP-I and TBP-II respectively (see Wallach, U.S. Pat. No. 5,359,037 and Tartaglia et al., 1992; Loetscher et al., 1991). Web site: http://www.delphion.com/details?pn=US06608044__ •
Low-molecular heparin modification and remedy for skin ulcer Inventor(s): Okayama; Minoru (Kyoto, JP), Toda; Ken-ichi (Kyoto, JP), Yamashina; Ikuo (2, Higashi Morigamae-Cho, Shimogamo, Kyoto, JP 606-0866) Assignee(s): Yamashina; Ikuo (Kyoto, JP) Patent Number: 6,569,840 Date filed: May 9, 2000 Abstract: The invention is direct to modified heparins, especially low-molecular weight modified heparins that are adapted for used in preparing an agent for treating a skin ulcer. The low-molecular weight modified heparins have been substantially deprived of the anticoagulant activity, yet they retain the ability to bind to cell growth factors, cytokines and cell adhesion molecules. Excerpt(s): This is a 371 of PCT/JP98/05191 filed Nov. 18, 1998. This invention relates to modified heparins and an agent for remedying skin ulcer. More particularly, this invention relates to using as an agent for remedying skin ulcer modified heparins, especially low molecular weight modified heparins which have been substantially deprived of the anticoagulant activity yet retain the ability to bind to cell growth factors, cytokines and cell adhesion molecules, and also relates to modified heparins, especially low molecular weight modified heparins adapted for use in preparing an agent for remedying skin ulcer. Heparin is one of glycosaminoglycans and is characterized by having anticoagulant activity. A lot of heparin has been found in liver, lung, intestine, spleen and other organs of healthy edible animals, and heparin is largely produced by mast cells around capillary vessels. A heparin is glycosaminoglycan including various amounts of O-sulfate, N-sulfate and N-acetyl groups and belongs to a heteropolysaccharide having a molecular weight of 6,000.about.20,000. Web site: http://www.delphion.com/details?pn=US06569840__
•
Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity Inventor(s): Aiken; Jennifer C. (Wheat Ridge, CO), DeBiase; Barbara A. (Wheat Ridge, CO), Henderson; Jon H. (Wheat Ridge, CO) Assignee(s): Sienco, Inc. (Wheat Ridge, CO) Patent Number: 6,632,678 Date filed: January 3, 2001
150
Heparin
Abstract: A coagulation test for determining the activated clotting time (ACT) of blood in the presence of heparin that produces test results that are substantially insensitive to the drug aprotinin. The activator is formulated to be a combination of celite and bentonite. The ACT results obtained with this formulation are similar to celite ACT tests on heparinized blood while simultaneously being unaffected by aprotinin. Additionally, a method for quantifying the aprotinin effect of different ACT formulations is disclosed. Excerpt(s): This invention relates to the determination of the activated clotting time (ACT) of blood or plasma, specifically for patients receiving the drugs heparin and aprotinin. Heparin is an anticoagulant drug used during surgeries requiring the use of extracorporial circuits, such as cardiopulmonary bypass (CPB). Heparin prevents blood clots from forming while blood is flowing through the circuit. In order to ensure sufficient anticoagulation, doctors must be able to measure heparin's anticoagulant effect on blood. The anticoagulant effect of heparin is often managed using the activated clotting time (ACT) as determined by in vitro diagnostic tests. The ACT is prolonged after heparin administration. For example, without heparin, the ACT is generally about 120 seconds, while the ACT after heparin administration is typically beyond 480 seconds. An ACT of greater than 480 seconds is considered by many clinicians to be the minimum amount of heparin anticoagulation effect necessary for CPB surgery. The object of an ACT test is to indicate if adequate heparin has been administered to the patient in order to proceed with the surgical procedure without risk of forming blood clots. Heparin is metabolized during surgery. Consequently, heparin must be administered both before and during CPB surgery in order to maintain a sufficient level of anticoagulation. Also, the anticoagulant effect of heparin varies from patient to patient. Therefore, different patients require different amounts of heparin, both before and during CPB surgery. Web site: http://www.delphion.com/details?pn=US06632678__ •
Method of covalent coupling Inventor(s): Gouda; Ibrahim (Sollentuna, SE), Larm; Olle (Bromma, SE) Assignee(s): Medicarb AB (Bromma, SE) Patent Number: 6,653,457 Date filed: June 27, 2002 Abstract: A method of preparing conjugates by means of covalent coupling of a polysaccharide selected from heparin, heparin derivatives, at least partially deacerylated dermatan sulphate and dextran sulphate and a solid substance containing primary amino groups, said method comprising the following steps: a) reduction of the saccharide so that its terminal monosaccharide unit is converted to an alditol; b) periodate oxidation of the alditol formed in step a) to the formation of a terminal aldehyde group under cleavage of the monosaccharide unit between two vicinal groups selected from hydroxyl and amino groups; and c) reductive coupling of the alditol via the aldehyde group to the amino group of the solid substrate. Excerpt(s): The present invention relates to the manufacture of conjugates between oligo- or polysaccharides and aminated substrates. The invention also covers the products hereby obtained. Covalent coupling of saccharides to substrates can be made mainly in two different ways, on the one hand through so-called "end-point attachment" (EPA), on the other hand by so-called "multipoint attachment" (MPA). In the first case the saccharide is coupled via its terminal reducing monosaccharide unit. In the second
Patents 151
case, which is relevant with polysaccharides, it is coupled via several monosaccharide units inside the polysaccharide. Most of the high molecular carbohydrates present in nature, which are coupled to some other high molecular compound, are immobilized via their reducing monosaccharide unit, and such natural conjugates are for example glycoproteins, glycolipides, proteoglycines and lipopolysaccharides. Coupling via "endpoint attachment" means contrary to "multipoint attachment" that the molecule in an immobilized state to a high degree maintains its natural conformation and thereby maintains its capacity to specifically interact with other molecules, such as plasma proteins, growth factors, antibodies, lectins and enzymes. Web site: http://www.delphion.com/details?pn=US06653457__ •
Method, reagent and test cartridge for determining clotting time Inventor(s): Bruegger; Berndt B. (Camarillo, CA) Assignee(s): Roche Diagnostics Corporation (Indianapolis, IN) Patent Number: 6,699,718 Date filed: August 24, 2000 Abstract: The invention is a method, reagent and test cartridge for the determination of the clotting time of a blood sample by means of a reagent containing tissue factor and a sulfatide. In an alternative embodiment, the reagent may contain tissue factor and at least one of the group consisting of a phosphatide and a sulfatide. This invention is preferably used to monitor the effectiveness of heparin therapy in patients that have been administered low to moderate heparin doses to achieve blood heparin levels from 0 to about 3 U/mL, and may also be used for determining clotting time at higher heparin levels of up to about 6 U/mL. Excerpt(s): The present invention relates to the field of determining the clotting time of blood samples and more specifically relates to the determination of the clotting time of blood samples from patients receiving heparin treatment, particularly patients that have been administered low to moderate heparin doses, as well as that of patients that have been administered high heparin doses. The activated clotting time (ACT) assay is a blood test that monitors the effectiveness of heparin dosing. The levels of heparin that the ACT assay is monitoring are generally beyond the range of the activated partial thromboplastin time (APTT) assay. Some APTT assays can monitor plasma heparin levels as high as 1.5 U/mL (which is equivalent to a blood heparin level of about 0.75 U/mL), while the ACT assay can monitor blood heparin levels generally as high as 6 U/mL. The higher end of the blood heparin range (high range; HR) is often used in cardiac pulmonary bypass surgery, while blood levels under 3 U/mL (moderate to low range; LR) but above the effective range of the APTT assay, are used in situations such as cardiac catheterization, extracorporeal membrane oxygenation (ECMO), hemodialysis, and percutaneous transluminal coronary angioplasty (PTCA). There are various commercially available ACT assays. These typically differ in the specific component that activates clotting, which difference can affect the blood heparin range in which the assay is reliable. Consequently, these assay types are often categorized by the heparin range and corresponding surgical or medical application. One example of such a test is known as the Hemochron.RTM. sold by International Technidyne Corporation. The basic procedure for this test is as follows: A two mL sample of blood is added to a test tube containing dried celite (diatomaceous earth) and a small magnetic bar. The test tube is capped and shaken, then placed in an instrument that starts spinning of the magnetic bar. When the blood begins to clot, the magnetic bar slows or stops spinning.
152
Heparin
The instrument then notes the length of time till the magnet stopped spinning as the celite ACT time. A variation of this test is known as the Hemochron.RTM. glass ACT assay wherein the test tube is plastic and contains glass particles with a magnetic bar and the sample is only 0.4 mL of blood. Web site: http://www.delphion.com/details?pn=US06699718__ •
Methods for quality control of prothrombin time (PT) and activated partial thromboplastin time (APTT) assays using coagulation controls Inventor(s): Hawkins; Pamela L. (Ballwin, MO) Assignee(s): Trinity Biotech Manufacturing, Ltd. (Jamestown, NY) Patent Number: 6,528,273 Date filed: January 26, 2001 Abstract: Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls comprise plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin cofactor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa. The anticoagulant is preferably a glycosaminoglycan such as heparin, a heparin derivative or a heparin analog. The anticoagulant is preferably combined with (1) an abnormal plasma (e.g. activated plasma or factor-deficient plasma) and/or (2) a primate plasma (e.g. human plasma), and a non-primate mammalian plasma (e.g. bovine plasma). In the latter case, the nonprimate mammalian plasma is preferably present in the coagulation control composition in an amount of not more than about 12% by volume, relative to total volume. Excerpt(s): The present invention generally relates to diagnostic coagulation assays, and specifically, to control samples suitable for use in connection therewith. The invention particularly relates to coagulation controls suitable for both prothrombin time and activated partial thromboplastin time assays. Coagulation control materials are used in the clinical laboratory for quality control of the prothrombin time (PT) and activated partial thromboplastin time (APTT) assays. PT assays employ thromboplastin reagents and have been used extensively for evaluating blood coagulation associated with the extrinsic pathway. APTT assays employ an intrinsic pathway activator, such as micronized silica, and a phospholipid component of a thromboplastin reagent (without tissue factor protein) for evaluating coagulation associated with the intrinsic pathway. Both PT and APTT assays are used clinically for screening patients' plasma for coagulation factor deficiencies. Clinical screenings are employed, for example, during routine checkups and prior to surgery. PT and APTT assays are also used for monitoring treatment with anticoagulants. For example, PT assays are routinely employed to monitor oral anti-coagulant treatment with coumarin (Warfarin.TM., Coumadin.TM.), and APTT assays are typically used for monitoring anticoagulant treatment with heparin. Coagulation controls are used for quality control evaluations of the PT and APTT assay systems. The controls are essential in view of potential variation in reagents employed in these assays, potential inaccuracies in the devices used to measure clotting time, and potential effects of inaccurate anticoagulant dosage. Commercial coagulation controls have been designed to mimic three physiologic conditions: (1) "Control Level I" controls mimic normal coagulation and are intended to be representative of an individual without coagulation deficiencies; (2) "Control Level II" controls are intended to mimic the coagulation of an individual undergoing mild anticoagulant therapy; and
Patents 153
(3) "Control Level III" controls are intended to mimic the coagulation of an individual undergoing relatively high anticoagulant therapy. Web site: http://www.delphion.com/details?pn=US06528273__ •
Nucleic acid coating compositions and methods Inventor(s): Osaki; Shigemasa (Sandy, UT), Tsang; Ray (Salt Lake City, UT), Zamora; Paul O. (Gaithersburg, MD) Assignee(s): BioSurface Engineering Technologies, Inc. (College Park, MD) Patent Number: 6,596,699 Date filed: January 22, 2002 Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction. Excerpt(s): The present invention relates to coatings, methods of making and using coating compositions, and coated contacting surfaces of medical devices, wherein the coating includes a negatively-charged polymeric substrate forming a part of the coating surface, with a condensate complex of nucleic acid and a positively-charged polymer bound thereto by non-covalent means. Note that the following discussion refers to a number of publications by author(s) and year of publication, and that due to recent publication dates certain publications are not to be considered as prior art vis-a-vis the present invention. Discussion of such publications herein is given for more complete background and is not to be construed as an admission that such publications are prior art for patentability determination purposes. There is a need for localized or regional (loco-regional) delivery of nucleic acids, such as DNA, for use in treatment of a variety of diseases by gene therapy and as a preventative or adjunct to other therapeutic modalities. However, systemic administration of DNA constructs, such as those including adenovirus vectors, frequently results in adverse consequences, and requires a substantially greater amount of gene construct than would be required with effective loco-regional transfection. In addition, for many conditions there is a need for controlled or sustained release of nucleic acids over a period of time, such that the gene construct may be continuously delivered. A number of methods and devices for gene transfection have been developed, but all involve significant limitations. There is thus a need for a biologically compatible method of loco-regional delivery of gene constructs, which may be incorporated and used with traditional implantable medical devices, or may be used with bioresorbable devices. Web site: http://www.delphion.com/details?pn=US06596699__
154
•
Heparin
Occlusion device with non-thrombogenic properties Inventor(s): Buonomo; Peter M. (Shorewood, MN), Corcoran; Michael P. (Woodbury, MN), Marino; Joseph A. (Apple Valley, MN) Assignee(s): Cardia, Inc. (Burnsville, MN) Patent Number: 6,656,206 Date filed: January 23, 2002 Abstract: A method of forming a PVA foam structure for use in an occlusion device such that the PVA foam structure comprises non-thrombogenic properties. The method comprises forming a PVA gel and incorporating heparin into the PVA gel. The PVA foam structure is then treated with the PVA gel and heparin mixture, such as by soaking the PVA foam structure in the gel. Excerpt(s): This invention relates to an occlusion device for the closure of physical anomalies like vascular or septal apertures, such as patent ductus arteriosus, patent foramen ovale, atrial septal defects, or ventricular septal defects. More specifically, this invention relates to a method of forming a polyvinyl alcohol (PVA) foam treated with heparin for use in occlusion devices. The resulting PVA foam structure minimizes blood clotting. Normally, permanently repairing certain cardiac defects in adults and children requires open heart surgery, a risky, expensive, and painful procedure. To avoid the risks and discomfort associated with open heart surgery, modern occlusion devices have been developed are that small, implantable devices capable of being delivered to the heart through a catheter. Rather than surgery, a catheter inserted into a major blood vessel allows an occlusion device to be deployed by moving the device through the catheter. One method of inserting an occlusion device begins by using a guide catheter introduced through the femoral vein and lower vena cava and placed in the right ventricle of the heart. After passing through the defect in the atrial septum, the distal portion of the implant is forced out of the catheter and unfolded in the left atrium, much like unfolding an umbrella. The unfolded portion is drawn back against the septum due to the pre-tensioning of the fixation devices. Then, the proximal parts of the implant are likewise pushed out of the catheter and independently unfolded in the right atrium. The insertion forceps used to guide the occlusion device through the catheter are then separated from the center piece. This procedure is performed in a cardiac cathlab and avoids the risks and pain associated with open heart surgery. These modem occlusion devices can repair patent foramen ovale, patent ductus arteriosis, atrial septal defects, ventricular septal defects, and other cardiac and non-cardiac apertures. One such device is that disclosed in PCT application PCT/US98/15961, entitled Occlusion Device for the Closure of a Physical Anomaly Such as a Vascular Aperture or an Aperture in a Septum, filed on Jul. 31, 1998 by Bernhard Schneidt, now issued U.S. Pat. No. 6,174,322. This patent discloses a non-thrombogenic occlusion device that is insertable into an anomaly via a catheter. In addition, a similar device filed as German Appln. 297 14 242.9 on Aug. 8, 1997, discloses an occlusion device which can be inserted via a catheter. Another devices is that disclosed in U.S. Pat. No. 6,206,907, entitled Occlusion Device with Stranded Wire Support Arms, filed on May 7, 1999, invented by Joseph A. Marino, Michael P. Corcoran, and Peter M. Buonomo. Web site: http://www.delphion.com/details?pn=US06656206__
Patents 155
•
Oral delivery of macromolecules Inventor(s): Byun; Youngro (Gwangju, KR), Lee; Yong-Kyu (Gwangju, KR) Assignee(s): Mediplex Corporation, Korea (Seoul, KR) Patent Number: 6,656,922 Date filed: April 30, 2001 Abstract: Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivatives were synthesized by conjugation to bile acids, sterols, and alkanoic acids, respectively. These heparin derivatives were slightly hydrophobic, exhibited good solubility in water, and have high anticoagulation activity. These slightly hydrophobic heparin derivatives are efficiently absorbed in the gastrointestinal tract and can be used in oral dosage forms. Methods of using these amphiphilic heparin derivatives and similarly modified macromolecules for oral administration are also disclosed. Excerpt(s): This invention relates to derivatives of macromolecules, including polysaccharide derivatives, having increased hydrophobicity as compared to the unmodified macromolecules or polysaccharides. More particularly, the invention relates to oral delivery and absorption of hydrophobized macromolecules and amphiphilic polysaccharide derivatives, such as amphiphilic heparin derivatives, wherein the bioactivity of the macromolecule or polysaccharide is preserved. In preferred embodiments of the invention, the hydrophobized macromolecules and amphiphilic polysaccharide derivatives have a molecular weight of greater than 1000, yet are absorbed after oral administration. Heparin is a polysaccharide composed of sulfated Dglucosamine and D-glucuronic acid residues. Due to its numerous ionizable sulfate groups, heparin possesses a strong electronegative charge. It is also a relatively strong acid that readily forms water-soluble salts, e.g. heparin sodium. It is found in mast cells and can be extracted from many body organs, particularly those with abundant mast cells. The liver and lungs are especially rich in heparin. The circulating blood contains no heparin except after profound disruption of mast cells. Heparin has many physiological roles, such as blood anticoagulation, inhibition of smooth muscle cell proliferation, and others. In particular, heparin is a potent anticoagulant agent that interacts strongly with antithrombin III (ATIII) to prevent the formation of fibrin clots. Heparin is one of the most potent anticoagulants used for treatment and prevention of deep vein thrombosis and pulmonary embolism. In vivo, however, applications of heparin are very limited. Because of its hydrophilicity and high negative charge, heparin is not absorbed efficiently from the GI tract, nasal or buccal mucosal layers, and the like. Therefore, the only routes of administration used clinically are intravenous and subcutaneous injections. Moreover, since heparin is soluble in relatively few solvents, it is hard to use for coating surfaces of medical devices or in delivery systems. To improve the properties of heparin, R. J. Linhardt et al., 83 J. Pharm. Sci. 1034-1039 (1994), coupled lauryl (C.sub.12) and stearyl (C.sub.18) groups to single heparin chains, resulting in a derivatized heparin having increased hydrophobicity but with low anticoagulation activity. This result demonstrated that coupling a small linear aliphatic chain to heparin was ineffective in enhancing the hydrophobicity of heparin while preserving activity. Thus, known heparin derivatives have been ineffective in preserving anticoagulation activity. Web site: http://www.delphion.com/details?pn=US06656922__
156
•
Heparin
Plaster for topical use containing heparin and diclofenac Inventor(s): Donati; Elisabetta (Cavallasca, IT), Rapaport; Irina (Rovio, CH) Assignee(s): Altergon S.A. (Lugano, CH) Patent Number: 6,592,891 Date filed: April 14, 2000 Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising:a substrate layer;an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid;a protective film which can be removed at the moment of use. Excerpt(s): Plaster for topical use having an analgesic activity and being able to reabsorb haematomas, containing diclofenac in association with heparin or a heparinoid. Known and available on the market are creams for topical use with a base of heparinoids, possibly in association with hyaluronidase, for re-absorption of haematomas and ecchymoses. Though remarkably effective, these creams involve a number of drawbacks. In fact, they do not present a more specific analgesic activity, which would be particularly necessary in the case of serious ecchymoses. Web site: http://www.delphion.com/details?pn=US06592891__
•
Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography Inventor(s): Feussner; Annette (Marburg, DE), Roemisch; Juergen (Marburg, DE), Stoehr; Hans-Arnold (Wetter, DE) Assignee(s): Aventis Behring GmbH (Marburg, DE) Patent Number: 6,670,455 Date filed: August 4, 2000 Abstract: A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by the use of a chromatography separation processes and/or fractional precipitation is described. The process used may include adsorption on calcium phosphate/hydroxyapatite, a hydrophobic matrix, a chelate matrix, a matrix on which heparin or a substance related to heparin, such as heparin sulfate or dextran sulfate, is immobilized, or a matrix that is coated with an immobilized monoclonal or polyclonal antibody directed against the protein to be isolated, or F(ab) or F(ab).sub.2 fragments of antibodies directed against the protein to be isolated. A pharmaceutical preparation and a reagent are described which contain the said protease and/or its proenzyme. Excerpt(s): The invention relates to a process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins, and of pharmaceutical preparations which contain the proteins mentioned individually or as a mixture. German patent application 19 903 693.4 has already disclosed a protease for the activation of blood clotting factor VII, a process for its production, for its detection and for its inactivation, and pharmaceutical preparations which contain this protease. This protease, first isolated from plasma, occurs there together with a nonactivated form, which is designated below as "proenzyme". The protease activates blood clotting factor VII and accelerates clotting, as was shown by numerous experiments. In the further investigation of the biological properties of this
Patents 157
protein, identified as serine protease, it emerged that single-chain plasminogen activators, such as prourokinase, are also effectively activated. Moreover, inactivation of factors V and VIII in vitro was observed. In addition to the sequenced regions already described in German patent application 19 903 693.4, N-terminal sequencings of protease fractions were carried out. The following amino acid sequences characterize the FVII-activating protease: IYGGFKSTAGKHP; LLESLDPDXTPD; EFHEQSFRVEKI; SKFTXAXPXQFK; where X means not identified. The sequences of the protease mentioned elucidated up to now show that they agree 100% with sequences of the protease published by Choi-Miura (Choi-Miura et al. J. Biochem. 1996; 119: 1157 to 1165). The investigations until now have especially concentrated on the protease in its activated form. The inactive form of the protease present in the plasma as a proenzyme was only recently discovered by means of a protein band pattern in the SDS-PAGE after reduction of the sample. Since, on the activation of the protease, a cleavage at a site of the primary structure typical for serine proteases and thus activation takes place, two or more bands are visible on electrophoresis. On reduction of the chains which are connected by disulfide bridges, the individual bands become visible in accordance with their lower molecular weight, the proenzyme remaining as a large individual chain. This was also clear in more complex solutions after transfer of the proteins to membranes and subsequent Western blotting using suitable antibodies. Web site: http://www.delphion.com/details?pn=US06670455__ •
Protamine fragment compositions and methods of use Inventor(s): Byun; Youngro (Kwangsan-Ku Kwangju, KR), Yang; Victor C. (Ann Arbor, MI) Assignee(s): The Regents of The University of Michigan (Ann Arbor, MI) Patent Number: 6,624,141 Date filed: November 16, 2000 Abstract: Provided are bioactive, low-toxicity protamine fragments, compositions, combinations, kits and methods of using these components in a variety of embodiments, including neutralizing heparin and reducing post-operative bleeding. Improved protamine fragment-insulin solutions and methods for treating diabetes are also provided. Excerpt(s): The present invention relates generally to the fields of protein biochemistry and medicine. More particularly, it concerns bioactive, low-toxicity fragments of protamine, and a number of different uses of such protamine fragment compositions. Provided are protamine fragments, compositions, combinations and kits and various methods and uses of such fragments, e.g., in the neutralization of heparin and for association with a variety of therapeutic proteins, including insulin. Heparin consists of a heterogeneous mixture of sulfated glycosaminoglycans with a molecular weight ranging from 3,000 to 40,000 daltons. It is made of a repeating unit of D-glucuronic acid and N-acetyl-D-glucosamine residues (Bourin and Lindahl, 1993). The anticoagulant function of heparin was discovered over 70 years ago (Howell, 1922). Heparin exerts its anticoagulant activity primarily via interaction with antithrombin III (Rosenberg, 1987). Antithrombin III (ATIII) is a circulating inhibitor of the serine proteases in the coagulation cascade, acting more particularly on thrombin and factor Xa but also on factors IXa, XIa, and XIIa. It possesses an arginine center that binds to the active serine site of thrombin (and also the other coagulation factors) to form a covalent bond (Griffith, 1983). Normally this reaction proceeds rather slowly. Binding of heparin to
158
Heparin
ATIII, however, induces a conformational change of ATIII, rendering the arginine center more accessible to thrombin interaction, and producing a 1000-fold acceleration of the inhibitory effect (Rosenberg, 1987). The binding of heparin to ATIII involves a unique pentasaccharide sequence containing a 3-O-sulfated glucosamine residue (Choay et al., 1981), and entails interaction between specific lysine residues on ATIII and sulfate and carboxylate groups in heparin (Choay et al., 1981; Rosenberg et al., 1979). Web site: http://www.delphion.com/details?pn=US06624141__ •
Protease for activating clotting factor VII Inventor(s): Feussner; Annette (Marburg, DE), Romisch; Jurgen (Marburg, DE), Stohr; Hans-Arnold (Wetter, DE) Assignee(s): Aventis Behring GmbH (Marburg, DE) Patent Number: 6,528,299 Date filed: April 21, 1999 Abstract: A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the nonreduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin. Excerpt(s): The invention relates to a protease for activating the blood clotting factor VII, to a process for isolating it, detecting it and inactivating it, and to medicinal preparations which comprise this protease. The blood clotting system comprises two different, cascade-like pathways for activating clotting factors which are present in the plasma. The intrinsic or the entrinsic pathway is preferentially used for initiating clotting, depending on the triggering mechanism. When a tissue is damaged, thromboplastin (tissue factor, TF with phospholipids) is exposed by the affected cells as the starter of the extrinsic clotting pathway. The membrane-located thromboplastin can bind both clotting factor VII (FVII) and circulating, activated FVII (FVIIa). In the presence of calcium ions and lipids, this TF-FVIIa complex leads to the binding of FX, which is converted into its activated form (FXa) by limited proteolysis. FXa in turn leads, by activating prothrombin to form thrombin, to the formation of fibrin and thereby ultimately to closure of the wound. Web site: http://www.delphion.com/details?pn=US06528299__
Patents 159
•
Treating metal surfaces to enhance bio-compatibility and/or physical characteristics Inventor(s): Al-Lamee; Kadam Gayad (Leeds, GB), Taktak; Yousef Samih (Matlock, GB) Assignee(s): Polybiomed Limited (GB) Patent Number: 6,599,558 Date filed: December 2, 1999 Abstract: A metal, glass or ceramics surface is treated to enhance its compatibility with biological material such as blood or blood related products. Treatment involves covalently bonding to the surface by means of a catalyst functional molecules each of has at least one alkoxysilane group which can form at least one first covalent bond by reaction with the oxide or hydroxide of said surface and at least one other group which can participate in free-radical polymerisation. Free-radical polymerisation from said functional molecules is then effected to build bio-compatible and/or hydrophilic polymer chains. The compatibility of the metal surface with biological material may be further improved by bonding bio-active molecules, such as heparin or heparin derived molecules to the polymer chains. Suitable metal surfaces are those of medical devices such as heat exchangers, coronary and peripheral stents and guide wires used in angioplasty. In the case of a stent, restenosis may be inhibited by incorporating into the coating a radio-labelled compound, foe example radio-labelled heparin and/or by incorporating a compound that inhibits cell proliferation e.g. mitoxantrone. Excerpt(s): The present invention relates to a method of treating metal surfaces to enhance the bio-compatibility and/or physical characteristics of said surfaces. The invention also relates to bio-compatible metal articles. The invention is particularly relevant to surfaces of medical devices. Many medical techniques are known in which human or animal blood is brought into contact with foreign surfaces, either within the body or outside the body. In some situations, usually due to mechanical characteristics, it is necessary to use metallic surfaces, as required by coronary stents (vascular endoprostheses) located within arteries or, for example, within heat exchanger assemblies external to the body. Thus, in the first application, the mechanical strength of the metal object is required whereas in the external application it is the heat transfer characteristics that are required. However, in both applications, blood or related blood products are brought into contact with metal surfaces, which may in turn have detrimental effects upon the blood itself. Heparin is a naturally occurring substance that consists of a polysaccharide with a heterogeneous structure and a molecular weight ranging from approximately 6000 to 30000 Dalton (atomic mass units). It prevents uncontrolled clotting by suppressing the activity of the coagulation system through complexing with antithrombin (III), whose activity it powerfully enhances. Approximately one in three heparin molecules contains a sequence of highly specific structures to which antithrombin binds with high affinity. When bound to the specific sequence, the coagulation enzymes are inhibited at a rate that is several order of magnitude higher than in the absence of Heparin. Thus, the heparin molecule is not in itself an inhibitor but acts as a catalyst for natural control mechanisms without being consumed during the anticoagulation process. The catalytic nature of heparin is a desirable property for the creation of a bio-active surface, because the immobilised heparin is not functionally exhausted during exposure to blood but remains a stable active catalyst on the surface. Web site: http://www.delphion.com/details?pn=US06599558__
160
•
Heparin
Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas Inventor(s): Mary; Veronique (Evry, FR), Pratt; Jeremy (Paris, FR), Stutzman; Jean-Marie (Villecresnes, FR), Uzan; Andre (Paris, FR), Wahl; Florence (Paris, FR) Assignee(s): Aventis Pharma S.A. (Antony, FR) Patent Number: 6,579,858 Date filed: November 29, 1999 Abstract: Cerebral edema is prevented and treated by administering an effective amount of a low molecular weight heparin. Excerpt(s): The present invention relates to the use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas. The invention also relates to the use of low-molecular-weight heparins for the preparation of a medicament for the prevention and treatment of cerebral edemas. Standard heparin is a sulphated polysaccharide having an average molecular weight of 12,000-15,000 daltons which is isolated from bovine, ovine and porcine intestinal mucous membranes. Heparin is clinically used for the prevention and treatment of thromboembolic disorders but sometimes causes haemorrhages. Web site: http://www.delphion.com/details?pn=US06579858__
Patent Applications on Heparin As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to heparin: •
Analysis of sulfated polysaccharides Inventor(s): QI, Yi-Wei; (Charlestown, MA), Sasisekharan, Ram; (Cambridge, MA), Shriver, Zachary; (Boston, MA), Sundaram, Malikarjun; (Ashland, MA), Venkataraman, Ganesh; (Bedford, MA) Correspondence: Fish & Richardson PC; 225 Franklin ST; Boston; MA; 02110; US Patent Application Number: 20030203385 Date filed: March 11, 2003 Abstract: The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described. Excerpt(s): This application claims priority under 35 USC.sctn.119(e) to U.S. Provisional Patent Application Serial No. 60/393,973, filed on Jul. 5, 2002, U.S. Provisional Patent Application Serial No. 60/383,903, filed on May 28, 2002, and U.S. Provisional Patent Application Serial No. 60/363,240, filed on Mar. 11, 2002, the entire contents of which are hereby incorporated by reference. The invention relates to methods and products
9
This has been a common practice outside the United States prior to December 2000.
Patents 161
associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular, therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described. Coagulation is a physiological pathway involved in maintaining normal blood hemostasis in mammals. Under conditions in which a vascular injury occurs, the coagulation pathway is stimulated to form a blood clot to prevent the loss of blood. Immediately after the vascular injury occurs, blood platelets begin to aggregate at the site of injury forming a physical plug to stop the leakage. In addition, the injured vessel undergoes vasoconstriction to reduce the blood flow to the area and fibrin begins to aggregate forming an insoluble network or clot, which covers the ruptured area. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Analytical test cartridge; and, methods Inventor(s): Sin, Kee Van; (Lino Lakes, MN) Correspondence: Merchant & Gould PC; P.O. Box 2903; Minneapolis; MN; 55402-0903; US Patent Application Number: 20040002161 Date filed: June 28, 2002 Abstract: An analytical test cartridge is provided. The analytical test cartridge can be used for medical analyses of liquid samples removed from a patient, for example blood. The analytical test cartridge is configured to provide for titration experiments. An example of a titration experiment that can be performed with the arrangement, is titration of heparin with protamine. Methods of assembly and use are provided. Excerpt(s): Analyses of patient fluids, for example blood, have become an increasingly important part of medicine. As a result, various analytical systems have been developed to allow for convenient sample handling and evaluation. In many instances the analytical system utilizes a portable analysis station that can be moved to various locations, for convenience. Two such analysis systems are the IRMA Blood Analysis System (IRMA), and the Blood Analysis Portal System (PORTAL), both of which are available from Diametrics Medical, Inc. of Roseville, Minn., 55113, the assignee of the present application. General features of such systems are characterized, for example, in U.S. Pat. No. 6,066,243 ('243), assigned to Diametrics Medical, Inc., the complete disclosure of which is incorporated herein by reference. In general, such cartridges have relatively short useful lifetimes, with respect to the expected lifetime of the analytical componentry with which they are used. As a result, such cartridges are sometimes referred to as "disposable cartridges" or "disposable test cartridges." Indeed, in many instances, the removable cartridge is a single use cartridge. Besides the '243 and '853 references cited and incorporated above, the assignee of the present application, Diametric Medical, Inc., is also assignee of the following U.S. patents that describe technology related to, or useable with, disposable cartridges and their use, namely: U.S. Pat. Nos. 5,384,031; 5,223,433; 6,060,319; and 5,232,667. The complete disclosure of each of the patents identified in the previous sentence is incorporated herein by reference. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
162
•
Heparin
Antibodies to trisulfated heparin disaccharide in painful sensory axonal neuropathy Inventor(s): Pestronk, Alan; (St. Louis, MO) Correspondence: Hamilton, Brook, Smith & Reynolds, P.C.; 530 Virginia Road; P.O. Box 9133; Concord; MA; 01742-9133; US Patent Application Number: 20040038311 Date filed: August 20, 2002 Abstract: Methods aiding in the diagnosis of certain painful, predominantly sensory, polyneuropathies are disclosed, in which the amount of antibodies to trisulfated disaccharide is assessed in a test sample. Also disclosed are kits that can be used in the methods of the invention. Excerpt(s): The binding of serum IgM antibodies, including M-proteins, to glycolipids or glycoproteins is associated with several chronic polyneuropathy syndromes (O'Leary, C. P. and Willison, J. J., Curr. Opin. Neurol. 13:583-588 (2000); Quarles, R. H. and Weiss, M. D., Muscle Nerve 22:800-822 (1999)). IgM binding to myclin-associated glycoprotein (MAG) is a marker for a demyelinating sensory-motor polyneuropathy syndrome (Nobile-Orazio, "Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies," in Latov, N., Wokke, J. H. J., Kell, J. J. Jr., Eds., Immunology and Infectious Diseases of the Peripheral Nerves, Cambridge, UK: Cambridge University Press, 1998:168-189; Erb, S. et al., J. Neurol. 247:767-772 (2000)). IgM binding to sulfatide (Lopate, G., et al., J. Neurol. Neurosurg. Psychiatry 62:581-585 (1997); Carpo, M. et al., J. Neurol. Sci. 176:144-150 (2000); Erb, S. et al., J. Neurol. 247:767-772 (2000)) and to.beta.-tubulin (Connoly, A. M. et al., Neurology 48:243-248 (1997)) may also be associated with demyelinating sensory-motor polyneuropathies. IgM binding to GM1 ganglioside is related to a multifocal motor neuropathy that commonly has conduction block as the predominant demyelinating feature on electrophysiological testing (Parry, G., Muscle Nerve 19:269-276 (1996); Pestronk, A. and Choksi, R., Neurology 49:12891292 (1997); Pestronk, A., Neurology 51:S22-S24(1998)). Serum IgM with selective binding to GD1b ganglioside is associated with an axonal sensory polyneuropathy and ophthalmoplegia (O'Leary, C. P. and Willison, J. J., Curr. Opin. Neurol. 13:583-588 (2000); Susuki, K. et al., J. Neuroimmunol. 112:181-187 (2001)). However, the antigenic targets of serum antibodies in approximately 40% of patients with IgM M-proteins and polyncuropathies, especially those with primary axonal involvement, have been undefined. Because polyneuropathies are potentially treatable, correct identification of a patient's particular polyneuropathies is important. Methods of diagnosing such polyneuropathies based on specific disease-related criteria would facilitate identification of treatable disease and expedite commencement of treatment. The current invention pertains to methods for diagnosing, in an individual, the presence or absence of a painful, predominantly sensory, polyneuropathy. The methods include assaying a test sample of bodily fluid, blood, serum or other tissue from an individual for the presence of antibodies, such as IgM antibodies, that bind to a trisulfated disaccharide sample (e.g., to a sample containing IdoA2S-GlcNs-6S). In the methods, a trisulfated disaccharide sample, which can include trisulfated disaccharide that is a component of an oligosaccharide (e.g., heparin oligosaccharide), and/or tri sulfated disaccharide that is not a component of an oligosaccharide, is contacted with the test sample. The amount of antibody that binds to the tri sulfated disaccharide is then assessed and compared to a reference amount, or to the amount of anti-trisulfated disaccharide antibody in at least one negative control sample of a comparable bodily fluid or tissue. The presence of the polyneuropathy is indicated by an amount of anti-trisulfated disaccharide antibody that is greater than a reference amount, or by an amount of anti-trisulfated disaccharide
Patents 163
antibody that is significantly greater in the test sample than in the negative control sample(s). The absence of the polyneuropathy is indicated by an amount of antitrisulfated disaccharide antibody that is less than a reference amount, or by an amount of anti-trisulfated disaccharide antibody that is not significantly greater in the test sample than in the negative control sample(s). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Apparatus and method for in-vivo plasmapheresis using periodic backflush Inventor(s): Cooper, Tommy; (Friendswood, TX), Gorsuch, Reynolds G.; (Yountville, CA), Handley, Harold H.; (Novato, CA) Correspondence: Knobbe Martens Olson & Bear Llp; 2040 Main Street; Fourteenth Floor; Irvine; CA; 92614; US Patent Application Number: 20030236482 Date filed: April 4, 2003 Abstract: Apparatus and method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance. Excerpt(s): In U.S. Pat. Nos. 4,950,224, 5,152,743, 5,151,082, 5,735,809 and 5,980,481 there are disclosed methods and apparatus for carrying out in-vivo plasmapheresis for separating plasma from other blood components within the body and blood vessels of a patient. In the apparatus pumping is used to create a trans-membrane pressure and motivate the flow of fluid from within the in-vivo system, whereby blood plasma is pumped from the patient to a treatment system such as a dialyzer or other apparatus in which toxic metabolic waste in the plasma is removed. After the plasma is treated for removal of waste products, excess fluids, toxins, and/or other deleterious plasma proteins, the treated plasma is returned and reintroduced to the patient's blood stream. Methods of toxin removal from blood, as taught by the aforesaid patents and referred to as plasma dialysis, ultrafiltration or blood purification, are unique from and substantially superior to conventional hemodialysis as presently practiced for both acute and chronic kidney failure, primarily because removal of whole blood from the patient's vasculature is eliminated from the procedure using plasma, or portions of the plasma. The methods and apparatus described in the aforesaid patents are incorporated herein by reference. In U.S. Pat. Nos. 5,224,926, 5,735,809 and 5,968,004 there are disclosed improved filter assemblies including elongated hollow fibers and various filter assembly designs incorporating such hollow fibers to be used in the above-described methods and apparatus. In U.S. patent application Ser. No. 09/549,131, filed Apr. 13, 2000 (TRANSVI.007), there is disclosed specialized hollow fiber membranes which are superior in biocompatibility, performance and morphology for use in the aforesaid invivo plasmapheresis. In U.S. patent application Ser. No. 09/981,783, filed Oct. 17, 2001 (TRANSVI.011A) there is disclosed a plasmapheresis filter device and catheter assembly incorporating the aforesaid specialized hollow fiber membranes. In U.S. patent application Ser. No. 10/219,082, filed Aug. 13, 2002 (TRANSVI.012A) there are disclosed apparatus and methods for therapeutic apheresis using the aforesaid specialized hollow fiber membranes, filter device and catheter assembly. Such fibers, filter device, catheter
164
Heparin
assembly, apparatus and methods as disclosed in the aforesaid patents and applications are incorporated herein by reference. In the aforesaid systems, the hollow fiber membranes function as filters, where the primary purpose of said membranes is separation of specific blood or plasma components from whole blood. In such systems, the blood (permeate) flows on the outside of the fiber and the plasma (exudate) is diffused through the fiber membrane to the interior lumen of the hollow fiber. However, as use is continued, performance of the fibers as filters becomes degraded over time. For example, clogging or fouling of the filter occurs on the surface of the filter as the pore void spaces become more occluded with particulate matter from the permeate building up within the pore void such that the minute volume of the exudate is progressively degraded to the point of failure and cessation of exudate flow. Such clogging or fouling of the filter membranes, as well as clotting problems with prior art filter systems as disclosed in the aforesaid application Ser. No. 09/549,131 (TRANSVI.007), causes major operational and economic problems with current ex-vivo systems performing Continuous Renal Replacement Therapy (CRRT) for acute and chronic kidney failure. It is reported by Ramesh, Prasad, et al., in Clinical Neprology, Vol. 53, p. 55-60 (January 2000), that over 50% of such filters fail in 10 hours and over 75% fail in 30 hours of usage. Because short-term filter replacement